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Inflammatory breast cancer (IBC) is a rare and highly aggressive form of breast 
cancer that is characterized by survival signaling through overexpression and/or 
activation of the epidermal growth factor receptors EGFR/ErbB1 and Her2/ErbB2 and 
defects in the apoptotic program. The development of therapeutic resistance is a 
significant barrier to successful treatment in IBC, and thus, strategies targeting the 
mechanisms that drive drug resistance could prevent or reverse therapeutic resistance, 
significantly improving patient prognosis. Based on analysis of previously developed 
models of therapeutic resistant IBC, we hypothesized that apoptotic dysregulation and 
redox adaptive mechanisms were central to the drug resistant phenotype in IBC cells, 
and that targeting of these mechanisms could overcome therapeutic resistance. Our 
objectives to address this hypothesis were: 1. to develop and characterize an isotype-
matched IBC cellular model to investigate the mechanisms of acquired therapeutic 
resistance; 2. to characterize IAP-specific small molecule inhibitors as a means of 
targeting the mechanism of apoptotic dysregulation in IBC; and 3. to characterize a 
novel redox modulatory combination as a means of targeting redox adaptive 
mechanisms in IBC. 
Analysis of cell viability, proliferation, and growth parameters, evaluation of 
protein expression and signaling via western immunoblot, and measurement of reactive 
  
v 
oxygen species (ROS), antioxidants, and apoptosis in patient-derived IBC cell lines and 
isogenic derivatives revealed that resistance to the ErbB1/2 inhibitor lapatinib was 
protective against other targeted agents and chemotherapeutics. Additionally, reversal 
of resistance was associated with enhanced ability to accumulate ROS and 
downregulation of anti-apoptotic and antioxidant proteins. Targeting of resistance 
mechanisms using small molecule IAP inhibitors and a redox modulatory strategy both 
effectively induced apoptosis in therapy resistant IBC cells. Together, these results 
confirm XIAP and the redox adaptive phenotype as promising therapeutic targets for 










Abstract ....................................................................................................................................... iv 
List of Tables ............................................................................................................................. xiv 
List of Figures ............................................................................................................................ xv 
List of Abbreviations ............................................................................................................... xix 
Acknowledgements ................................................................................................................ xxv 
1 Introduction ........................................................................................................................... 1 
1.1 Inflammatory Breast Cancer ..................................................................................... 1 
1.1.1 Clinical, pathological, and epidemiological features of IBC ............................ 1 
1.1.2 Molecular features of IBC ..................................................................................... 4 
1.1.2.1 Hormone receptor negativity ...................................................................... 4 
1.1.2.2 Survival and growth signaling .................................................................... 5 
1.1.2.3 p53 mutation .................................................................................................. 7 
1.1.2.4 Overexpression of E-cadherin and eIF4G1 ................................................ 8 
1.1.2.5 Increased angiogenesis, lymphangiogenesis, and vasculogenesis ......... 9 
1.1.2.6 Apoptotic dysregulation ............................................................................ 11 
1.1.3 Current treatment options for IBC .................................................................... 11 
1.1.3.1 Standard of care treatment ......................................................................... 11 
1.1.3.2 Introduction of targeted therapies ............................................................ 13 
1.1.4 Unmet needs for the disease .............................................................................. 17 
1.1.4.1 Increased IBC awareness and refinement of diagnostic parameters .... 17 
  
viii 
1.1.4.2 Identification of molecular targets that contribute to IBC’s highly 
aggressive nature and development of strategies to target these 
pathways ...................................................................................................... 18 
1.1.4.3 Development of drugs targeting therapeutic resistance mechanisms .. 19 
1.2 Apoptotic Dysregulation and Therapeutic Resistance in Cancer ...................... 22 
1.2.1 Overview of apoptosis ........................................................................................ 22 
1.2.1.1 The apoptotic pathways ............................................................................. 22 
1.2.1.2 Negative regulators of apoptosis .............................................................. 25 
1.2.2 Dysregulation of apoptosis in cancer ................................................................ 26 
1.2.2.1 Dysregulation of p53 and the mitochondrial pathway .......................... 26 
1.2.2.2 Dysregulation of caspases .......................................................................... 26 
1.2.2.3 Dysregulation of death receptors and DISC components ...................... 27 
1.2.2.4 Dysregulation of the Bcl-2 family.............................................................. 28 
1.2.2.5 Dysregulation of the IAPs .......................................................................... 29 
1.2.3 Apoptotic dysregulation in IBC ......................................................................... 31 
1.3 Oxidative Stress, Redox Adaptation, and Therapeutic Resistance in Breast 
Cancer ........................................................................................................................ 32 
1.3.1 Reactive species are required for normal cell function ................................... 32 
1.3.2 High levels of ROS can be damaging to cells ................................................... 34 
1.3.3 ROS can promote oncogenesis ........................................................................... 36 
1.3.4 Redox adaptation in breast cancer cells promotes resistance to anti-tumoral 
therapies ................................................................................................................ 38 
1.3.4.1 Redox adaptation through increased ROS detoxification ...................... 38 
  
ix 
1.3.4.2 Redox adaptation through activation of redox-sensitive transcription 
factors ........................................................................................................... 40 
1.3.4.3 Redox adaptation through activation of survival signaling and 
upregulation of anti-apoptotic factors ...................................................... 42 
1.3.4.4 Interplay of redox adaptive mechanisms in therapeutic resistance ...... 45 
1.4 IBC Cell Line Models ............................................................................................... 46 
1.4.1 Patient-derived IBC models: SUM149, SUM190, and MDA-IBC-3................ 46 
1.4.2 Models of acquired resistance in IBC: rSUM149 and rSUM190 ..................... 47 
1.5 Research Objectives ................................................................................................. 51 
1.5.1 Objective 1 ............................................................................................................ 51 
1.5.2 Objective 2 ............................................................................................................ 51 
1.5.3 Objective 3 ............................................................................................................ 51 
2 Materials and Methods ...................................................................................................... 53 
2.1 Cell Culture............................................................................................................... 53 
2.1.1 Cell lines and reagents ........................................................................................ 53 
2.1.2 Generation of resistance reversal IBC cell line model ..................................... 57 
2.1.3 shRNA-mediated knockdown of XIAP ............................................................ 57 
2.1.4 shRNA-mediated knockdown of TNFR1 ......................................................... 57 
2.2 Determination of cell viability and proliferation ................................................. 58 
2.2.1 Trypan blue exclusion assay .............................................................................. 58 
2.2.2 MTT assay ............................................................................................................. 58 
2.2.3 High-throughput MTT assay ............................................................................. 59 
2.2.4 TMRE flow cytometric staining ......................................................................... 60 
  
x 
2.2.5 Clonogenic growth assay .................................................................................... 60 
2.3 Determination of apoptosis .................................................................................... 61 
2.3.1 Annexin-V flow cytometric staining ................................................................. 61 
2.3.2 Caspase activity assay ......................................................................................... 61 
2.4 Assessment of Smac mimetics ................................................................................ 62 
2.4.1 Determination of Smac mimetic binding affinities by fluorescence 
polarization assay ................................................................................................ 62 
2.4.2 TNF-α measurement of Smac mimetic-treated cells ....................................... 63 
2.5 Western immunoblotting ........................................................................................ 63 
2.6 Measurement of intracellular reactive oxygen species ........................................ 66 
2.7 Measurement of antioxidant capacity and signaling........................................... 66 
2.7.1 Measurement of reduced glutathione ............................................................... 66 
2.7.2 Measurement of Nrf2 activity ............................................................................ 67 
2.8 Copper assays ........................................................................................................... 67 
2.8.1 . Complementation of Ctr1/Ctr3-deficient yeast cells with copper ionophores 
 ................................................................................................................................ 67 
2.8.2 Measurement of intracellular copper ................................................................ 68 
2.9 Assessment of anchorage-independent growth potential .................................. 68 
2.10 Examination of intracellular ALDH activity .................................................... 69 
2.11 Analysis of drug interactions ............................................................................. 70 
2.12 Statistical analysis ................................................................................................ 70 
3 Development and characterization of a model to investigate the reversibility of 
acquired therapeutic resistance in IBC ............................................................................. 71 
  
xi 
3.1 Introduction .............................................................................................................. 71 
3.2 Lapatinib-resistant rSUM149 cells are cross-resistant to multiple chemo- and 
targeted therapies .................................................................................................... 75 
3.3 Reversal of resistance to lapatinib resensitizes rrSUM149 cells to a number of 
agents to which rSUM149 is insensitive ................................................................ 80 
3.4 Mechanism of resistance reversal: the rrSUM149 model behaves similarly to 
parental SUM149 cells in response to oxidative stress ........................................ 83 
3.5 Resistance reversal rrSUM149 cells have reduced expression of anti-apoptotic 
and antioxidant molecules compared to rSUM149 cells ..................................... 86 
3.6 Discussion ................................................................................................................. 89 
4 Targeting IAPs with Smac mimetics with differential IAP specificity ......................... 95 
4.1 Introduction .............................................................................................................. 95 
4.2 IAP binding affinity of novel bivalent Smac mimetics ........................................ 98 
4.3 Smac mimetics enhance TRAIL potency in TRAIL-sensitive SUM149 IBC cells .  
  .................................................................................................................................... 99 
4.4 Smac mimetics induce apoptosis as single agents in TRAIL-resistant SUM190 
cells .......................................................................................................................... 105 
4.5  Smac mimetics inhibit clonogenic growth capacity in combination with TRAIL 
and as single agents ............................................................................................... 113 
4.6 Smac mimetics inhibit anchorage-independent growth potential in 
combination with TRAIL and as a single agent ................................................. 117 
4.7 Smac mimetic efficacy in SUM149 and SUM190 cells is TNF-α-independent 
and caspase-dependent ......................................................................................... 119 
4.8 Discussion ............................................................................................................... 125 
5 Targeting XIAP with the small molecular functional inhibitor embelin ................... 129 
5.1 Introduction ............................................................................................................ 129 
  
xii 
5.2 XIAP overexpression inversely correlates with TRAIL sensitivity in IBC cells ...  
  .................................................................................................................................. 130 
5.3 The XIAP inhibitor embelin enhances TRAIL sensitivity ................................. 135 
5.4 Embelin modulates the ERK signaling pathway ............................................... 143 
5.5 Embelin induces generation of intracellular ROS by downregulation of SOD1 
and oxidation of glutathione ................................................................................ 145 
5.6  SOD mimetic/antioxidant reverses efficacy of the Embelin+TRAIL combination 
  .................................................................................................................................. 147 
5.7 Discussion ............................................................................................................... 149 
6 Targeting redox adaptation in IBC using the redox modulator disulfiram .............. 153 
6.1 Introduction ............................................................................................................ 153 
6.2 DSF induces death in IBC cells, and potency is enhanced by the addition of 
copper ...................................................................................................................... 155 
6.3 DSF is a copper ionophore that induces Ctr1-independent copper uptake .... 163 
6.4 DSF strongly induces copper accumulation in IBC cells ................................... 166 
6.5 DSF-Cu induces ROS accumulation and redox signaling in therapy-resistant 
rSUM149 cells ......................................................................................................... 168 
6.6 DSF-Cu inhibits intracellular antioxidants SOD1 and GSH ............................. 172 
6.7 DSF-Cu downregulates XIAP and induces apoptosis in IBC cells .................. 174 
6.8 DSF-Cu inhibits ALDH1 activity in SUM149 IBC cells ..................................... 176 
6.9  DSF-Cu potently inhibits anchorage-independent growth potential in SUM149 
and rSUM149 cells ................................................................................................. 178 
6.10 Discussion ........................................................................................................... 180 
7 Conclusions and Implications ......................................................................................... 191 
  
xiii 
References ................................................................................................................................ 203 




List of Tables 
Table 1.1: Prevalence of molecular phenotypes in IBC and non-IBC breast cancer ............ 4 
Table 2.1: Antibodies used in this dissertation ...................................................................... 65 
Table 3.1: IC50 values for the 15 most efficacious drugs in the SUM149 cell line from the 
NCI-DTP library ........................................................................................................................ 76 
Table 3.2: IC50 values for drugs most efficacious in SUM149 cells for the three isogenic-
derived IBC models* ................................................................................................................. 79 
Table 4.1: Binding constants (Kd) of Smac mimetics for IAPs as determined by 
fluorescence polarization assay ............................................................................................... 99 
Table 5.1: Combination indices (CI) for the interactions between embelin and TRAIL in 
SUM149-derived isogenic cell lines ...................................................................................... 137 





List of Figures 
Figure 1.1: The apoptotic pathways ........................................................................................ 24 
Figure 1.2: IBC cell line models used in this dissertation ..................................................... 50 
Figure 1.3: Hypothesis .............................................................................................................. 52 
Figure 2.1: Chemical structure of drugs used in this thesis ................................................. 56 
Figure 3.1: Validation of qHTS and isogenic-derived IBC cell line models ....................... 74 
Figure 3.2: Comparative efficacy profiling of the NCI-DTP 89 oncology drug set in 
parental SUM149 and isogenic-derived rSUM149 and rrSUM149 cell lines...................... 77 
Figure 3.3: Comparative IC50 values for drugs displaying cross-resistance and cross-
resensitization in SUM149 and isogenic-derived rSUM149 and rrSUM149 cell line 
models ........................................................................................................................................ 82 
Figure 3.4: Resistance reversal in the rrSUM149 cell line is associated with enhanced ROS 
accumulation and activation of the AMPK stress response................................................. 85 
Figure 3.5: The resistance reversal rrSUM149 cell line model is characterized by 
downregulation of anti-apoptotic proteins and reduced antioxidant capacity ................. 88 
Figure 3.6: Schematic representation of drug sensitivity and tolerance in isogenic 
SUM149-derived IBC models .................................................................................................. 92 
Figure 4.1: Smac mimetics enhance TRAIL-induced cell death in SUM149 cells ............ 100 
Figure 4.2: Birinapant reduces cIAP1/2 expression and induces caspase cleavage to 
enhance TRAIL-mediated apoptosis in SUM149 cells ........................................................ 102 
Figure 4.3: Birinapant is more effective than GT13402 at sensitizing SUM149 wtXIAP 
cells to TRAIL-mediated cell death ....................................................................................... 104 
Figure 4.4: TRAIL resistance in SUM190 is mediated in part by XIAP ............................ 106 
Figure 4.5: Smac mimetics induce death as single agents in SUM190 cells, and Birinapant 
is more efficacious than GT13402 due to its high affinity for XIAP .................................. 108 
  
xvi 
Figure 4.6: Birinapant induces apoptosis as a single agent in SUM190 cells ................... 110 
Figure 4.7: Birinapant does not activate NF-κB signaling .................................................. 112 
Figure 4.8: Smac mimetics inhibit clonogenic growth potential in combination with 
TRAIL in SUM149 cells .......................................................................................................... 114 
Figure 4.9: Smac mimetics inhibit clonogenic growth potential as single agents in 
SUM190 cells ............................................................................................................................ 116 
Figure 4.10: Birinapant inhibits anchorage-independent growth in combination with 
TRAIL and as a single agent in SUM149 and SUM190 cells respectively ........................ 118 
Figure 4.11: SUM190 cells produce low levels of autocrine TNF-α after treatment with 
Birinapant, but exogenous TNF-α does not sensitize SUM190 cells to Birinapant ......... 120 
Figure 4.12: Inhibition of TNF-α signaling through knockdown of TNFR1 does not 
inhibit Birinapant-induced cell death in SUM190 cells ...................................................... 122 
Figure 4.13: Birinapant acts in a TNF-α-independent, caspase-dependent manner to kill 
SUM190 cells as a single agent and sensitize SUM149 cells to TRAIL ............................. 124 
Figure 5.1: Effect of TRAIL expression on viability of isogenic-derived SUM149 cell line 
models ...................................................................................................................................... 132 
Figure 5.2: TRAIL sensitivity in SUM149 is associated with downregulation of XIAP and 
caspase activation.................................................................................................................... 134 
Figure 5.3: Embelin enhances the pro-apoptotic effects of TRAIL in SUM149, SUM149 
wtXIAP, and rSUM149 ........................................................................................................... 136 
Figure 5.4: Combinatorial analysis reveals synergy between embelin and TRAIL ........ 138 
Figure 5.5: Embelin does not effect death receptor expression in SUM149 cells ............. 140 
Figure 5.6: Sensitization to TRAIL by embelin is associated with reduced XIAP 
expression ................................................................................................................................ 142 
Figure 5.7: Embelin+TRAIL has differential effects on ERK signaling in SUM149 and 
SUM149 wtXIAP cells ............................................................................................................. 144 
  
xvii 
Figure 5.8: Embelin reduces cellular antioxidant capacity and generates ROS in rSUM149 
cells to induce cell death ........................................................................................................ 146 
Figure 5.9: Addition of an exogenous antioxidant (SOD mimetic) partially rescues 
embelin+TRAIL-induced cell death in SUM149 wtXIAP cells .......................................... 148 
Figure 6.1: DSF induces cell death in patient-derived IBC cell lines, and potency is 
significantly enhanced by the addition of copper ............................................................... 156 
Figure 6.2: DSF induces cell death in isogenic-derived IBC models of therapeutic 
resistance, and potency is significantly enhanced by the addition of copper ................. 158 
Figure 6.3: DSF-Cu-mediated cell death is potently reversed by the addition of copper 
chelators ................................................................................................................................... 162 
Figure 6.4: DSF acts as an ionophore to facilitate the uptake of copper into Ctr1/Ctr3 
mutant yeast ............................................................................................................................ 165 
Figure 6.5: DSF strongly induces copper uptake in IBC cells, which is associated with 
significant accumulation of ROS ........................................................................................... 167 
Figure 6.6: DSF-Cu activates redox-sensitive signaling and inhibits the pro-survival NF-
κB pathway .............................................................................................................................. 169 
Figure 6.7: DSF-Cu activates the Nrf2 transcription factor but decreases cellular 
antioxidant capacity ................................................................................................................ 171 
Figure 6.8: Addition of an SOD mimetic potently reverses DSF-Cu-mediated cell death 
in rSUM149 cells ...................................................................................................................... 173 
Figure 6.9: DSF-Cu reduces XIAP and eIF4G1 expression and induces apoptosis in 
SUM149 and rSUM149 cells ................................................................................................... 175 
Figure 6.10: DSF-Cu inhibits ALDH activity in SUM149 cells ........................................... 177 
Figure 6.11: DSF-Cu potently inhibits anchorage-independent growth of SUM149 and 
rSUM149 cell lines ................................................................................................................... 179 
Figure 6.12: Mechanisms of DSF-Cu-induced cell death .................................................... 182 
  
xviii 
Figure 7.1: Schematic of IBC therapeutic resistance mechanisms and targeting of those 




List of Abbreviations 
4E-BP1   eIF4E binding protein 1 
8-OHdG   8-hydroxydeoxyguanosine 
AI   aromatase inhibitor 
ALDH   aldehyde dehydrogenase 
AML   acute myeloid leukemia  
AMPK   AMP-activated protein kinase 
AP-1   activator protein-1 
Apaf-1   apoptotic protease activating factor 1 
ARE   antioxidant response element 
Bcl-2   B cell lymphoma 2 
BCS   bathocuproine sulfonate 
bFGF   basic fibroblast growth factor 
BH   Bcl-2 homology 
BIR   baculovirus IAP repeat 
BMI   body mass index 
CAF   cyclophosphamide, doxorubicin, 5-fluorouracil 
CCS   copper chaperone for superoxide dismutase 
CDK   cyclin-dependent kinase  
  
xx 
CEF   cyclophosphatmide, epirubicin, 5-fluoruracil 
CI   combination index 
cIAP   cellular inhibitor of apoptosis protein 
COMMD1  copper metabolism Murr1 domain-containing protein 1 
CR   clinical response 
CSC   cancer stem cell 
DEAB    diethylaminobenzaldehyde  
DHE   dihydroethidium 
DISC   death-inducing signaling complex 
DMSO   dimethyl sulfoxide 
DSF   disulfiram 
DTP   drug tolerant persister 
Dvl   disheveled 
EGF   epidermal growth factor 
EGFR/ErbB1  epidermal growth factor receptor 
EMT   epithelial to mesenchymal transition 
ER   estrogen receptor 
ERK   extracellular signal-related kinase 
FADD   Fas-associated protein with death domain  
FTI   farnesyl transferase inhibitor 
  
xxi 
GSH   reduced glutathione 
GSSG   oxidized glutathione 
GSR   glutathione reductase 
GPx   glutathione peroxidase 
GST   glutathione S-transferase 
H2DCFDA   2',7'-dichlorodihydrofluorescein diacetate 
HDAC   histone deacetylase  
Her2/ErbB2  human epidermal growth factor receptor 2 
HIF-1   hypoxia-inducible factor 1 
HO-1   heme oxygenase 1 
HSP   heat shock protein 
IAP   inhibitor of apoptosis protein 
IBM   IAP-binding motif 
IKK   IκB kinase  
ILPIP    ILP-interacting protein 
IBC   inflammatory breast cancer 
ILP2   inhibitor of apoptosis-like protein 2 
IRES   internal ribosomal entry site 
JNK   c-Jun N-terminal kinase  
LABC   locally advanced breast cancer 
  
xxii 
MAPK   mitogen-activated protein kinase 
MDA   malondialdehyde 
ML-IAP  melanoma inhibitor of apoptosis protein (livin) 
MMP   matrix metalloproteinase 
MOMP  mitochondrial outer membrane permeabilization  
mtDNA  mitochondrial DNA 
MTT   3-[4, 5-dimethylthiazol-2yl]-2, 5 diphenyl tetrazolium bromide  
NAIP   neuronal apoptosis inhibitory protein 
NCI-DTP  National Cancer Institute Developmental Therapeutics Program  
NF-κB    nuclear factor-kappa B  
NIK   NF-κB-inducing kinase 
Nrf2   nuclear factor (erythroid-derived 2)-like 2 
Nrx   nucleoredoxin 
NQO1   NADPH quinone oxidoreductase  
PARP   poly-ADP ribose polymerase 
pCR   pathologic complete response 
PDGF   platelet-derived growth factor 
PI3K   phosphatidylinositol 3-kinase  
PKC   protein kinase C 
PLC-γ   phospholipase C γ 
  
xxiii 
PR   progesterone receptor 
Prx   peroxiredoxin 
PTEN   phosphatase and tensin homolog  
PTP   protein tyrosine phosphatase 
qHTS   quantitative high throughput screening 
RING   really interesting new gene 
ROS   reactive oxygen species 
RT   room temperature 
RTK   receptor tyrosine kinase 
SAPK   stress-activated protein kinase 
SCLC   small cell lung cancer 
SERM   selective estrogen receptor modulators  
Smac   second mitochondrial activator of caspases 
STAT   signal transducer and activator of transcription  
SOD   superoxide dismutase 
TF   transcription factor 
TGF-β   transforming growth factor β 
TM   tetrathiomolybdate 
TMRE   tetramethylrhodamine, ethyl ester, perchlorate  
TN   triple negative 
  
xxiv 
TNF-α   tumor necrosis factor α 
TNFR   TNF-α receptor 
TRAF   TNF receptor-associated factor 
Trx   thioredoxin 
VEGF   vascular endothelial growth factor 




I want to thank my wonderful husband James, who has stood by me through the 
good times and the bad. He’s been my rock and always knows what goofy little thing to 
do to make me laugh when I might want to cry. He’s also been there to celebrate my 
successes as my biggest cheerleader, and no victory would be half as sweet without him 
at my side. He makes my life better just by being a part of it, and I couldn’t imagine it 
any other way.  
Of course I have to thank my advisor, Gay, for all of her help and guidance over 
the years; she has helped me to grow as a scientist and taught me a lot about dealing 
with people and the importance of collaboration. I truly appreciate all the time and care 
she spent helping me get through graduate school successfully. I would also like to 
thank the members of my committee- Mark Dewhirst, Bruce Sullenger, Robin Bachelder, 
Kevin Williams, and Kim Lyerly- for their moral support, thoughtful advice, and 
scientific guidance. Additionally, I would like to thank my DGS Soman Abraham for his 
listening ear and invaluable advice throughout the process. All of you helped to make 
this success possible for me, and for that I am truly grateful. 
I want to thank my friends, labmates, co-workers, and co-conspirators on the 4th 
floor of MSRB I, which has been my second home for the last four years. I have been so 
lucky to fall into such a wonderful group of people; Amy, Myron, Scott, and Katherine, 
  
xxvi 
it has been so much fun getting to work with all of you that at times work didn’t seem 
like work at all. You guys are like family to me, and I can’t tell you how instrumental 
having you there for me has been. Katherine, you were such a great mentor and 
inspiration to me; seeing your brilliance in action inspired me to be a better scientist, and 
seeing your success after you left made me excited to continue my journey as well. Amy, 
you’ve been a part of my life from Day One in the Devi Lab all the way through to my 
graduation, and I hope you know that I couldn’t have made it through without you! 
I would also like to thank my amazing friends outside the lab; meeting people in 
a new place is always hard, but I feel so lucky that I came to know you guys. Having a 
lifeline outside of the lab has been so crucial; from trivia nights to camping trips, being 
able to escape science and just have fun with you guys helped me get through grad 
school with a smile.  
Lastly, I would of course like to thank my family. Your love and support is 
always with me, and it’s made me feel just a little less far from home knowing that. It’s 
been hard to be so far away from you guys for this time, but I always knew it was only a 
temporary separation, and I can’t wait to be close to you all again very soon. 
 
 1 
1 Introduction  
1.1 Inflammatory Breast Cancer 
Inflammatory breast cancer (IBC) is a highly aggressive and lethal subtype of 
breast cancer that is distinct from other forms of locally advanced breast cancer (LABC). 
IBC is relatively rare, accounting for somewhere between 1 and 5% of all breast cancers 
diagnosed in the United States [1].  IBC progresses very rapidly, and is often not 
diagnosed until the patient has already progressed to Stage IIIb (lymph node and chest 
wall involvement) or IV (distant metastasis). Rapid progression combined with late 
stage at diagnosis and therapeutic intervention often results in poor patient prognosis; 
survival rates for IBC are much lower than those for other types of breast cancer, with a 
median overall survival of women with IBC at only three to four years. There has been 
little improvement in patient prognosis since the introduction of neoadjuvant 
chemotherapy over 30 years ago despite advances in multimodality treatment [2]. 
1.1.1 Clinical, pathological, and epidemiological features of IBC  
IBC’s rarity combined with non-classical breast cancer symptoms often results in 
misdiagnosis. IBC often presents as redness or erythema of the skin, which is diffuse and 
can extend to cover the entire breast; this is commonly also associated with swelling, or 
edema [3]. These clinical symptoms mimic an inflammatory response, which can cause 
the disease to be mistaken for relatively innocuous conditions such as mastitis or 
dermatitis. The onset of symptoms can occur very rapidly, sometimes even overnight, 
 2 
which is generally more characteristic of an infectious process than cancer. [4]. In most 
cases there is no palpable mass, and less than half of cases show a discrete mass upon 
mammographic examination, a classical finding for most other types of breast cancer [5]. 
In addition to redness and swelling, the patient may present with peau d’orange (orange 
peel) appearance of the skin of the breast, dramatic changes in skin color, skin 
thickening, nodules that may ulcerate, and/or nipple retraction or blistering; however, 
each case is different, and some women exhibit very few symptoms, adding to the 
difficulty in diagnosing IBC [3]. At the time of detection, lymph node involvement is 
apparent in 55-85% of patients [6]. Distant metastases are also common at diagnosis due 
to rapid disease progression, and these contribute to the poor prognosis of IBC [7].  
IBC tumor cells often display a ductal phenotype and high histological and 
nuclear grades. The disease tends to present as small clusters of tumor cells (emboli) in 
the dermal tissue rather than as a discrete tumoral mass. A skin punch biopsy is the best 
technique for tissue analysis when IBC is suspected as it allows for analysis of both the 
underlying breast tissue and the skin above.  The primary pathological finding 
associated with IBC is the presence of tumor emboli in the dermal lymphatics [3]. 
Blockage of the lymphatic vessels by these emboli is generally the underlying cause of 
the edema that is common [5]. However, confirmation of dermal lymphatic involvement 
is not always achieved; less than 75% of diagnosed IBC cases are positively identified as 
 3 
having dermal lymphovascular tumor emboli [8]. Thus, while this histopathological 
finding can confirm a suspected IBC diagnosis, its absence does not rule out IBC. 
 Epidemiologically, IBC is diagnosed at significantly higher rates in African 
American women than in Caucasian women, with about 50% higher incidence of IBC in 
that population comparatively; Asian and Pacific Islander women are believed to be at 
lowest risk [9, 10]. Age at diagnosis is significantly lower for IBC patients (median 58 
years) than those with non-IBC breast cancer (median 68 years) regardless of race, and 
African American women tend to be diagnosed at a younger age than Caucasian 
patients [1]. Median survival is also shorter in African American patients by 
approximately one year [9]. In addition to race, obesity also correlates with the 
occurrence of IBC; women with a body mass index (BMI) of greater than 26 are at a 
significantly higher risk for IBC than those with a BMI below 22.3 [11]. Examination of a 
cohort of IBC patients at MD Anderson Cancer Center revealed that 50% of registry 
patients are considered to be obese (BMI over 30) [3]. There is also a significant 
geographical disparity in IBC occurrence; while the rate of incidence in the United States 
is between 1 and 5%, IBC is much more common in North African countries including 
Morocco, Algeria, Tunisia, and Egypt, where IBC reportedly accounts for as many as 10-
15% of all breast cancer cases [12, 13]. 
 4 
1.1.2 Molecular features of IBC 
Just as IBC is a distinct form of breast cancer clinically and histopathologically, 
there are certain molecular features that are common in or specific to IBC. Many of these 
features are involved in mediating IBC pathogenesis and may represent potential 
therapeutic targets in combating the disease. A summary of the prevalence of selected 
molecular phenotypes in IBC and non-IBC can be found in Table 1.1. 
Table 1.1: Prevalence of molecular phenotypes in IBC and non-IBC breast cancer 
Phenotype IBC (%) Non-IBC (%) Reference 
Basal type 34 16 [14] 
Triple negative 29 10-20 [15, 16] 
Her2 amplified 36-42 17 [17, 18] 
EGFR positive 30 18 [19, 20] 
ER/PR positive 59 69 [21] 
p53 mutated 57 37 [22] 
Highly vascular 51 14 [23] 
1.1.2.1 Hormone receptor negativity 
A large proportion of IBC tumors are negative for expression of progesterone 
and estrogen receptors (PR and ER respectively). IBC cases most often fall into one of 
two categories: the basal subtype, which is characterized by expression of genes usually 
found in normal basal or myoepithelial breast cells including cytokeratin 5/6, P-
cadherin, and epidermal growth factor receptor (EGFR/ErbB1) [24, 25], or the human 
epidermal growth factor receptor 2 (Her2/ErbB2)-overexpressing subtype in which the 
oncogene Her2 is amplified or overexpressed [26]. Of the five molecular subtypes for 
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breast cancer as a whole (luminal A and B, basal, ERBB2-overexpressing and normal-
like), basal and ErbB2-overexpressing are associated with the worst prognosis [14]. 
Basal type breast cancer is highly aggressive and associated with especially poor 
prognosis. IBC tumors show a high incidence of basal type tumors, with these cases 
making up 33.8% of IBC cases in one study compared to only 15.93% of non-IBC cases 
[14]. Tumors of the basal subtype are commonly also of the triple negative (TN) 
phenotype based on the absence of ER, PR, and Her2/ErbB2 [24]. Unlike ER and Her2 
positive breast cancers, there are relatively fewer therapies available for these tumors, as 
they are insensitive to estrogen- or Her2-targeting therapies like tamoxifen and 
trastuzumab [27]. TN IBC tumors are associated with increased likelihood for 
locoregional recurrence (38.6% for TN IBC vs. 8-22.6% non-TN) and distant metastasis 
(56.7% for TN IBC vs. 28.8-52.1% non-TN) and poor overall survival (42.7% 5 year 
survival for TN IBC vs. 54-74% for non-TN) as compared to IBC patients with some 
combination of ER, PR, and Her2 positivity [15]. 
1.1.2.2 Survival and growth signaling 
The other main subtype of breast cancer that makes up the IBC population is the 
ErbB2/Her2-overexpressing group, which comprises approximately 42% of IBC cases 
[18]. There is an increased frequency of this subtype in IBC specifically; in a panel of 178 
non-IBC and 67 IBC patients, Prost et al. determined that ErbB2 is amplified in 36% of 
IBC specimens compared to only 17% of non-IBC samples [17]. ErbB2 is a 
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transmembrane receptor tyrosine kinase and member of the epidermal growth factor 
receptor (EGFR/ErbB) family. It mediates signal transduction through mitogen-activated 
protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, phospholipase C γ 
(PLC- γ), protein kinase C (PKC), and signal transducer and activator of transcription 
(STAT) pathways which promote survival and proliferation while inhibiting apoptosis 
[28]. Thus, inappropriate activation of ErbB2 signaling results in the uncontrolled cell 
growth and resistance to apoptosis that is characteristic of aggressive cancers like IBC.  
EGFR/ErbB1 is another member of the EGFR/ErbB family of membrane 
receptors. EGFR overexpression is frequent in IBC and is commonly associated with the 
basal subtype; an immunohistochemical study found that EGFR overexpression occurs 
in approximately 30% of IBC cases, consistent with its association with basal type 
tumors, which account for ~33% of IBC [14, 19, 29]. Similarly to ErbB2, EGFR also 
stimulates cell signaling networks including the PLC-γ, MAPK, and PI3K/Akt pathways 
to promote cell proliferation, tumor progression, invasion, and metastasis [30, 31], thus 
playing a role in both tumorigenesis and tumor progression. EGFR has also shown 
strong prognostic significance for IBC patients, with overexpression correlating with 
increased risk of disease recurrence and a significantly worse 5 year survival rate 
compared to EGFR negative IBC tumors [19].  
The nuclear factor κB (NF-κB) pro-survival transcription factor (TF) is also 
commonly activated in IBC, with a significant upregulation of NF-κB target genes in IBC 
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relative to non-IBC [18, 32-34]. NF-κB activation promotes tumorigenesis, tumor 
progression, and therapeutic resistance through a number of downstream 
transcriptional targets. NF-κB promotes survival through the expression of anti-
apoptotic proteins from the B cell lymphoma 2 (Bcl-2) and inhibitor of apoptosis protein 
(IAP) families; cell cycle progression via upregulation of cyclin D1; resistance to 
oxidative stress through modulation of antioxidants; and metastasis through 
transcription of genes involved in invasion and angiogenesis including cell adhesion 
molecules, matrix metalloproteinases (MMPs), vascular endothelial growth factor 
(VEGF), and inflammatory cytokines [35-37]. 
1.1.2.3 p53 mutation 
The p53 TF is a tumor suppressor that can either induce cell cycle arrest and 
DNA repair mechanisms or apoptotic cell death in response to cellular stresses. As a 
significant barrier to transformation and tumor progression, p53 is very commonly 
inactivated in cancer; p53 mutations are the most common mutations found amongst all 
cancers, and IBC is no different [38]. Compared with LABC, IBC patients have higher 
levels of mutated p53 protein [39]; Turpin et al. found that IBC exhibited a 57% rate of 
p53 mutation, while LABC showed only 37% [22]. The prognostic power of p53 
mutation in IBC is powerful; patients with p53 mutation and nuclear overexpression of 
mutant p53 protein had an 8.6-fold higher risk of death than those without mutation or 
overexpression [40]. Mutations in p53 have been associated with more aggressive 
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tumors, anthracycline resistance, reduced progression free and overall survival, and less 
favorable long-term outcome in IBC [41].  Thus, p53 status is important when 
considering patient outcomes and potential treatment regimens. 
1.1.2.4 Overexpression of E-cadherin and eIF4G1  
E-cadherin is a transmembrane glycoprotein that mediates epithelial cell-to-cell 
adhesion. In most cancers, the epithelial to mesenchymal transition (EMT) represents a 
crucial switch toward an invasive phenotype and metastatic potential that is associated 
with poor prognosis [42], while expression of E-cadherin is predictive of low metastatic 
potential [43]. However, E-cadherin is highly expressed in IBC despite its 
characterization as highly aggressive and invasive [44]. That is because in IBC, E-
cadherin is essential for the formation of tumor emboli through the promotion of tumor 
cell-to-tumor cell interactions rather than adherence to the surrounding stromal tissue 
[45]. In this way, E-cadherin actually promotes the dissemination of tumor cells through 
a form of continuous invasion called passive metastasis [46].  
eIF4G1 is a translation initiation factor that acts in concert with eIF4E and eIF4A 
to form the eIF4F complex, which recruits ribosomes to capped mRNAs to initiate 
translation [47]. In the case of IBC, in which eIF4G1 is overexpressed, it has been 
determined that eIF4G1 preferentially promotes the cap-independent translation of 
internal ribosomal entry site (IRES)-containing mRNAs. This translational 
reprogramming by eIF4G1 contributes to the pathogenic properties of IBC through 
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upregulation of p120 catenin mRNA, which contains an IRES element in its 5’ region. 
p120 catenin is responsible for anchoring E-cadherin at cell adherens junctions, and is 
thus indispensable for the formation of tumor emboli by IBC cells [46]. Hence, eIF4G1 
overexpression in IBC cells promotes their highly aggressive nature by enhancing p120 
catenin mRNA translation, which works with E-cadherin to mediate the formation of 
tumor emboli and promote continuous invasion through passive metastasis.  
1.1.2.5 Increased angiogenesis, lymphangiogenesis, and vasculogenesis 
IBC tumors tend to be highly angiogenic; comparison of IBC and non-IBC tumors 
reveals a much higher percentage of tissue with moderate to high microvascular density 
in IBC patients compared to non-IBC patients (51% vs. 14%) [23]. In addition, IBC 
specimens show a significant increase in genes associated with angiogenesis including 
those that encode angiopoietin, bFGF-2 (basic fibroblast growth factor 2), VEGF receptor 
2 (VEGFR2) and R3, and VEGF-C and -D [48]. 
In addition to p120 catenin, overexpression of eIF4G1 promotes the translation of 
IRES-containing VEGF mRNA as a means of driving IBC pathogenesis. VEGF is a key 
regulator of angiogenesis that promotes the growth of vascular endothelial cells [49]. 
Increased expression of VEGF in IBC enhances tumor vascularity and protects against 
damaging hypoxia [50]. As IBC displays upregulation of genes and TFs [such as 
activator protein 1 (AP-1) and hypoxia-inducible factor 1 (HIF-1)] activated by hypoxia 
and environmental stress, a high level of intratumoral hypoxia may be characteristic of 
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the disease [51]. Hypoxia induces a switch from cap-dependent to cap-independent 
translation, which promotes increased tumor angiogenesis in an eIF4G1- and eIF4E 
binding protein 1 (4E-BP1)-dependent manner [52]. Silvera et al. determined that IBC 
cells have adapted to mimic a state of constant hypoxia at the translational level by 
upregulation of eIF4G1 and constitutive activation of 4E-BP1 which promotes the 
production of proteins required for tumor emboli survival and dissemination including 
VEGF and p120 catenin. They postulate that this adaptive mechanism allows tumor 
emboli to continue growing despite constant cycling between hypoxia and normoxia in 
the tumor microenvironment [50]. 
Lymphatic metastasis was originally thought to occur via the pre-existing 
lymphatic network; however, analysis of animal models and human tumors indicates 
that tumors can induce growth and remodeling of lymphatic vessels [53, 54]. 
Lymphangiogenesis is the formation of new lymphatic vessels from pre-existing ones; 
because cancer cells tend to travel via the lymphatic system and the lymph nodes are 
often the first site of metastasis, this process is highly important to tumor invasion and 
metastatic potential [55].  IBC specimens show a significant increase in genes associated 
with lymphangiogenesis and contain significantly higher fractions of proliferating 
lymphatic endothelial cells than non-IBC breast cancer specimens [48], consistent with 
their highly metastatic behavior.  
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Vasculogenesis, also referred to as vascular mimicry, is the process by which 
tumor cells form vessel-like structures that allow the flow of oxygen and nutrients in the 
absence of endothelial cells [3]. Animal xenograft models of IBC indicate that 
vasculogenesis may play a role in the disease [56, 57], but further clinical studies are 
needed to determine whether this feature is relevant in the patient population [54]. 
1.1.2.6 Apoptotic dysregulation 
The ability to resist apoptotic cell death is one of the hallmarks of cancer [58] and 
a common mechanism by which cancer cells do this is through the dysregulation of 
components of the apoptotic machinery. Comparison of IBC and non-IBC tumor 
samples indicates that IBC cells have an enhanced capability to avoid apoptosis; this will 
be discussed in detail in Section 1.2.5, after a thorough introduction of the apoptotic 
pathways and components.  
1.1.3 Current treatment options for IBC 
1.1.3.1 Standard of care treatment 
The standard of care therapy for primary IBC has evolved over the last four 
decades to include a number of different approaches working in concert to combat this 
aggressive disease, which has resulted in distinct improvements in patient prognosis 
from what was once a mere 5% rate of 5 year overall survival [7]. Currently, the accepted 
therapeutic plan includes systemic neoadjuvant chemotherapy, most often a 
combination of anthracyclines and taxanes [59], in combination with trastuzumab in the 
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case of ErbB2 positivity or hormonal therapies in the case of ER positive cases, followed 
by surgery, radiotherapy, and possible continuation of targeted agents [3, 4, 7, 60].   
The anthracycline family of chemotherapeutics includes daunorubicin, 
doxorubicin, and epirubicin. Anthracycline activity is related to the inhibition of 
topoisomerase II activity, which occurs as a result of DNA intercalation by the drug, and 
production of free oxygen radicals that damage cellular DNA and lipid membranes [61]. 
The taxane family of chemotherapeutics includes docetaxel and paclitaxel. Taxanes are a 
form of mitotic inhibitors that function via stabilization of microtubules within the cell, 
which blocks cell division [62]. Most often, chemotherapeutic combinations including 
cyclophosphamide, doxorubicin, 5-fluorouracil (CAF) or cyclophosphamide, epirubicin, 
5-fluorouracil (CEF) are followed by paclitaxel for the treatment of IBC, since addition of 
paclitaxel improved pathologic complete response (pCR) rates from approximately 10% 
to 25% [3, 4, 7]. 
Although mastectomy alone provides no prognostic benefit to IBC patients, 
yielding 5 year survival rates of 0-10% [63], surgery is a key component of 
multimodality therapy in patients that respond to chemotherapy, which is intended to 
shrink the disease and allow for complete surgical resection. The most common surgical 
procedure for IBC is a mastectomy with axillary lymph node dissection [3, 4, 7]. A poor 
prognosis is associated with positive margins, highlighting the importance of complete 
tumor resection [64]. Due to this fact, patients who do not respond to chemotherapy may 
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not benefit from surgical resection, and it may be preferable to start radiation therapy 
and reevaluate the benefits of surgery later or seek out clinical trials for alternative 
therapies [65]. 
Aggressive radiotherapy is recommended for IBC patients following 
mastectomy; in this process, the chest wall, internal mammary regions, and the 
surrounding undissected lymph nodes (axillary, infraclavicular, and supraclavicular) are 
targeted. Coverage of the chest wall is critical in order to target tumor emboli that are 
located in the dermal lymphatic system [3, 4, 7]. Though radiation treatment regimens 
vary among institutions, it is common for patients to receive once or twice daily 
treatment with a total dose of up to 66 Gy, as greater benefit is observed with high doses 
[3, 7, 66]. In a study of 115 IBC patients, Liao et al. determined that escalation of dosage 
from 60 to 66 Gy in a twice daily delivery format increased 5 year locoregional control 
rates from 58% to 84% [67]. 
1.1.3.2 Introduction of targeted therapies 
Targeted therapies are constantly being developed, and some have already been 
integrated into IBC treatment regimens [4]. The targeted approach is beneficial because 
in comparison to systemic chemotherapy, drug specificity toward certain molecular 
aspects of the disease results in lower systemic toxicity and high anti-tumoral efficacy.  
Hormonal therapy targets ER and PR positive tumors, which require estrogen to 
survive and grow; the most commonly used hormonal therapies are the ER antagonist 
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tamoxifen, aromatase inhibitors (AI), which block the synthesis of estrogen, and ovarian 
ablation, which blocks estrogen production at the primary source [68].  In a recent study 
of 100 patients with non-metastatic IBC, those who received hormone therapy in 
addition to chemotherapy showed improvement in 3 year disease-free and overall 
survival rates [69]. However, a large proportion of IBC cases are negative for the 
hormone receptors and thus resistant to this strategy. 
Trastuzumab (Herceptin) is a humanized monoclonal antibody that targets 
ErbB2/Her2 and is commonly used in combination with chemotherapy for Her2 positive 
IBC patients, which make up a large percentage of the IBC population. Mechanisms of 
action include inhibition of Her2-mediated PI3K/Akt and MAPK signaling, induction of 
cell cycle arrest through induction of the cyclin-dependent kinase (CDK) inhibitor p27,  
induction of apoptosis, inhibition of angiogenesis, promotion of immune targeting via 
the antibody-dependent cellular cytoxicity (ADCC) response, and inhibition of DNA 
repair mechanisms [70]. Addition of anti-Her2 therapy to the chemotherapeutic regimen 
has been noted to improve pCR rates in IBC patients; a study in 76 Her2 positive IBC 
patients found a 54.8% pCR rate in patients receiving the standard doxorubicin, 
paclitaxel, cyclophosphamide chemotherapy plus trastuzumab compared to a 19.3% 
pCR rate in patients receiving the same chemotherapeutic regimen without trastuzumab 
[71]. However, the majority of patients who achieve an initial response to trastuzumab-
based regimens generally acquire resistance within 1 year [72, 73]. 
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Lapatinib (Tykerb) is a dual tyrosine kinase inhibitor that blocks PI3K/Akt and 
MAPK signaling through ErbB1/EGFR and ErbB2/Her2 [74]. Over the years, alternative 
mechanisms for lapatinib anti-tumor efficacy have been discovered. Xia et al. found that 
ErbB2 regulates expression of the anti-apoptotic protein survivin, and that lapatinib 
efficacy is associated with inhibition of survivin [75]. Additionally, lapatinib was found 
to reverse multidrug resistance through inhibition of drug transporters including the 
ABC subfamily members ABCB1 and ABCG2, P-glycoprotein (Pgp), and breast cancer 
resistance protein (BCRP) [76, 77]. A recent study in our lab determined that lapatinib 
mediates oxidative stress-induced apoptosis in IBC cells [78]. Clinically, lapatinib has 
shown anti-tumoral efficacy; one study reported 50% clinical response (CR) in Her2-
overexpressing patients; the expression of phosphorylated Her2 and Her3 predicted a 
favorable response to treatment, while response was low in EGFR+/Her2- tumors [79]. A 
more recent study incorporating lapatinib and paclitaxel showed a stronger response for 
the combination, with a 78.1% CR rate for patients with Her2 overexpression [80]. 
However, the efficacy of lapatinib is limited by the development of acquired resistance, 
which commonly occurs within 12 months of starting lapatinib therapy, even in patients 
who initially respond well to treatment [81]. 
The angiogenic process has also seen recent attention in the development of new 
targeted therapies. Bevacizumab is a human monoclonal antibody targeting VEGF 
which has shown efficacy in IBC; a clinical study combining bevacizumab with 
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chemotherapy showed a 67% response rate in 20 IBC patients, which was associated 
with reduction in phosphorylated VEGFR2 [82].  The small molecule inhibitor of 
VEGFR2 semaxinib has also been investigated for use in IBC patients; however, 
toxicities toward the cardiac system when used in combination with doxorubicin 
prevented further investigation [83]. Another angiogenesis inhibitor called pazopanib 
was recently studied in a Phase II trial with lapatinib in Her2 positive IBC; the overall 
response rates were improved from 47 and 31% with lapatinib or pazopanib 
monotherapy to 58% with the combination. However, single agent pazopanib and the 
combination were both associated with toxicities that resulted in increased patient 
discontinuation due to adverse effects [84].  
The GTP-ase RhoC, a member of the Ras superfamily, has been found to be 
overexpressed in IBC as is associated with the highly metastatic phenotype [85]. 
Farnesyl transferase inhibitors (FTIs) have been investigated in preclinical models of IBC 
as a way to modulate RhoC expression and inhibit motility and invasion [86]. A recent 
clinical study combining the FTI tipifarnib with chemotherapy determined that 18% had 
a clinical complete response (compared to the historical rate of ~10-15% with 
chemotherapy) and 59% had a clinical partial response, yielding an overall clinical 
response rate of 77% [87]. 
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1.1.4 Unmet needs for the disease 
Despite significant advances in multimodality treatment which have greatly 
improved patient survival, most patients ultimately experience recurrence and succumb 
to the disease. For this reason, it is essential IBC research continues, with focuses on 
understanding the basic biology of this disease as well as the development of new 
therapies. 
1.1.4.1 Increased IBC awareness and refinement of diagnostic parameters  
One reason that patient prognosis is so poor for IBC patients is the fact that most 
patients have already progressed to Stage IIIb  or Stage IV by the time of diagnosis. This 
is in part due to the rarity of the disease; patients often have never heard of it, and 
doctors may never have seen a case before. Increased patient awareness would decrease 
the “wait and see” approach when some of the early symptoms arise, compelling 
patients to seek medical help as soon as possible. Additionally, the current diagnostic 
approach for IBC is very subjective, with much emphasis placed on physical symptoms, 
which can vary significantly from patient to patient. Improved diagnostic parameters 
would allow physicians inexperienced with IBC to diagnose it rapidly, saving precious 
time during which cancer progression occurs in the absence of treatment. While 
standard multimodality therapy shows some efficacy in treating primary IBC, there is no 
standard of care for metastatic disease, and the associated prognosis is especially dismal 
 18 
[3]. Thus, detection of the cancer before it has the opportunity to metastasize to other 
organs could significantly improve patient survival rates.  
1.1.4.2 Identification of molecular targets that contribute to IBC’s highly aggressive 
nature and development of strategies to target these pathways 
As discussed in Section 1.1.2, several molecular features that contribute to IBC 
pathogenesis have been identified. These factors provide targets for the development of 
novel therapies against IBC. Some examples of these are already used clinically, 
including the ErbB2-targeting agents trastuzumab and lapatinib, and the anti-estrogens 
tamoxifen and AIs. Other potential molecular targets for anti-IBC therapy that have been 
investigated include p53 mutation, E-cadherin overexpression, and hyperactivation of 
NF-κB.  
Gene therapy to restore wildtype p53 function has shown success in breast 
cancer; one clinical study of Ad5CMV-p53 (Advexin) in combination with chemotherapy 
observed a partial CR in all patients, which was attributed to increased chemotherapy-
related apoptosis due to effective wt-p53 gene transfer and expression as well as 
activation of a local immune response directed against the gene-transduced cancer cells 
[88]. Preclinical data show that anti-E-cadherin treatment reduces tumorigenicity and 
emboli formation in IBC xenografts [89]. The proteasome inhibitor bortezomib, which 
blocks NF-κB activity, has been tested in combination with capecitabine in patients with 
metastatic breast cancer and showed moderate anti-tumor activity, with a 15% response 
rate and 40% stable disease [90].  
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The combination of pre-clinical studies in IBC and clinical studies in LABC 
suggest that these therapies might be effective against clinical IBC; however, none of 
these treatments has been tested in IBC patients as of yet [2]. The development of clinical 
trials to treat IBC patients with novel potential therapeutics like these will allow for the 
expansion of current IBC treatment regimens to include specific targeting of 
pathogenesis factors which may improve survival rates similar to the way that ER- and 
Her2-targeted therapies have. Additionally, further characterization of the basic biology 
of IBC in in vitro and animal models will elucidate other molecular determinants and 
pathogenesis factors that may prove to be viable therapeutic targets.  
1.1.4.3 Development of drugs targeting therapeutic resistance mechanisms 
While Her2-targeting agents have shown promise in IBC clinical trials, most 
patients develop acquired resistance within 12 months of starting therapy [72, 73, 81]. 
Therefore, studies to identify the mechanisms of trastuzumab and lapatinib resistance in 
IBC are needed in order to provide a durable response for patients.  
Trastuzumab resistance has been extensively studied in many different breast 
cancer models and cohorts of patient samples. Noted trastuzumab resistance 
mechanisms include expression of the truncated, constitutively active p95-Her2 receptor 
[91, 92]; epitope masking by membrane-associated Muc4 [93] or a CD44/hyaluronan 
complex [94]; Her2-independent activation of downstream signaling via loss of the 
PI3K/Akt inhibitor PTEN [95] or activating mutations in PI3K [96, 97] or Akt [98]; co-
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expression of the insulin-like growth factor IGF-1R [99, 100]; and downregulation of the 
CDK inhibitor p27 [101, 102]. A recent study in our lab was the first to examine 
trastuzumab sensitivity in an IBC model; this revealed that upregulation of the IAPs X-
linked inhibitor of apoptosis protein (XIAP) and survivin in response to treatment was 
associated with resistance [103].  
Although both agents target the Her2 pathway, resistance mechanisms to 
lapatinib are mostly distinct from those against trastuzumab. For example, loss of PTEN 
and PI3K mutations do contribute to lapatinib resistance [104-106], and expression of 
truncated p95-Her2 [92, 107, 108] and IGF-1R [109] are also unrelated.  One reported 
mechanism of lapatinib resistance was elucidated in two non-IBC Her2-overexpressing 
models of breast cancer (BT474 and SKBR3). In these models, resistance is mediated by 
derepression of the FOXO3A forkhead box TF, which is negatively regulated by the 
PI3K/Akt pathway, as a result of Her2/PI3K/Akt inhibition by lapatinib. This promotes a 
switch from Her2 to ER signaling and induces upregulation of the anti-apoptotic protein 
survivin. This mechanism was confirmed in patient biopsies, in which some Her2 
positive LABC tumors treated with lapatinib showed activation of FOXO3a and 
increased expression of ER and its gene products [81, 110]. Further study of the same 
lapatinib-resistant models revealed activation of a cytoprotective stress response 
mediated by the NF-κB family member RelA, which controls transcription of the IAPs; 
inhibition of RelA overcame therapeutic resistance, and examination of clinical 
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specimens revealed significant differences in p-RelA expression in lapatinib responders 
and non-responders, corroborating the in vitro findings [111]. Another model of 
lapatinib resistance in Her2-overexpressing breast cancer cell lines also indicated that 
resistance was mediated through NF-κB signaling [112]. Lapatinib resistance in a cell 
line model of colorectal cancer was determined to be the result of modulation of 
members of the Bcl-2 family of apoptosis-regulatory proteins; expression of anti-
apoptotic Mcl-1 was increased in the resistant cells concurrent with a reduction in pro-
apoptotic Bak and Bax protein activation [113]. These studies highlight the importance 
of the apoptotic pathways in lapatinib resistance mechanisms, although none were 
conducted in IBC models.  
Development of two IBC models of acquired therapeutic resistance to lapatinib 
in our lab supports the involvement of apoptotic factors in lapatinib resistance. Acquired 
resistance in Her2-overexpressing (SUM190) and EGFR-activated (SUM149) IBC cell 
lines was associated with the upregulation of XIAP, and ectopic expression of XIAP in 
the parental cell lines reversed lapatinib sensitivity [114]. Further examination of the 
resistant cell lines revealed overexpression of antioxidant enzymes superoxide 
dismutase (SOD) 1/2 and an increase in cellular GSH; again, exogenous addition of 
antioxidants was able to reverse lapatinib sensitivity in the parental lines, revealing a 
novel mechanism of resistance in IBC [78]. These results suggest a multifactorial 
resistance mechanism and indicate that in addition to the apoptotic response, redox 
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modulation may be important to consider for therapies aimed at restoring lapatinib 
sensitivity.  
Because Her2-overexpressing and EGFR-activated tumors make up the bulk of 
the IBC patient population, strategies aimed at enhancing therapeutic response to these 
targeted agents has the potential for significant clinical improvement. Development of 
novel therapeutics or identification of agents that may repurposed for combination with 
trastuzumab or lapatinib to provide a durable response for patients with IBC would be 
highly beneficial for the patient population [3].  
1.2 Apoptotic Dysregulation and Therapeutic Resistance in 
Cancer 
1.2.1 Overview of apoptosis 
Apoptosis is a tightly controlled form of programmed cell death with a large 
number of modulatory factors; failure of those internal regulatory mechanisms promotes 
pathological conditions from autoimmunity to cancer [115]. Because apoptotic 
dysregulation is a key factor in IBC (detailed in Section 1.1.2.6), this section introduces 
apoptotic cell death and mechanisms by which the process can become dysregulated. 
1.2.1.1 The apoptotic pathways  
The caspase enzymes are a family of cysteine proteases activated by proteolytic 
cleavage [116] that act as the executioners of apoptotic cell death. Caspases cleave 
specific substrates, resulting in the hallmarks of apoptosis including cell shrinkage, 
membrane blebbing, chromatin condensation, and DNA fragmentation [115, 117]. 
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There are two main pathways by which apoptosis occurs. The intrinsic, or 
mitochondrial pathway, is activated in response to internal stimuli including oxidative 
stress, DNA damage, and cytokine or nutrient deprivation, as well as stress induced by 
gamma irradiation and many chemotherapeutics [118, 119]. Activation of BH3-only 
proteins (Bid, Bad, and Bim) liberates Bak and Bax proteins from anti-apoptotic Bcl-2 
family members. These oligomerize and insert into the mitochondrial membrane to 
promote mitochondrial outer membrane permeabilization (MOMP), allowing efflux of 
cytochrome c and second mitochondrial activator of caspases (Smac/DIABLO). 
Cytochrome c binds to apoptotic protease activating factor 1 (Apaf-1) to form the 
apoptosome, which recruits and activates pro-caspase-9 [115, 120]. The extrinsic, or 
death receptor (DR)-mediated pathway, is activated by the binding of extracellular 
ligands to DRs on the cell surface including TNF-TNFR1/2, Fas ligand-Fas/CD95, and 
TNF-α-related apoptosis-inducing ligand (TRAIL)-DR4/5. This recruits the Fas-
associated protein with death domain (FADD) adaptor protein and pro-caspase-8 to 
form the death inducing signaling complex (DISC), which promotes activation of 
caspase-8 [115, 121]. The intrinsic and extrinsic pathways converge on the activation of 
effector caspases-3 and -7 by caspase-8 or -9. A summary of the apoptotic pathways can 




Figure 1.1: The apoptotic pathways 
Adapted from [122]. 
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1.2.1.2 Negative regulators of apoptosis 
The Bcl-2 family is made up of over 20 proteins, all of which contain at least one 
Bcl-2 homology (BH) domain. Anti-apoptotic members include Bcl-2, Bcl-xL, Bcl-w, and 
Mcl-1; there are two groups of pro-apoptotic proteins: the BH3-only subfamily including 
Bim, Bid, Bad, Bmf, Noxa, and Puma, and the Bax subfamily, composed of Bax, Bak, and 
Bok [123]. Anti-apoptotic Bcl-2 proteins guard mitochondrial integrity and block 
apoptosis through the intrinsic pathway by interacting with pro-apoptotic members of 
the BH3-only subfamily [119, 124].  
The IAPs are a family of caspase inhibitors that includes cellular IAP1/2 
(cIAP1/2), XIAP, livin/melanoma IAP (ML-IAP), IAP-like protein 2 (ILP2), neuronal 
apoptosis-inhibitory protein (NAIP), Bruce/Apollon, and survivin [116]. IAPs can inhibit 
both intrinsic and extrinsic apoptotic pathways, suggesting they are potentially more 
potent apoptotic inhibitors than the Bcl-2 family [123]. IAPs are characterized by 1-3 
baculovirus IAP repeat (BIR) motifs, and cIAP1/2, XIAP, ILP2, and livin/ML-IAP also 
contain a really interesting new gene (RING) domain which functions as an E3 ubiquitin 
ligase [125]. The IAPs bind to caspases through their BIR domains, although only XIAP 
can potently inhibit caspase activity through direct binding [126-128]. Some IAPs can 
ubiquitinate caspases to promote their inactivation or proteasomal degradation [129-
134], and apoptogenic Smac/DIABLO is sequestered or targeted for degradation through 
ubiquitination by IAPs [131, 134-138]. IAPs can also ubiquitinate proteins such as the 
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TNF receptor-associated factors (TRAFs), receptor-interacting protein kinases (RIPKs), 
and NF-κB-inducing kinase (NIK) to mediate signaling [134, 135].  
1.2.2 Dysregulation of apoptosis in cancer 
Dysregulation of apoptosis can lead to disease, and the ability to evade apoptotic 
cell death is one of the hallmarks of cancer [58]. Mechanisms by which cancer cells 
achieve apoptotic dysregulation are detailed below. 
1.2.2.1 Dysregulation of p53 and the mitochondrial pathway 
The tumor suppressor p53 is a major mediator of the intrinsic apoptotic pathway. 
p53 loss or inactivation is a common event in human cancers; apoptotic stimuli induce 
p53-mediated upregulation of pro-apoptotic factors including Bcl-2 family members 
Bax, Bid, Noxa, and Puma. Cancer cells that have lost this p53-mediated response are 
thus desensitized to apoptosis associated with DNA damage and rendered insensitive to 
chemotherapy [124, 139, 140]. As p53 induces the intrinsic apoptotic pathway, defects in 
the activators of this pathway are associated with apoptotic dysregulation even in p53-
competent cells [124]. Both loss of Apaf-1 expression and plasma membrane 
sequestration of Apaf-1 have been reported as mechanisms of chemoresistance [141-143]. 
1.2.2.2 Dysregulation of caspases 
Inactivation of caspases can cripple the apoptotic response. Loss of pro-caspase-3 
expression has been observed in breast cancer cells and results in resistance to some 
apoptosis-inducing treatments [115]. Downregulation of pro-caspase-3 expression levels 
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has also been shown to correlate with progression of gastric carcinoma and gastric 
lymphoma [144]. Hypermethylation of caspase-8 regulatory sequences resulting in 
reduced caspase-8 expression is associated with therapeutic resistance in a number of 
tumor cell lines and primary tumors [145]. Caspase-8 is frequently inactivated through 
gene deletion or DNA methylation in neuroblastomas and medulloblastomas, where it 
confers resistance to apoptosis and is a negative prognostic factor [146-149]. Caspase-8 is 
frequently silenced in small cell lung cancer (SCLC) tumors (79% of tumors tested) and 
cell lines, usually by aberrant promoter methylation. Inactivating point mutations in 
caspase-8 have also been associated with increased resistance to apoptosis [150, 151].  
1.2.2.3 Dysregulation of death receptors and DISC components 
DR pathways are downregulated in many tumors; Fas/CD95 expression is 
decreased in hepatocellular carcinomas and melanomas, and deletions or mutations in 
DR4/5 have also been observed in some cancers [141]. DISC components including DR5, 
FAS/CD95 and FASL are frequently lost in SCLC, which is associated with resistance to 
TRAIL-induced apoptosis [152, 153]. Additionally, expression of soluble DRs that act as 
decoys for death-inducing ligands can block extrinsic apoptosis. Soluble Fas/CD95 has 
been found in several cancer types, with elevated levels associated with poor prognosis 
[154-156]. Loss of CD95- or TRAIL-mediated apoptosis contributes to immune evasion, 
facilitating tumor metastasis [157].  
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Absence of the FADD adaptor protein, which helps to mediate caspase-8 
activation by the DISC, has also been observed in human malignancies.  A study of 70 
acute myeloid leukemia (AML) patients found that leukemic cells from two thirds of 
patients expressed low or no FADD protein; this was an independent prognostic factor 
for poor response to chemotherapy in terms of remission rate and survival [158]. 
Overexpression of c-FLIP, a negative regulator of caspase-8 activity, has been reported 
in a number of human cancers [159] and renders many types of cancer cells resistant to 
DR-mediated apoptosis [160, 161]. c-FLIP expression is inversely correlated with TRAIL 
sensitivity in prostate cancer cells [162], and expression was associated with higher 
tumor stage and shorter survival times in colorectal carcinoma [163].  
1.2.2.4 Dysregulation of the Bcl-2 family 
The Bcl-2 family members are commonly dysregulated in human cancers. A 
chromosomal translocation that results in Bcl-2 upregulation is responsible for more 
than 50% of all non-Hodgkin’s lymphomas (NHL) [115, 164], and elevated Bcl-2 levels 
have been found to correlate with chemoresistance and poor prognosis in patients with 
hematopoietic malignancies [165, 166]. Overexpression of Bcl-2 in MCF7 breast cancer 
cells is associated with enhanced resistance to TNF-α [167], and upregulation of Bcl-2 
expression in metastatic breast cancer cells mediates resistance to chemotherapy [168]. 
Increased expression of Bcl-xL is associated with disease progression in colorectal and 
prostate cancers [169, 170], and a strong negative correlation was found between Bcl-xL 
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expression and sensitivity to standard chemotherapeutic agents in a panel of 60 cancer 
cell lines [171]. Increased expression of Mcl-1 has also been linked to poor chemotherapy 
response [172, 173]. 
As an alternative to increased expression of anti-apoptotic proteins, reduced 
expression of pro-apoptotic members can also enhance cell survival. Inactivating 
mutations of pro-apoptotic Bax are observed in several types of cancer [174-177], and 
reduction in Bax expression and/or the Bax:Bcl-2 ratio is associated with poor prognosis 
in chronic lymphocytic leukemia, colon, and gastric cancers [166, 178, 179]. Bax 
downregulation is also associated with poor response to chemotherapy and shortened 
survival in women with metastatic breast cancer [180].  
1.2.2.5 Dysregulation of the IAPs 
Many tumors have high expression of IAPs, which is associated with poor 
prognosis [181]. Though survivin is not found in normal adult tissues, it is highly 
expressed in many human cancers including lung, colon, pancreas, prostate, and breast 
[182-184]. Survivin expression has been associated with a significantly reduced 5 year 
survival rate in colon cancer patients [185] and poor prognosis in gastric cancer and 
neuroblastoma [186-188]. Amplification of the chromosome region that encompasses 
cIAP1 and cIAP2 has been observed in several cancers [189] and is regularly associated 
with cIAP1 overexpression in esophageal squamous cell carcinomas [190]. Upregulation 
of cIAP2 via chromosomal translocation is highly associated with marginal cell 
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lymphomas of the mucosa-associated lymphoid tissue [191, 192], and increased cIAP2 
expression in prostate cancer is associated with decreased relapse-free survival [193]. 
Overexpression of the IAP livin has also been associated with chemotherapy resistance 
in primary cultures derived from melanoma patient tissue, and expression correlates 
negatively with melanoma patient survival [194, 195].  
XIAP is the most potent IAP in part due to its unique ability to bind and 
suppress the activity of caspases directly [125, 161, 196]. XIAP also activates the 
PI3K/Akt signaling pathway and can participate in a pro-survival feedback loop by 
promoting the activity of its transcriptional regulator NF-κB [197, 198]. XIAP-mediated 
ubiquitination of copper metabolism Murr1 domain-containing protein 1 (COMMD1), a 
negative regulator of NF-κB activity, further promotes survival signaling through this 
pathway [199]. Overexpression of XIAP has been reported in many different types of 
cancer and has been associated with unfavorable response to chemotherapy [200-204], 
resistance to TRAIL [205], lymph node metastasis [206], poor tumor differentiation [207, 
208], increased risk of relapse and metastasis [203, 209, 210], and shortened survival 
[200-202, 211-214]. XIAP expression correlates positively with tumor stage and 
pathological grade of breast, colorectal, and laryngeal carcinomas [215-217], suggesting a 
role of XIAP in disease progression.  Increased XIAP expression in melanomas 
compared to benign nevi, with even higher expression in metastases, indicate that XIAP 
may also be involved in regulating the metastatic process [204]. 
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1.2.3 Apoptotic dysregulation in IBC 
As mentioned in Section 1.1.2.6, analysis of the molecular characteristics of IBC 
has revealed that apoptotic dysregulation is a relevant feature that separates IBC from 
LABC. IBC tumors show enhanced NF-κB activation compared to non-IBC tumors [18, 
32-34], and a number of anti-apoptotic genes are transcriptionally activated by NF-κB 
including Bcl-2, Bcl-xL, cIAP1/2, XIAP, survivin, and TRAF1/2 [35]. The IAPs have also 
been reported to promote NF-κB activation, suggesting the presence of an anti-apoptotic 
feedback loop between the two [197, 218, 219]. Bertucci et al. determined that the anti-
apoptotic genes defender against apoptotic cell death (DAD1), which encodes a protein 
that interacts with Mcl-1 [220], and ALS2CR2, which encodes the ILP-interacting protein 
(ILPIP) that interacts with XIAP to inhibit apoptosis via activation of c-Jun terminal 
kinase (JNK) [221], are upregulated in IBC relative to non-IBC [222]. Another gene 
profiling study discovered differential expression of the pro-apoptotic protein Bax in 
IBC patient samples compared to other types of breast cancer [223]. Iwamoto et al. found 
that genes associated with the apoptosis pathways were overexpressed in a subset of 
IBC tumors compared with non-IBC cancers of the same receptor phenotype [224]. A 
recent study of lapatinib resistance in IBC cell lines determined that the E3 ligase MDM2 
inhibits apoptosis via ubiquitination and destabilization of p53 and the apoptosome 
activator CAS; MDM2 also ubiquitinates the E3 ligase HUWE1, blocking its inhibitory 
effects on the anti-apoptotic Mcl-1 protein to promote survival [225]. Our own studies in 
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IBC cell line models revealed that the anti-apoptotic proteins survivin and XIAP mediate 
resistance to Her2 targeted therapies trastuzumab and lapaitnib [103, 114]; together, 
these data highlight the importance of apoptotic dysregulation in IBC pathogenesis and 
indicate that therapies aimed at restoring normal function to the apoptotic pathways 
could benefit patients with IBC. 
1.3 Oxidative Stress, Redox Adaptation, and Therapeutic 
Resistance in Breast Cancer 
Recent studies in our lab indicate that redox adaptive mechanisms may play a 
role in acquired therapeutic resistance in IBC cell line models (discussed in detail in 
Section 1.4.2) [78]. Thus, thus section will provide an overview of oxidative stress and 
redox adaptation, as well as their roles in therapeutic resistance and sensitivity. 
1.3.1 Reactive species are required for normal cell function 
Although ROS are generally thought of as damaging to cells due to their ability 
to induce oxidative stress at high concentrations, low levels of ROS that act as second 
messengers in signaling cascades are essential for cellular responses to external stimuli 
[226]. Due to their high reactivities that preclude substrate specificity, most reactive 
species are not considered second messengers; however, the enzymatic production and 
degradation of H2O2, along with its preferential reactivity toward protein thiols make it 
a second messenger [227]. H2O2 oxidizes cysteine residues to relay signals, and substrate 
specificity is derived from the fact that not all cysteines are susceptible to H2O2-mediated 
oxidation. Most cysteine residues in the cell have pKas that are too high for H2O2 to react 
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with, but some exist as thiolate anions due to nearby charged amino acids and thus have 
low pKas [226, 228]. Protein tyrosine phosphatases (PTPs), whose function is the 
removal of phosphate groups from substrates, contain an active site cysteine with low 
pKa. Oxidation of cysteine residues in the catalytic domain of PTPs by H2O2 results in 
reversible inactivation, temporarily promoting a phosphorylated state for proteins in the 
vicinity [226, 228]. Oxidative inactivation of the PTP PTEN promotes activation of 
PI3K/Akt signaling [226, 229]. PTP inactivation plays an important role in cellular 
response to growth factors; binding of ligands like platelet-derived growth factor 
(PDGF) and epidermal growth factor (EGF) to receptors produces a burst of ROS that 
inactivates PTPs; blockage of that production inhibits normal signaling [230]. Binding of 
other ligands including bFGF, transforming growth factor β (TGF-β), and angiotensin II 
also elicits production of H2O2 to mediate downstream signaling events [226, 231].  
ROS activate a number of cellular signaling pathways that regulate growth, 
proliferation, stress responses, and apoptosis, including the MAPKs. H2O2 promotes p38 
and JNK MAPK signaling by relieving the inhibition of their activator ASK1 by Trx [227, 
232]. H2O2 also modulates extracellular-reguated kinase (ERK) 1/2 signaling by inducing 
autophosphorylation of growth factor receptors such as EGFR and PDGF, which 
activates Ras and Raf/MEK/ERK [232-234]; alternatively, activation of Ras via oxidation 
can achieve the same effects [235, 236]. Wnt/β-catenin signaling is activated by H2O2 
through oxidation of the Trx-like protein nucleoredoxin (Nrx), which binds Dishevelled 
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(Dvl) to suppress Wnt signaling under normal conditions. Nrx oxidation releases Dvl, 
resulting Wnt/β-catenin activation [226, 237]. Generation of H2O2 following cell 
attachment to the extracellular matrix results in oxidation of cysteine residues to activate 
the tyrosine kinase Src [238, 239]. 
ROS also mediate signaling through modification of redox-sensitive TFs such as 
NF-κB, HIF-1, p53, and AP-1; these contain cysteine residues in their DNA-binding 
domains that render them susceptible to activation by oxidative modification [238]. The 
TF nuclear factor (erythroid-derived 2)-like 2 (Nrf2) can also be activated by ROS via the 
oxidation of its negative regulator Keap1 [226, 240]. Thus, ROS are important for 
activation of signaling cascades that are essential for normal cell function. 
1.3.2 High levels of ROS can be damaging to cells 
Oxidative stress occurs when there is an imbalance between the levels of ROS 
within the cell and the antioxidant systems responsible for detoxifying ROS. While low 
to moderate doses of ROS are required for the propagation of cellular signals, high levels 
of ROS can damage cells through interactions with critical cellular components.  
ROS promote mutagenesis through modifications of bases, the deoxyribose 
backbone, DNA strand breaks, and cross-linking to other molecules [241]. If the cells are 
allowed to survive and divide, those genomic alterations can promote oncogenesis 
(discussed in Section 1.3.3) [242]. However, high levels of irreparable damage to the 
genome promote cell death. DNA damage most commonly activates the intrinsic, or 
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mitochondrial, apoptotic pathway through the tumor suppressor p53 [243]. In addition 
to nuclear DNA, mitochondrial DNA (mtDNA) is a critical cellular target for oxidative 
damage [244]. mtDNA is especially susceptible to ROS due to its close proximity to the 
electron transport chain (the major source of cellular free-radical production) and lack of 
protective histones. Damage to mtDNA could lead to lethal cell injury through the loss 
of electron transport, mitochondrial membrane potential, and ATP generation [241].  
Proteins are also sensitive to oxidative stress, which can result in oxidation of 
sulfhydryl groups, oxidative adducts on amino acid residues, reactions with aldehydes, 
protein-protein cross-linking, and protein fragmentation [241, 245]. Oxidation of amino 
acids promotes the formation of protein carbonyls, which alter protein structure and 
promote unfolding; this is associated with enhanced proteolytic degradation [241].  Due 
to the vital role of proteins in regulating cell signaling, cell structure, and enzymatic 
processes like metabolism, their oxidation rapidly contributes to oxidative stress [246].  
Lipid peroxidation results in the conversion of unsaturated lipids to polar lipid 
hydroperoxides [247]; this process causes increased membrane fluidity, efflux of 
cytosolic solutes, and loss of membrane–protein activities. Extensive lipid peroxidation 
correlates with the ultimate disintegration of membrane integrity and cell death [248]. 
Additionally, products of lipid peroxidation including malondialdehyde (MDA) and 4-
hydroxy-2-nonenal are themselves reactive and promote DNA degradation, further 
damaging the cell [248]. 
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1.3.3 ROS can promote oncogenesis 
As mentioned in Section 1.3.2, ROS can react with cellular and mitochondrial 
DNA, promoting the acquisition of mutations. Oxygen radicals react with DNA bases to 
produce a variety of adducts [249], which can result in mutations, deletions, gene 
amplification, and rearrangements [250]. Changes in the cellular DNA sequence can 
activate proto-oncogenes or inactivate tumor suppressor genes, both of which contribute 
to tumorigenesis. DNA damage as measured by levels of oxidative DNA lesions (8-
hydroxydeoxyguanosine, 8-OHdG) has been noted in various tumors types [242]. While 
there are mechanisms to repair DNA lesions, defects in cell cycle arrest and apoptosis 
(such as p53 mutation) allow for the propagation of cells with DNA mutations [251]. 
Because the mitochondria, which are the primary source of intracellular ROS [241], are 
heavily involved in maintaining genomic stability through functions in DNA replication, 
repair, and recombination, oxidative damage to the mitochondria promotes increased 
mutation rates and contributes to oncogenesis [252]. 
Despite their potential for cellular damage, ROS are often upregulated in cancer 
cells; their role in promoting certain signaling cascades is one reason for this adaptation 
[253]. The EGFR signaling pathway, which requires H2O2 for activation and downstream 
signaling, is central to breast cancer pathogenesis. EGFR is a major oncogenic factor that 
is associated with large tumors, poor differentiation, and has been reported to correlate 
with poor prognosis [29, 254, 255]. While EGFR is found in all breast cancer subtypes, it 
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is overexpressed more frequently in TN and IBC breast cancers, both of which are highly 
aggressive [29]. Downstream targets of EGFR signaling include PLC-γ/PKC, PI3K/Akt, 
Ras/Raf/ERK, and the STATs; activation of these pathways promotes proliferation, 
tumorigenesis, invasion and metastasis, and therapeutic resistance [29, 31]. The 
PI3K/Akt signaling pathway, also promoted by ROS, has been noted to be upregulated 
in breast cancer, where it: inhibits apoptosis by upregulating survival factors such as 
NF-κB and downregulating pro-apoptotic proteins [256, 257]; stimulates cell cycle 
progression; promotes cell growth and proliferation; and plays a role in EMT through 
upregulation of the transcriptional repressor of E-cadherin, Snail [256]. ROS-mediated 
Raf/Mek/ERK signaling inhibits apoptosis through the suppression of pro-apoptotic 
mRNAs and proteins like Bim and Bad and increased expression of anti-apoptotic 
proteins including Bcl-2, Bcl-xL, and Mcl-1 [258]. The Wnt/β-catenin pathway is also 
induced by ROS; this pathway supports EMT through induction of vimentin [259] and 
Snail [260, 261], which are associated with the mesenchymal state. Further, Wnt/β-
catenin signaling is positively correlated with expression of the stem cell marker CD44 
and mediates radiation resistance in mouse mammary progenitor cells [260, 262, 263]. 
Thus, many important signaling pathways that are central to oncogenesis and tumor 
progression are regulated by ROS. 
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1.3.4 Redox adaptation in breast cancer cells promotes resistance to 
anti-tumoral therapies 
Cancer cells are often characterized by increased levels of ROS due to aberrant 
metabolism, mitochondrial dysfunction, oncogene activation (c-Myc, Ras, Bcr-Abl), and 
loss of p53 [253]. In order to compensate for high levels of ROS, some cancer cells 
activate redox adaptive mechanisms [264]. Many anti-cancer regimens work at least in 
part through the generation of ROS, and thus may be rendered ineffective by redox 
adaptation. Chemotherapies including the anthracyclines (doxorubicin), taxanes 
(paclitaxel, docetaxel), alkylating agents, and platinum compounds (cisplatin, 
carboplatin) as well as radiation therapy all rely heavily on the induction of oxidative 
stress-induced apoptosis for their anti-tumor activities [235, 253, 265]; thus, redox 
adaptation confers resistance to many breast cancer therapies. 
1.3.4.1 Redox adaptation through increased ROS detoxification 
The ability to increase antioxidant function is essential for cancer cells with high 
ROS levels to return cellular redox status to normal. The concurrent elevation of markers 
of oxidative stress and increased expression and activity of antioxidants in breast cancer 
indicates redox adaptation. Due to their highly reactive nature, ROS are difficult to 
measure in tissue samples; as such, oxidative stress in tissue is often measured through 
quantification of oxidized cellular constituents including MDA, lipid hydroperoxides, 
and conjugated dienes (products of lipid peroxidation) [266] and 8-OHdG (a base lesion 
that results from DNA oxidation) [267].  
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Several groups observed increased levels of oxidative stress indicators 
accompanied by augmentation of SOD1/2, GSH, GPx, glutathione S-transferase (GST), 
and catalase expression and activity in breast cancer patient tissue in comparison to 
healthy controls [268-273]. Interestingly, the degree of increase in oxidative stress and 
antioxidant levels correlated with advanced disease, with greater increases in both 
observed in Stage III samples than in Stage I and II samples [271]; these findings support 
the role redox adaptive mechanisms in tumor progression. One study determined that 
GSH levels were increased by two fold in breast cancer tissue relative to normal breast, 
while tissue from lymph node metastases showed a four-fold increase in GSH over 
normal tissue [274]. Similarly, breast cancer brain metastases showed significant 
upregulation of GSH-associated enzymes glutathione reductase (GSR) and GST, which 
help them maintain a reduced cellular environment [275]. These observations indicate 
that redox adaptation is crucial for metastatic breast cancer, as metabolic pressures 
associated with a foreign environment can promote oxidative stress [276].  
GSH has long been recognized as having an important role in cancer drug 
resistance [277]; alterations in ROS-scavenging systems can have significant effects on 
the metabolism of alkylating agents and platinum compounds, inactivating electrophilic 
intermediates [235, 253]. Introduction of exogenous antioxidants GPx or SOD to MCF7 
cells is sufficient to induce therapeutic resistance to doxorubicin [278], and GPx mRNA 
and activity were also increased in MCF7 cells with acquired doxorubicin resistance 
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[279]. Antioxidants GST and SOD were also found to be elevated in tamoxifen-resistant 
MCF7 tumors in a xenograft study, indicating a role for antioxidants in resistance to 
targeted therapies [280]. Increased GSH was also associated with resistance to ROS-
inducing drugs in a mouse model of breast cancer brain metastasis; upregulation of GSH 
in response to bortezomib resulted in a 60-fold reduction in sensitivity of metastatic cells 
compared to parental cells [275]. Thus, redox adaptation via enhanced antioxidant 
capacity plays a vital role in mediating resistance to anti-cancer regimens, affecting both 
tumor response and patient prognosis. 
1.3.4.2 Redox adaptation through activation of redox-sensitive transcription factors 
Redox sensitive TFs including NF-κB, Nrf2, AP-1, and HIF-1α promote the 
expression of antioxidant molecules [253], and thus promote redox adaptation through 
the mechanisms described in Section 1.3.4.1. Some redox-sensitive TFs also induce 
expression of pro-survival and anti-apoptotic genes, which are also protective against 
oxidative stress [253, 281].   
 The Nrf2 TF is an important regulator of the oxidative stress response, 
modulating the transcription of genes with an antioxidant response element (ARE) [282] 
including antioxidants and phase II detoxifying enzymes [NADPH quinone 
oxidoreductase (NQO1), heme oxygenase 1 (HO-1), peroxiredoxin (Prx), Trx, GST, and 
GSH synthesis enzymes] and proteasomal and heat shock protein (HSP) genes, which 
prevent apoptosis via the misfolded protein response [283]. The GSH synthesis system is 
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under the transcriptional control of Nrf2, and tumor cell lines with acquired resistance to 
chemotherapeutic drugs often display abundant levels of GSH and Nrf2 activation [284, 
285]. In MCF7 cells, ROS induction and depletion of GSH activates Nrf2; upregulation of 
ARE genes restores cellular pools of GSH and protects against oxidative stress [286]. 
Nrf2 is an important prognostic factor in determining drug response in a number of 
cancer types [287]. In a panel of breast cancer cell lines, paclitaxel sensitivity correlated 
negatively with antioxidant capacity, and co-treatment with a Nrf2 inhibitor enhanced 
sensitivity [225]. Stabilization of Nrf2 in MCF7 cells resulted in resistance to H2O2, 
paclitaxel, and doxorubicin [288], and acquired resistance to doxorubicin in MCF7 cells 
was associated with high expression of Nrf2 and its target proteins [289].  Activation of 
Nrf2 in MCF7 cells with acquired tamoxifen resistance resulted in upregulation of 
antioxidants and was associated with reduced ROS production in resistant cells [290]. 
NF-κB activity is induced by oxidative stress [35, 37], and transcriptional target 
genes include antioxidants (SOD1/2, Trx, and the GSH-associated enzymes GPx, GST-pi, 
and γ glutamylcysteine synthetase) and anti-apoptotic proteins (Bcl-2, Bcl-xL, cIAP1/2, 
and XIAP) [35, 37]. These detoxify intracellular ROS and block oxidative stress-induced 
apoptosis, regulating the cellular response to an altered redox state at multiple levels. 
Constitutive activation of NF-κB is observed in many types of cancer [291] and can 
inhibit apoptosis induced by chemotherapy and ionizing radiation [285, 292].  Taxane-
resistant MCF7 cell line variants revealed consistitutive NF-κB activation, and inhibition 
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of NF-κB signaling reestablished sensitivity [293]. Constitutive activation of NF-κB is 
also associated with resistance to ER-targeting by tamoxifen and AIs [294, 295]. A 
cytoprotective stress response mediated by NF-κB subunit p65/RelA was found in breast 
cancer cell lines with acquired resistance to lapatinib, and these results were 
corroborated by analysis of biopsies from ErbB2 positive breast cancer patients receiving 
lapatinib monotherapy. Responders showed a median 40% decrease in p-RelA after 28 
days of treatment, while non-responders showed ~75% increase, supporting a central 
role for NF-κB in response to lapatinib therapy [111]. Examination of radioresistant 
variants of MCF7 cells revealed NF-κB-mediated upregulation of SOD2 and other genes 
that participate in radiation-induced adaptive responses; inhibition of NF-κB signaling 
decreased expression of target genes and sensitized cells to radiation [296]. Together, 
these data indicate that redox-sensitive TFs can induce a redox adapted state that 
promotes resistance to chemo-, targeted, and radiotherapies in breast cancer. 
1.3.4.3 Redox adaptation through activation of survival signaling and upregulation 
of anti-apoptotic factors 
Sustained oxidative stress promotes constitutive activation of survival signaling 
and upregulation of anti-apoptotic molecules; this promotes cell survival in response to 
oxidative stress such as that induced by anti-cancer drugs and radiotherapy. The 
PI3K/Akt pathway is activated in times of oxidative stress [226, 229] and promotes cell 
cycle progression and proliferation by modulating cell cycle regulators and controls cell 
death by inducing anti-apoptotic proteins and inhibiting pro-apoptotic molecules [256].  
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In a study of breast cancer cell lines, constitutive Akt activation was associated 
with cell survival, while treatment with a PI3K inhibitor enhanced sensitivity to a 
myriad of therapies including doxorubicin, paclitaxel, trastuzumab, and etoposide. 
Ectopic expression of constitutively active Akt renders MCF7 breast cancer cells 
insensitive to tamoxifen treatment [297] through Akt-mediated activation of NF-κB 
[298]. p-Akt positivity was associated with poor disease-free survival in breast cancer 
cases where patients received post-operative hormonal therapy [299]. Trastuzumab-
mediated activation of the phosphatase PTEN is required for drug sensitivity, rendering 
PTEN null cells resistant in in vitro and in vivo models. Response to trastuzumab was 
also poorer in patients with PTEN-deficient breast cancers than those with functional 
PTEN [95]. Introduction of constitutively active Akt confers radioresistance on MCF7 
cells [300], and endogenous constitutive activation of the PI3K/Akt pathway in BT-474 
cells is associated with resistance to radiation, supporting the importance of PI3K/Akt 
signaling in the determination of breast cancer susceptibility to therapy [301].   
ERK signaling promotes survival through upregulation of anti-apoptotic 
proteins and inhibition of pro-apoptotic molecules [258]. Evaluation of the activity of 
Raf-1, an upstream activator of the ERK cascade, in a panel of cancer cell lines revealed 
an inverse correlation between Raf-1 activity and doxorubicin sensitivity [302], while 
expression of constitutively active Raf-1 in MCF7 cells conferred resistance to 
doxorubicin and paclitaxel [295]. In a study of 109 patients with TN breast cancer, 
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overexpression of ERK correlated with anthracycline resistance and poor survival [302]. 
The ERK signaling pathway also plays a role in resistance to targeted therapies; in an 
MCF7-derived cell line model, acquired tamoxifen resistance was linked to increased 
ERK phosphorylation [290]. Tamoxifen inhibits ERK phosphorylation in parental cells, 
while cells with acquired resistance show increased ERK phosphorylation in response to 
treatment [303]. A clinical study found that patients with >1% ERK1/2 phosphorylation 
did not respond to tamoxifen, while patients without ERK1/2 phosphorylation did [304]. 
Upregulation of anti-apoptotic factors can mediate resistance against a wide 
variety of therapeutic mechanisms including oxidative stress; the Bcl-2 family has been 
implicated in resistance to a number of anti-cancer drugs. Bcl-2 modulation of 
mitochondrial respiration enhances GSH turnover in the cell to combat exogenous 
increases in ROS [305]. A study in breast cancer cell lines revealed that sensitivity to 
cisplatin and paclitaxel could be induced by knockdown of Bcl-2 or pre-treatment with a 
small molecule inhibitor. XIAP is the most potent member of the IAP family and has 
been linked with poor prognosis and therapy resistance in several cancer types [201, 207, 
208, 210-215]. In cell line models of TRAIL-resistant breast cancer, XIAP depletion 
overcame resistance; XIAP targeting with siRNA or a Smac mimetic also enhanced 
therapeutic response to ErbB antagonists trastuzumab, lapatinib, and gefitinib [306]. 
Another study in MCF7 cells revealed that Smac mimetics enhanced the apoptotic 
response to paclitaxel, doxorubicin, etoposide, and tamoxifen [307]. These data indicate 
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that increases in the expression and activity of anti-apoptotic proteins can protect breast 
cancer cells from therapeutic apoptosis induced by anti-cancer drugs.  
1.3.4.4 Interplay of redox adaptive mechanisms in therapeutic resistance 
While these redox adaptive mechanisms have each been discussed separately as 
mediators of therapeutic resistance, these factors interact with and modulate one 
another in many ways. The crosstalk between them results in greater resistance to 
oxidative stress than could be achieved by any one factor alone; indeed, some of these 
mechanisms could not function without the others. Activation of survival signaling 
pathways such as PI3K/Akt and ERK1/2 via H2O2 can activate redox-sensitive TFs such 
as Nrf2 and NF-κB. Many of the antioxidants discussed above are under the control of 
redox-sensitive TFs, and many anti-apoptotic proteins are also controlled by those same 
TFs [35-37, 308]. Enhancement of cellular antioxidant capacity likely could not occur 
without modulating the activities of the TFs upstream from them. Increased 
transcriptional activity of Nrf2 and NF-κB has also been linked with upregulation of 
survival pathway components, culminating in the activation of those pathways; for 
example, activation of NF-κB promotes the phosphorylation of Akt [309]. Additionally, 
some targets of the redox-sensitive TFs can modulate the transcriptional activity of their 
activators. Because IκB kinase (IKK) is a substrate of Akt, Akt activation can stimulate 
NF-κB activity, promoting a feedback loop between the two [197, 198, 310, 311]. It has 
also been shown that the anti-apoptotic protein XIAP, a target of NF-κB-mediated 
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transcription, can modulate the transcriptional activity of NF-κB via interaction with the 
TAB1 adaptor protein and TAK1 kinase [198]. 
Thus, redox adaptive mechanisms work in concert to regulate one another and 
participate in feedback loops, resulting in reduction of oxidative stress sensitivity. This 
confers resistance to drugs whose mechanism of action involve the generation of ROS 
and promotes the development of tumors that are highly refractory to therapeutic 
intervention. As such, redox adaptation represents a powerful therapeutic target for the 
development of new anti-tumoral agents for breast cancer. 
1.4 IBC Cell Line Models 
1.4.1 Patient-derived IBC models: SUM149, SUM190, and MDA-IBC-3 
Three primary patient-derived IBC cell lines were used in this dissertation: 
SUM149, SUM190, and MDA-IBC-3 (Fig. 1.2). SUM149 is a basal type cell line with 
EGFR/ErbB1 activation; absence of ER, PR, and ErbB2/Her2 qualify it as TN breast 
cancer [312, 313]. SUM149 cells have a short doubling time of 14-21 h and are enriched 
for cells with a CD44+/CD24-/low phenotype, which is associated with stem cell-likeness 
[114, 313]. SUM190 belongs to the Her2-overexpressing subtype and is also negative for 
ER and PR. SUM190 has a much slower doubling time than SUM149, at ~42 h and does 
not express a CD44+/CD24-/low population [312, 313]. Both SUM149 and SUM190 are 
characterized by p53 mutation [41]. MDA-IBC-3 is a cell line recently isolated from 
primary tumor cells in the pleural effusion of an IBC patient [314]. As a newer cell line, 
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less is known about MDA-IBC-3 cells; however, they are known to be Her2-
overexpressing and negative for ER and PR expression. They also have a very slow 
doubling time of approximately 76 h and, similar to SUM190, do not express a 
CD44+/CD24-/low population [313]. SUM149, SUM190, and MDA-IBC-3 cell line models 
represent the two most common subtypes of IBC: the basal, ErbB1/EGFR-activated 
subtype (SUM149), and the ErbB2/Her2-overexpressing subtype (SUM190, MDA-IBC-3). 
1.4.2 Models of acquired resistance in IBC: rSUM149 and rSUM190 
The rSUM149 and rSUM190 models of acquired therapeutic resistance were 
generated by Dr. Katherine Aird through continued exposure of parental SUM149 and 
SUM190 IBC cells to increasing concentrations of an analog of the ErbB1/2 inhibitor 
lapatinib analog (GW583340; Fig. 1.2). Initially, exposure of the parental lines to 
GW583340 resulted in massive cell death, but a few cells survived and grew out into 
colonies over a period of weeks following each increase in drug concentration. 
GW583340 concentration was continually increased over a period of ~3 months, after 
which the resistant lines- rSUM149 and rSUM190- were maintained in regular growth 
media supplemented with 7.5 and 2.5µM GW583340 respectively [114]. 
Examination of ErbB1/2 phosphorylation in the resistant rSUM149 and rSUM190 
cell lines revealed that the primary mechanism of action of lapatinib, inhibition of 
ErbB1/2 signaling, remained intact in these cells. Both p-ErbB1 (in rSUM149) and p-
ErbB2 (in rSUM190) levels, as well as downstream p-Akt, were reduced in the resistant 
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cells, similar to results in the parental SUM149 and SUM190 cells. Acquisition of 
resistance to lapatinib in the rSUM149 and rSUM190 cell lines was determined to be the 
result of overexpression of XIAP through an increase in IRES-mediated translation. 
Lentivirus-mediated overexpression of XIAP in parental SUM149 cells was protective 
against lapatinib-induced cell death, and targeting of XIAP with a small molecule 
inhibitor in rSUM149 and rSUM190 enhanced lapatinib response [114]. These studies 
reveal that apoptotic dysregulation via enhancement of XIAP translation/expression is a 
novel mechanism of lapatinib resistance in IBC and indicate that targeting of XIAP may 
be a rational strategy to enhance apoptosis and prevent or reverse lapatinib resistance. 
Further studies of the resistant cell lines revealed a novel mechanism of 
lapatinib-mediated cell death: the induction of oxidative stress. While lapatinib induced 
ROS at levels similar to the classical ROS-inducing agents paraquat and H2O2 in parental 
SUM149 and SUM190 cells, rSUM149 and rSUM190 cells maintained low levels of ROS 
in the presence of lapatinib. Additionally, the resistant cell lines were insensitive to ROS 
induction by H2O2 and paraquat and associated cell death. rSUM149 and rSUM190 cells 
showed a lack of AMP-activated protein kinase (AMPK) phosphorylation, a marker of 
oxidative stress [315] that was observed in the parental lapatinib-treated cells, in 
response to lapatinib. Interrogation of cellular antioxidant capacity revealed a redox 
adaptive mechanism mediated by upregulation of SOD1 and SOD2 in the resistant cells, 
as well as an increase in the cellular pool of GSH. Redox modulation with an SOD 
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inhibitor or pro-oxidant reversed the resistance of rSUM149 and rSUM190 to ROS-
mediated apoptosis, and addition of an exogenous antioxidant was protective against 
lapatinib in the parental SUM149 and SUM190 cells, confirming the importance of ROS 
generation for lapatinib-induced cell death [78]. These studies reveal a new mechanism 
for lapatinib-induced apoptosis and highlight a novel, redox adaptive response in 
rSUM149 and rSUM190 cells that is protective against cell death associated with the 
induction of ROS by a number of agents. 
Taken together, these studies indicate a multifactorial resistance mechanism in 
rSUM149 and rSUM190 cells by which apoptotic dysregulation and redox adaptation 
both contribute to reduced cell death in response to treatment. Identification of these 
mechanisms enhances the current understanding of lapatinib resistance in IBC and 
opens the door for new therapeutic strategies targeting these resistance mediators as a 
way to prevent or reverse resistance to therapy-mediated apoptosis.  
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Figure 1.2: IBC cell line models used in this dissertation 
*Generation and characterization of the rrSUM149 isogenic-derived cell line is detailed 
in Chapter 3. 
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1.5 Research Objectives  
The studies outlined here are intended to address our hypothesis that apoptotic 
dysregulation and redox adaptive mechanisms mediate the drug resistant phenotype in 
IBC cells (Fig. 1.3), and thus, targeting of these mechanisms can overcome therapeutic 
resistance. 
1.5.1 Objective 1 
 Development and characterization of an isotype-matched IBC cellular model to 
investigate the mechanisms of acquired therapeutic resistance (discussed in Chapter 3) 
1.5.2 Objective 2 
Characterization of IAP-specific small molecule inhibitors as a means of targeting 
the mechanism of apoptotic dysregulation in IBC therapeutic resistance (discussed in 
Chapters 4 and 5) 
1.5.3 Objective 3 
Characterization of a novel redox modulatory combination as a means of 




Figure 1.3: Hypothesis  
We hypothesize that apoptotic dysregulation and redox adaptive mechanisms mediate the drug 
resistant phenotype in IBC cells.
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2 Materials and Methods 
2.1 Cell Culture 
2.1.1 Cell lines and reagents 
SUM149 and SUM190 cells were obtained from Asterand, Inc. (Detroit, MI). 
MDA-IBC-3 cells were provided by Wendy Woodward at MD Anderson Cancer Center 
[314]. SUM149 and SUM190 cells with acquired resistance to lapatinib analog GW583340 
(referred to as rSUM149 and rSUM190) were selected by Dr. Katherine Aird by culturing 
cells in normal growth medium supplemented with increasing concentrations of 
GW583340 (0.25–7.5 and 0.25–2.5 μM, respectively) [114]. Initially, marked cell death 
and decrease in cell growth were observed in the cells. However, after 2 weeks of each 
increase in drug concentration, small colonies of viable cells were observed, which were 
cultured until confluence before the next increase in drug concentration. This was 
continued for a minimum of 3 months. From then on, both rSUM149 and rSUM190 cells 
were routinely cultured in normal media with addition of 7.5 and 2.5 μM GW583340, 
respectively. Stable SUM149 cells overexpressing wild-type XIAP (SUM149 wtXIAP) 
and SUM190 cells with XIAP knockdown via shRNA (SUM190 shXIAP) were also 
generated by Dr. Aird. A detailed account of their creation can be found in [114, 316]. 
Ham’s F-12 nutrient mixture was purchased from Gibco (Carlsbad, CA). DMEM 
was purchased from Mediatech (Herdon, VA). Insulin, hydrocortisone, HEPES, 
penicillin, streptomycin, ethanolamine, transferrin, sodium selenite, and epidermal 
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growth factor (EGF) were all purchased from Sigma Aldrich. (St. Louis, MO). FBS was 
from Thermo Fisher Scientific (Hyclone Labs, Logan, UT). SUM149 cells were routinely 
cultured in Ham’s F-12 nutrient mixture supplemented with 5 µg/mL insulin, 1 µg/mL 
hydrocortisone, 10 mM HEPES, 10 units/mL penicillin, 10 µg/ml streptomycin, and 5% 
fetal bovine serum. SUM190 cells were routinely cultured in Ham’s F-12 nutrient 
mixture supplemented 5 µg/mL Insulin, 1 µg/mL hydrocortisone, 5 mM ethanolamine, 
10 mM HEPES, 5 µg/mL transferrin, 10 nM triiodo thyronine, 50 nM sodium selenite, 10 
units/mL penicillin, 10 µg/mL streptomycin and 2% fetal bovine serum. 24 h after 
splitting, media was changed to serum-free conditions. MDA-IBC-3 cells were cultured 
in Ham’s F12 nutrient mixture supplemented with 10% FBS, 5 µg/mL insulin, 1 µg/mL 
hydrocortisone, 10 units/mL penicillin, and 10 µg/mL streptomycin. 
Research-grade lapatinib analog GW583340 was obtained from Tocris Bioscience 
(Bristol, UK), and TRAIL was obtained from Enzo Life Sciences (Farmingdale, NY). 
Dimethyl sulfoxide (DMSO), embelin, paraquat, TNF-α, disulfiram (DSF), copper 
sulfate, bathocuproine sulfonate (BCS), and tetrathiomolybdate (TM) were obtained 
from Sigma Aldrich (St. Louis, MO). The SOD mimic (MnTnHex-2-PyP5+) was obtained 
from Dr. Ines Batinic-Haberle at Duke University [317]. The Smac mimetics Birinapant 
and GT13402 were obtained from TetraLogic Pharmaceuticals (Malvern, PA). The 
MEK1/2 inhibitor U0126 was obtained from Cell Signaling Technologies (Danvers, MA). 
A TNF-α neutralizing antibody was purchased from R&D Systems (Minneapolis, MN), 
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and Q-VD-OPh pan-caspase inhibitor was purchased from Cal Biochem (Billerica, MA). 
All cell culture plates were acquired from Corning Incorporated (Corning, NY) unless 
indicated otherwise. The chemical structures for lapatinib, paraquat, Birinapant, 
embelin, and DSF can be found in Figure 2.1. 
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Figure 2.1: Chemical structure of drugs used in this thesis 
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2.1.2 Generation of resistance reversal IBC cell line model 
In order to generate the rrSUM149 cells (resistance reversal model), rSUM149 
cells were transferred to regular SUM149 growth media without GW583340 lapatinib 
analog, and cells were maintained in GW583340-free media for an extended period (~2 
months) prior to use in these studies. Cells were tested on a weekly basis for sensitivity 
toward GW583340 by trypan blue exclusion and 3-[4, 5-dimethylthiazol-2yl]-2, 5 
diphenyl tetrazolium bromide (MTT) assay, and interrogation of previously discovered 
resistance-associated proteins was performed by western immunoblot. 
2.1.3 shRNA-mediated knockdown of XIAP 
rSUM149 cells were seeded at 30,000 cells per well into a 12 well plate and 
allowed to adhere overnight. After 24 h, cells were transfected with a plasmid 
containing XIAP-targeting shRNA using Mirus TransIT-2020 transfection reagent (Mirus 
Biosciences, Madison, WI) according to manufacturer’s instructions. Treatments were 
applied 48 h post transfection for 24 h, and then cells were harvested for trypan blue 
exclusion assay. Effective knockdown was confirmed by western immunoblot analysis.  
2.1.4 shRNA-mediated knockdown of TNFR1 
SUM190 cells were seeded in 6 well plates at 150,000 cells per well and allowed 
to adhere overnight. After 24 h, either scramble control siRNA or TNF-α receptor 1 
(TNFR1) targeting siRNA at 100 nM was applied in the presence of Dharmafect 
transfection reagent (Thermo Scientific, Waltham, MA). Treatments were added the day 
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after transfection, and cells were harvested after 24 h for trypan blue viability staining 
and western immunoblotting to confirm knockdown. 
2.2 Determination of cell viability and proliferation  
2.2.1 Trypan blue exclusion assay 
Cell viability was determined by trypan blue exclusion assay. Cells were seeded 
in 6 well plates at 75,000 (SUM149 and derivatives) or 150,000 (SUM190 and derivatives, 
MDA-IBC-3) cells per well and allowed to adhere overnight. Cells were treated with the 
agents described for 24 h unless otherwise indicated. Then cells were trypsinized and 
resuspended in 1x DPBS. 10 µL of cell suspension was added to 10 µL 0.4% trypan blue, 
and 10 µL of the mixture was loaded onto a hemocytometer; cells were counted, and live 
and dead cell numbers were recorded. Percent viability was calculated as the number of 
live cells over the total number of cells. 
2.2.2 MTT assay 
Proliferation was determined via MTT (Sigma Aldrich, St. Louis, MO) assay. 
Cells were seeded in a 96-well plate and allowed to reach 70% confluence. Culture 
medium was aspirated and changed the day of treatment. After treatment with 
indicated agents, culture media was aspirated and MTT was added at a concentration of 
5 mg/mL. Cells were incubated at 37°C until the MTT reaction caused the formation of 
granulated purple coloration. DMSO was added to each well, and absorbance was read 
at 550 nm in a BioRad plate reader (Hercules, CA). 
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2.2.3 High-throughput MTT assay 
An automated method developed and conducted by Shalonda P. Ingram and Dr. 
Kevin P. Williams at North Carolina Central University was used to measure cell 
proliferation by MTT [318] adapted from a manual version of the assay previously 
described by us [319] in which cells were seeded into a 96-well plates and reagent 
additions were made utilizing multichannel pipettors. More details on this method can 
be found in Ms. Ingram’s graduate thesis and in this publication [320]. For the fully 
automated procedure, SUM149 or SUM190 cells were seeded at a density of 800 or 1000 
cells per well respectively (40 µL) in columns 3-24 of clear 384-well tissue culture plates 
using a Multidrop 384 (Thermo Fisher, Waltham, MA) bulk dispenser and allowed to 
adhere for 24 h. For quantitative high throughput screening (qHTS) drug screening 
studies, media alone was added to columns 1 and 2 as minimum signal controls. All 
subsequent aspiration and reagent addition steps were carried out using the Biomek NX 
workstation which was equipped with a plate stacker, bar code reader, and wash 
station. Intermediate dose response compound plates were generated separately and 
added to the cell plates, allowing dilution of compounds directly in 100% DMSO prior to 
adding media and avoiding potential solubility issues with carrying out serial dilutions 
in aqueous cell culture media. Culture medium was aspirated and the drugs from the 
intermediate plates added (20 µL) to the cell plate. Cells were then incubated for 72 h 
unless otherwise stated. 
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After incubation, culture media was aspirated and MTT (5 mg/mL) added to 
each well using the Biomek NX. Cells were incubated at 37°C for 4 h to allow formation 
of the colored formazan product. The reagent was aspirated using the Biomek NX and 
DMSO was added using the Multidrop.  Plates were incubated for a further 2 h and then 
absorbance was read at 550 nm in a SpectraMax Plus 384 plate reader (Molecular 
Devices, Sunnyvale, CA).  
2.2.4 TMRE flow cytometric staining 
Viability and cell injury were assessed using the mitochondrial membrane 
potential marker tetramethylrhodamine, ethyl ester, perchlorate (TMRE). Cells were 
treated with the indicated concentrations for 1 h, then harvested and incubated for 30 
min with 500 nM TMRE (Molecular Probes, Life Technologies, Grand Island, NY). Cells 
were washed twice with 1% BSA/PBS and analyzed for fluorescence by flow cytometry.  
2.2.5 Clonogenic growth assay 
Cells were plated in triplicate in 6 well plates at 250-500 cells/well (SUM149) or 
500-1000 cells/well (SUM190) and allowed to adhere overnight. Cells were treated with 
the indicated agents or combinations for 24 h, after which the cells were washed twice 
with PBS and regular growth media was added. The cells were allowed to grow for 5-14 
days, with the addition of fresh media every 4-5 days. Once colonies of at least 50 cells 
were observed, the cells were washed with PBS, fixed, stained with 0.4% crystal violet, 
then rinsed in cold water and left to dry overnight. Colonies were counted and imaged 
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using a ColCount (Oxford Optronix, Oxford, UK), and colonies formed per cells plated 
was calculated. Numbers were normalized to the untreated sample.  
2.3 Determination of apoptosis 
2.3.1 Annexin-V flow cytometric staining 
Cells were seeded in 6 well plates at 75,000 (SUM149 and derivatives) or 150,000 
(SUM190 and derivatives) cells per well and allowed to adhere overnight. Cells were 
treated with the indicated agents for the indicated time. Cells were harvested with 0.25% 
trypsin (- EDTA), washed with PBS, and resuspended in biotin-conjugated Annexin-V 
(Beckman Coulter, Brea, CA) for 5 min at room temperature (RT). Cells were washed 
again with PBS and resuspended in streptavidin-conjugated FITC (Life Technologies, 
Grand Island, NY) and 7-AAD (BD Pharminogen, San Jose, CA) dyes for 15 min on ice. 
Cells were washed and resuspended in PBS, and then at least 25,000 events were 
collected on a BD FACSCalibur flow cytometer. Results were analyzed using FlowJo 
software (Tree Star, Inc., Ashland, OR). 
2.3.2 Caspase activity assay 
Cells were seeded in 6 well plates, and the next day cells were treated for 4 h in 
regular growth media. After incubation, an equal volume of Caspase-3/7-Glo reagent 
(Promega, Madison, WI) was added to the wells, and plates were incubated for 30 min at 
RT. Luminescent signal was measured on a Veritas microplate luminometer (Turner 
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BioSystems, Sunnyvale, CA) with a 1 s integration time. Caspase activity was 
normalized to the untreated sample. 
2.4 Assessment of Smac mimetics 
2.4.1 Determination of Smac mimetic binding affinities by 
fluorescence polarization assay 
Fluorescence polarization assays were conducted by Chris Benetatos and the 
TetraLogic Pharmeceuticals research team. The binding affinities of compounds to XIAP 
and cIAP1 were determined as described previously [321] using a fluorogenic substrate 
and are reported as Kd values.  Initially, the dissociation constant (Kd) for the 
fluorescently labeled modified Smac peptide (AbuRPF-K(5-Fam)-NH2; FP peptide) was 
determined by using a fixed concentration of peptide (5 nM) and titrating varying 
concentrations of protein (0.075 μM – 5 μM in half log dilutions).  The dose-response 
curves were produced by a non-linear least squares fit to a single-site binding model 
using GraphPad Prism (Graphpad Software, La Jolla, CA; data not shown), with 5 nM of 
FP peptide and 50 nM of XIAP used in the assay.  Various concentrations of Smac 
mimetics (100 μM – 0.001 μM in half log dilutions) were added to FP peptide:protein 
binary complex for 15 minutes at RT in 100 μL of 0.1 M potassium phosphate buffer, pH 
7.5, containing 100 mg/mL bovine -globulin.  Following incubation, the polarization 
values were measured on a Perkin-Elmer Victor2V multi-label plate reader using a 485 
nm excitation filter and a 520 nm emission filter.  IC50 values were determined from the 
plot using non-linear least squares analysis in Graphpad Prism. Calculations were based 
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on a maximum signal (protein BIR:FP peptide complex treated with DMSO alone) after 
subtraction of background. 
2.4.2 TNF-α measurement of Smac mimetic-treated cells 
Measurement of TNF-α was conducted by Chris Benetatos and the TetraLogic 
Pharmeceuticals research team. TNF-α protein levels were measured in cell culture 
supernatants using the BD OptEIA TNF-α ELISA kit II according to the manufacturer’s 
instructions. Briefly, 200 µL of culture supernatants were tested in triplicate.  A standard 
curve was generated using the manufacturer supplied standard.  Absorbance was read 
at 450 nm on a Perkin-Elmer Victor2 multi-label plate reader (Waltham, MA).  The 570 
nm background correction was subtracted from 450 nm values to yield the final results. 
2.5 Western immunoblotting 
Cells were harvested and immediately lysed in cell lysis buffer containing NP40 
with fresh protease inhibitor cocktail (Sigma Aldrich) and 1 mM PMSF or Halt Protease/ 
Phosphatase Inhibitor Cocktail and 2 mM DTT (Thermo Scientific). Protein 
concentration was determined by the Pierce BCA Protein Assay Kit (Rockford, IL) or the 
Pierce 660nm Protein Assay (Thermo Scientific). Equal amounts of cell lysates were then 
subjected to SDS-PAGE under reducing conditions. Before loading onto the gel, all 
lysates were boiled for 5 min and immediately cooled on ice. The protein was 
transferred onto Immobilon-P PVDF membrane (Millipore, Billerica, MA) previously 
soaked in methanol and transfer buffer by the TRANS-BLOT SD semi-dry transfer cell 
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(BioRad). After the transfer process was complete, membranes were incubated with 
blocking buffer (5% dry nonfat milk in 1 X TBS-0.1% Tween 20) for 1 h at RT. 
Membranes were incubated with primary antibodies at the indicated dilution overnight 
at 4°C; a list of antibodies used in this dissertation can be found in Table 2.1. The next 
day, membranes were washed three times with wash buffer (1 X TBS-0.1% Tween 20) for 
5 min each and subsequently incubated with appropriate secondary antibody 
conjugated with horseradish peroxidase (rabbit 1:1000, mouse 1:2000 dilution) for 1 h at 
RT. Membranes were again washed three times in wash buffer for 5 min each, and then 
bands were visualized using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific). Signals were developed after exposure to Kodak BioMax XAR X-ray 
film (X-Omat films, Eastman Kodak Co., Rochester, NY). Actin or GAPDH 
immunodetection was conducted as a loading control. This was done by stripping the 
membrane in stripping buffer [100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl 
(pH 6.7)] at 50°C for 30 min followed by washing and blocking procedure as described 
above. Densitometric analysis was performed using the NIH ImageJ software. 
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Table 2.1: Antibodies used in this dissertation 
Antibody Company Catalog # Dilution 2o Ab MW (kDa) 
Actin Santa Cruz sc-1615R 1:1000 rabbit 43 
AMPK Cell Signaling 2532 1:1000 rabbit 62 
Bcl-2 Santa Cruz sc-7382 1:1000 mouse 26 
c-FLIP Cell Signaling 8510 1:1000 rabbit 55 
Caspase-3 Cell Signaling 9662 1:1000 rabbit 17, 19, 35 
Caspase-8 Cell Signaling 9746 1:1000 mouse 18, 43, 57 
 Catalase Abcam ab16731 1:2000 rabbit 60 
cIAP1 Cell Signaling 4952 1:1000 rabbit 62 
cIAP2 Cell Signaling 3130 1:1000 rabbit 70 
DR4 Santa Cruz sc-6823 1:2000 goat 56 
DR5 Cell Signaling 3696 1:1000 rabbit 40, 48 
eIF4G1 Cell Signaling 2469 1:1000 rabbit 220 
ERK1/2 (p44/42) Cell Signaling 9102 1:1000 rabbit 42, 44 
GAPDH Santa Cruz sc-47724 1:2000 mouse 37 
JNK Cell Signaling 9252 1:1000 rabbit 46, 54 
NF-κB (p65) Cell Signaling 8242 1:1000 rabbit 65 
PARP Cell Signaling 9532 1:1000 rabbit 89, 116 
p38 Cell Signaling 9212 1:1000 rabbit 43 
p-AMPK (Thr172) Cell Signaling 2531 1:1000 rabbit 62 
p-ERK1/2 
(Thr202/Thr204) 
Cell Signaling 9101 1:1000 rabbit 42,44 
p-JNK 
(Thr183, Tyr185) 
Cell Signaling 9251 1:1000 rabbit 46, 54 
p- NF-κB (Ser536) Cell Signaling 3031 1:1000 rabbit 65 
p-p38 (Thr180, 
Tyr182) 
Cell Signaling 9211 1:1000 rabbit 43 
Smac/DIABLO Cell Signaling 2954 1:1000 mouse 21 
SOD1 Cell Signaling 2770 1:1000 rabbit 18 
SOD2 BD Biosciences 611580 1:1000 mouse 25 
Survivin Cell Signaling 2808 1:1000 rabbit 16 
TNFR1 Cell Signaling 3736 1:1000 rabbit 55 
XIAP BD Biosciences 610762 1:2000 mouse 57 
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2.6 Measurement of intracellular reactive oxygen species  
Cells were cultured in 6-well plates in regular growth media until reaching 70–
80% confluence and then treated for 24 h. Cells were harvested and incubated for 30 min 
with 10 μM dyes to detect ROS. 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), 
dihydroethidium (DHE), and MitoSOX Red (Molecular Probes, Carlsbad, CA) were used 
to detect hydrogen peroxide-derived radicals, cytoplasmic superoxides, and 
mitochondrial superoxides respectively. Cells were washed twice with 1% BSA/PBS and 
analyzed for fluorescence by flow cytometry. At least 25,000 events were collected on a 
FACScalibur flow cytometer (Beckton Dickinson, Rockville, MD) and analyzed using 
FlowJo software (Tree Star, Inc., Ashland, OR). For DHE and H2DCFDA staining, high 
fluorescence was calculated by setting a gate on the control cells where the peak reached 
a minimum, and all experimental samples were compared to this control gate. For 
MitoSOX Red staining, fold induction of ROS was calculated relative to the untreated 
sample.  
2.7 Measurement of antioxidant capacity and signaling 
2.7.1 Measurement of reduced glutathione 
Reduced glutathione levels were assessed using the GSH-Glo™ Glutathione 
Assay (Promega, Madison, WI) as per the manufacturer’s instructions. Briefly, 3 g total 
cell lysates were incubated at RT for 30 min with 50 μL of prepared GSH-Glo™ Reagent 
2X.  Then, 100 μL of reconstituted Luciferin Detection Reagent was added, plates were 
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mixed and incubated at RT for 15 min, and luminescence was read using a Veritas 96-
well luminometer with a 1 s integration time. 
2.7.2 Measurement of Nrf2 activity 
Cells were seeded at 4,000 cells/well in a white 96 well plate (Greiner Bio-One, 
Monroe, NC) and allowed to adhere overnight. Cells were then transfected with 
pGL4.37 (ARE firefly luciferase reporter, Promega) and pGL4.75 (Renilla luciferase 
control, Promega) plasmids using a 3:1 ratio of XTremeGene HP (Roche Applied 
Science) transfection reagent to DNA. The next day cells were treated for 24 h, after 
which an equal volume of Dual-Glo reagent (Promega) was added to the cells and firefly 
luminescence was read on a Veritas microplate luminometer. Then an equal volume of 
Dual-Glo Stop & Glo reagent (Promega) was added to the cells, and Renilla 
luminescence was read. Firefly luminescence was normalized to Renilla luminescence to 
account for differences in transfection efficiency or viability, and this value was 
normalized to the untreated sample. 
2.8 Copper assays 
2.8.1 Complementation of Ctr1/Ctr3-deficient yeast cells with copper 
ionophores 
SEY6210 (wildtype for Ctr1/3) [322] and Ctr1/Ctr3 deletion mutant MPY17 [323, 
324] Saccharomyces cerevisiae cells were grown in YPEG media (3% ethanol, 3% glycerol, 
1% yeast extract, 2% Bacto Peptone, 2% agar) with or without the addition of known 
copper ionophore zinc pyrithione (ZPT) [325] or DSF at 0-50 µM. Cells were allowed to 
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grow at 30oC for 3 days, after which absorbance at 600nm was measured on a 
Spectramax Plus 384 plate reader (Molecular Devices) as an indicator of growth. 
2.8.2 Measurement of intracellular copper  
SUM149 and rSUM149 cells were treated with DSF, copper, or DSF-Cu for 24 h, 
and lysates were prepared as described in Section 2.5. Lysates were analyzed for copper 
content using a Thermo Scientific Element2 inductively coupled plasma high resolution 
mass spectrometer (ICP-HRMS) at the W.M. Keck Elemental Geochemistry Laboratory 
(University of Michigan, Ann Arbor, MI) by Ted Huston, and copper content of the lysis 
buffer was subtracted from each sample. Values were normalized to protein 
concentration for reporting as ng Cu/mg protein. 
2.9 Assessment of anchorage-independent growth potential 
Cells were plated in 6 well plates at 75,000 (SUM149 and derivatives) or 150,000 
(SUM190 and derivatives) cells/well and allowed to adhere overnight. Treatments were 
applied for 24 h, after which cells were harvested and counted with trypan blue viability 
stain. A base layer of 0.7% agarose in regular growth medium was poured into wells of a 
12 well plate and allowed to solidify at 4oC. Then 12,500 cells/well from each treatment 
were plated in triplicate in 0.45% agarose in regular growth medium on top of the base 
layer and allowed to solidify at 4oC. Plates were then transferred to a 37oC incubator 
with 5% CO2 and allowed to grow for 14 to 21 days. Once visible colonies had formed, 
they were counted under a microscope, and colony counts were normalized to the 
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untreated sample. Images of representative fields were taken with 5x magnification 
using a Zeiss Axio Observer A1 microscope (Thornwood, NY), Hamamatsu Orca ER 
digital camera (Bridgewater, NJ), and MetaMorph software (Molecular Devices). 
2.10 Examination of intracellular ALDH activity 
The ALDEFLUOR kit (Stem Cell Technologies, Durham, NC) was used to 
identify cells with high aldehyde dehydrogenase (ALDH) enzymatic activity according 
to the manufacturer’s instructions. Briefly, SUM149 cells were suspended in 
ALDEFLUOR assay buffer containing ALDH substrate (1 µM, 1×106 cells) and incubated 
for 35 minutes at 37°C. For each treatment, a sample of cells was incubated with 50 mM 
of the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) as negative control. 
Flow cytometric analysis was conducted using a FACSCalibur flow cytometer (Beckton 
Dickinson, Franklin Lakes, NJ) and analyzed using Cellquest (Beckton Dickinson). 
ALDEFLUOR fluorescence was excited at 488 nm, and fluorescence emission was 
detected using a standard fluorescein isothiocyanate (FITC) 530/30 band pass filter. The 
sorting gates were established using the 7-AAD stained cells for viability and the 
ALDEFLUOR-stained cells treated with DEAB as negative controls. Dot plots from a 
representative experiment are shown with mean ± SEM from a total of four experiments. 
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2.11 Analysis of drug interactions 
Analysis of drug interactions was performed using Calcusyn software (Biosoft, 
Cambridge, UK), which uses the Chou-Talalay method [326] where a combination index 
(CI) <1 indicates synergism. 
2.12 Statistical analysis 
Statistical analyses were performed using Graphpad InStat (Graphpad Software, 
Inc., La Jolla, CA) and the Student’s two-tailed t-test. Differences were considered 
significant at p<0.05. 
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3 Development and characterization of a model to 
investigate the reversibility of acquired therapeutic 
resistance in IBC 
3.1 Introduction 
 Despite the improvements gained from multidisciplinary management and 
anthracycline- and taxane-based polychemotherapy regimens [327], women with IBC 
continue to have worse survival outcomes than those with LABC [328]. There is no 
standard IBC-specific treatment for patients with advanced disease, and enrollment in 
clinical trials has been strongly recommended [3]. Patients with IBC of the TN subtype 
are consistently associated with the worst outcomes [15]. Since endocrine and Her2-
targeting therapies are ineffective in TN IBC, EGFR inhibitors such as gefitinib and 
erlotinib and an anti-EGFR antibody (cetuximab) are in clinical trials; however, recent 
results from the cetuximab trials have been disappointing in EGFR-overexpressing 
TNBC patients [329]. 
 For IBC tumors with ErbB1/EGFR of ErbB2/Her2 overexpression, ErbB1/2 targeting 
agents including the Her2-targeting antibody trastuzumab and the dual ErbB1/2 
tyrosine kinase inhibitor lapatinib are approved for treatment. Although the CR rate of 
patients receiving lapatinib monotherapy has been remarkable (50% CR rate in ErbB2-
overexpressing IBC patients) [79], a significant number of patients are unresponsive to 
lapatinib, and acquired resistance is frequent [81, 330].  
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A major unmet clinical challenge in IBC that affects patients regardless of 
subtype is the rapid development of chemo- and radiotherapy resistance [287]. Efficacy 
of many therapeutics is largely influenced by induction of ROS, which induce cell death 
in response to therapy [253]. Previous identification of IBC cells with acquired 
therapeutic resistance to lapatinib revealed adaptation to oxidative stress induced by 
lapatinib, resulting in insignificant ROS accumulation [78]; this inhibits apoptosis and 
enhances cancer cell survival. The therapy-resistant IBC cells overexpress XIAP [114], 
which is correlated with redox adaptation in these models, with increased expression of 
the antioxidants SOD1/2 and GSH leading to enhanced ROS detoxification [78]. 
Few profiling studies have looked specifically at linking tumor cell drug 
responses to drug resistance. In this study, a qHTS approach was employed to profile 
the NCI Developmental Therapeutics Program (NCI-DTP) Approved Oncology Drug 
Set II in an IBC model established from a patient tumor [312] and its isogenic 
derivatives. To obtain pharmacological information from the screening data, compounds 
were screened at multiple concentrations. The study’s primary objective was to 
determine whether the development of resistance to lapatinib has any effect on 
sensitivity to other chemo- and targeted drugs. Secondly, we investigated whether 
removal of lapatinib as a selective pressure from rSUM149 would impact sensitivity to 
lapatinib and other anti-cancer agents. Therefore, efficacy of the NCI-DTP Approved 
Oncology Drug Set II was characterized in parental SUM149; rSUM149, an isogenic 
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derived line from SUM149 wherein a clonal population of cells was selected for acquired 
resistance to lapatinib [114]; and an isogenic derivative generated by removal of 
lapatinib from rSUM149 for an extended period of time (rrSUM149, resistance reversal 
model). Lapatinib sensitivity and resistance was confirmed for each cell line in the qHTS 
MTT format (Fig. 3.1). Analysis of the parental and isogenic-derived IBC cell lines 
provides a unique model system through which we can enhance our understanding of 





Figure 3.1: Validation of qHTS and isogenic-derived IBC cell line models 
Representative qHTS dose response curves for lapatinib in SUM190, SUM149, and isogenic-
derived rSUM149 and rrSUM149 cell lines.  
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3.2 Lapatinib-resistant rSUM149 cells are cross-resistant to 
multiple chemo- and targeted therapies 
A qHTS strategy developed by Shalonda M. Ingram and Kevin P. Williams at 
North Carolina Central University was used generate representative heat map profiles 
of proliferation in response to the complete 89 drug set, screened in dose response, in the 
SUM149 cells. Proliferation data was normalized to in-plate controls in order to generate 
a heat map for each drug response (Fig. 3.2A). Drugs were grouped in the heat map 
based on their mechanism of action. Analysis of the qHTS data identified potent drugs 
that consistently demonstrated IC50 values <15 µM for inhibition of proliferation in 
SUM149 (Table 3.1). In addition to lapatinib, the most efficacious drugs included anti-
metabolites, anti-neoplastic antibiotics, anthracyclines, tyrosine kinase inhibitors, an 
HDAC inhibitor, and a proteasome inhibitor. Alkylating agents (Fig. 3.2A, group 6) and 
platinum compounds (group 8) were generally ineffective in SUM149. Gemcitabine, the 
vinca alkaloids, and mTOR inhibitors rapamycin and everolimus demonstrated modest 
micromolar activity but were not amongst the top 15 drugs in SUM149 cells (Fig. 3.2A, 
Table 3.1). A number of approaches were undertaken to confirm the top 15 anti-cancer 
drugs identified from the primary qHTS; these are detailed in [320]. 
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Table 3.1: IC50 values for the 15 most efficacious drugs in the SUM149 cell line 
from the NCI-DTP library 
Drug qHTS MTT         
IC50 (µM) 
Drug Class 
Dactinomycin <0.02 Anti-neoplastic antibiotic 
Plicamycin <0.02 Anti-neoplastic antibiotic 
Bortezomib <0.02 Proteosome inhibitor 
Doxorubicin <0.02 Anthracycline 
Daunorubicin <0.02 Anthracycline 
Fludarabine 2.1 ± 1.1 Anti-metabolite 
Mitoxantrone 2.5 ± 0.6 Anti-neoplastic antibiotic 
Sorafenib 4.5 ± 0.4 Kinase inhibitor 
Sunitinib 5.0 ± 0.8 Kinase inhibitor 
Gefitinib 6.2 ± 2.3 Kinase inhibitor 
Vorinostat 8.9 ± 4.9 HDAC inhibitor 
Lapatinib 9.0 ± 0.3 Kinase inhibitor 
Mitomycin 9.1 ± 0.4 Anti-neoplastic antibiotic 
Bleomycin 13.8 ± 2.0 Anti-neoplastic antibiotic 




Figure 3.2: Comparative efficacy profiling of the NCI-DTP 89 oncology drug set in 
parental SUM149 and isogenic-derived rSUM149 and rrSUM149 cell lines 
Heat map profile for proliferation inhibitory effects of the NCI approved oncology set in SUM149 
(A), rSUM149 (B) and rrSUM149 (C) cells. Cells were incubated with drugs in a 10-point two-fold 
dilution series dose curve for 72 h; cell proliferation assessed by qHTS MTT assay. Each row 
represents dose response data for a single drug. Percent inhibition values were calculated for 
each concentration and data normalized to vehicle and no cell controls. The heat map key 
indicates red for 100% inhibition to green for 0% inhibition. Outlier values are shown as grey. 
Drugs are listed on the vertical axis and grouped for drug class. A representative experiment is 
shown.  Each cell line was profiled for a minimum of two independent screens. 
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Next, responses to the drugs which were identified as most potent in SUM149 
were profiled in the resistant rSUM149 cells; heat maps for dose effects in this cell line 
can be found in Figure 3.2B. Doxorubicin, bortezomib, dactinomycin, plicamycin and 
daunorubicin, which were previously identified as inhibiting proliferation in SUM149 
cells at all concentrations tested, were equally effective in the rSUM149 cells, with IC50s 
of <0.2 µM. In addition to those drugs, fludarabine and vorinostat were highly potent in 
the acquired resistance model as well as in the parental line (Fig. 3.2, Table 3.2). 
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Table 3.2: IC50 values for drugs most efficacious in SUM149 cells for the three 
isogenic-derived IBC models*  
Drug Mechanism of 
Action 
Primary IC50 ± SD (µM) 
   SUM149 rSUM149 rrSUM149 
Fludarabine Anti-metabolite 2.1 ± 1.1 1.7 ± 0.8 1.4 ± 0.9 
Mitoxantrone Anti-neoplastic 
antibiotic 
2.5 ± 0.6 11.4 ± 1.3 3.8 ± 3.4 
Sorafenib Kinase inhibitor 4.5 ± 0.4 14.6 ± 3.1 7.8 ± 1.6 
Sunitinib Kinase inhibitor 5.0 ± 0.8 >25 7.05 ± 6.3 
Gefitinib Kinase inhibitor 6.2 ± 2.3 >50 2.8 
Lapatinib Kinase inhibitor 9.0 ± 0.3 >50 9.1 
Vorinostat HDAC inhibitor 8.9 ± 4.9 6.2 ± 0.6 2.75 ± 2.1 
Mitomycin Anti-neoplastic 9.1 ± 0.4 18.5 ± 0.8 6.2 ± 0.4 
Bleomycin Anti-neoplastic 
antibiotic 
13.8 ± 2.0 >50 9.5 
Capecitabine Anti-metabolite 15.0 ± 9.5 >50 26 ± 1.4 
*Doxorubicin, bortezomib, dactinomycin, plicamycin, and daunorubicin all had IC50 values of 
>0.2 µM in all three isogenic cell lines. 
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Compared to the parental SUM149 cells, the lapatinib-resistant rSUM149 cells 
exhibited cross-resistance to multiple targeted- and chemo-therapeutic agents amongst 
the 15 most potent drugs identified in SUM149, as well as other lower potency drugs. 
Cross-resistance generally applied to drugs from four of the classes (highlighted by a 
bracket in Fig. 3.2) including the taxanes (Fig. 3.2B, group 1), a subset of the kinase 
inhibitors (group 2), vinca alkaloids (group 3), and aromatase inhibitors (group 4). A 
shift in the IC50 values from the parental to resistant SUM149 cells was observed for 
several of the drugs tested. From the initial top 15 drugs that were efficacious in the 
parental SUM149 cells, the tyrosine kinase inhibitors, capecitabine, mitomycin, 
mitoxantrone, and bleomycin were characterized by a dramatic reduction in potency in 
rSUM149, in addition to previously published lapatinib resistance (Table 3.2, Fig. 3.2B). 
IC50s for some of the most potent drugs in SUM149 (white bars) and their comparative 
efficacy in rSUM149 (black bars) is displayed graphically in Figure 3.3. 
3.3 Reversal of resistance to lapatinib resensitizes rrSUM149 
cells to a number of agents to which rSUM149 is insensitive 
We then sought to profile the entire drug panel in the resistance reversal 
(rrSUM149) cell line model. rrSUM149 is a unique isogenic cell line which was generated 
through the removal of lapatinib from rSUM149 culture conditions for a period of >2 
months, which allowed for outgrowth of a population of cells which were resensitized to 
lapatinib treatment. A comparative heat map profile for all 89 drugs in parental SUM149 
and its two isogenic derived cell lines rSUM149 and rrSUM149 is shown in Fig. 3.2A-C. 
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Doxorubicin, bortezomib, dactinomycin, plicamycin, and daunorubicin, which inhibited 
proliferation in SUM149 and rSUM149 cells at all concentrations tested, were highly 
efficacious in the rrSUM149 cells. Table 3.2 details other drugs from the top 15 identified 
from the NCI-DTP oncology set in SUM149 cells and the corresponding IC50 values in 
the rSUM149 and rrSUM149 cells; IC50 data is represented graphically for a selection of 
the top compounds in SUM149 for SUM149 (white bars), rSUM149 (black bars), and 
rrSUM149 (gray bars) in Figure 3.3. Interestingly, data in Table 3.2 and Figures 3.2 and 
3.3 indicate that the rrSUM149 cells regained sensitivity and potency comparable to the 
parental SUM149 cells not only in response to lapatinib, but also upon treatment with 
other targeted- and chemotherapeutic agents in the top 15 panel, indicating cross-
resensitization.  
Thus, comparative efficacy profiling of the approved oncology drug set in 
SUM149 parental and isogenic derived models of acquired resistance and re-
sensitization demonstrates that lapatinib-resistant IBC cells are cross-resistant to 
multiple oncology drugs, while resensitization to lapatinib is accompanied by increased 
sensitivity to other therapeutic agents.  
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Figure 3.3: Comparative IC50 values for drugs displaying cross-resistance and cross-
resensitization in SUM149 and isogenic-derived rSUM149 and rrSUM149 cell line 
models 
Mean and SD values based on a minimum of three independent qHTS MTT experiments.  IC50 
values determined with GraphPad Prism 5.0. 
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3.4 Mechanism of resistance reversal: the rrSUM149 model 
behaves similarly to parental SUM149 cells in response to 
oxidative stress 
 To further characterize the resistance reversal model and understand the 
mechanisms behind their cross-resensitization, the rrSUM149 cells were compared to 
rSUM149 and SUM149 cells using several important factors associated with acquired 
resistance in the rSUM149 model [78, 114]. Measurement of ROS (cytoplasmic 
superoxides and hydrogen peroxide-derived radicals) at two distinct time points during 
the generation of the resistance reversal model showed that after one month of growth 
in GW583340 (research grade lapatinib analog)-free media, at which time the cells were 
still resistant to lapatinib-induced cell death, the rrSUM149 cells (Fig. 3.4A and 3.4B, 
gray bars- One) remained insensitive to the induction of ROS accumulation by lapatinib; 
their response is consistent with the rSUM149 cells (Fig. 3.4A and 3.4B, black bars) which 
are constantly growing in lapatinib. However, after two months of growth in lapatinib-
free media, at which time the cells were resensitized to lapatinib, the rrSUM149 cells 
(Fig. 3.4A and 3.4B, gray bars- Two) regained the ability to accumulate ROS, showing 
levels comparable to the parental SUM149 cells in response to challenge with lapatinib. 
We previously showed that SUM149 cells treated with lapatinib exhibit increased 
phosphorylation of AMPK, which serves as a marker of oxidative stress, but that 
rSUM149 cells, which are maintained in media with lapatinib, do not show an increase 
in p-AMPK; this indicates a partial loss of stress responsive signaling to lapatinib [78]. 
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Thus, the phosphorylation status of AMPK in the resistant reversal cell line rrSUM149 
following lapatinib treatment was examined. Following one month of growth in 
lapatinib-free media, at which time the cells maintained resistance to lapatinib, the cells 
showed only a very minimal increase in p-AMPK levels upon treatment with lapatinib 
(Fig. 3.4C, One). However, after a period of two months of growth in lapatinib-free 
media, treatment of rrSUM149 cells with lapatinib induced approximately a two-fold 
increase in AMPK phosphorylation, indicating that the cells are experiencing significant 
oxidative stress (Fig. 3.4C, Two). 
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Figure 3.4: Resistance reversal in the rrSUM149 cell line is associated with enhanced 
ROS accumulation and activation of the AMPK stress response 
(A) Cytoplasmic superoxides and (B) H2O2-derived radicals as measured by flow cytometric 
staining with DHE and H2DCFDA in parental SUM149 cells (white bars) untreated and treated 
with 7.5 µM lapatinib, rSUM149 cells (black bars) growing in 7.5 µM lapatinib, and rrSUM149 
cells following removal of drug for one or two months (gray bars) treated with 7.5 µM lapatinib. 
(C) Western immunoblot analysis of AMPK expression and phosphorylation in rrSUM149 cells 
treated with 7.5 µM lapatinib following one or two months of growth in lapatinib-free media. 
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3.5 Resistance reversal rrSUM149 cells have reduced 
expression of anti-apoptotic and antioxidant molecules 
compared to rSUM149 cells 
 Acquired resistance in the rSUM149 model was previously correlated with 
upregulation of XIAP expression relative to the parental SUM149 cells [331]. To further 
investigate the mechanisms that mediate the reversal of resistance in rrSUM149 cells, the 
levels of XIAP and several other anti-apoptotic proteins, as well as Smac/DIABLO, a 
negative regulator of XIAP, were examined in the panel of SUM149, rSUM149, and 
rrSUM149 cells.  Data in Fig. 3.5A show that, consistent with previous results, XIAP 
expression was upregulated approximately two-fold in rSUM149, and interestingly, 
XIAP expression in the rrSUM149 cells was significantly reduced compared to rSUM149 
to levels comparable with the parental SUM149 cells. In addition, cIAP1 and Bcl-2 were 
both increased to some degree in rSUM149 cells, a further indication of their high degree 
of apoptotic dysregulation. While cIAP2 and survivin levels were unchanged in 
rSUM149 cells compared to SUM149, there was a decrease in all anti-apoptotic proteins 
that were examined in the rrSUM149 cells; expression either returned to parental 
SUM149 levels or in some cases was even lower (cIAP1/2, survivin). Levels of the IAP 
inhibitor Smac/DIABLO were unchanged across the panel of cell lines. 
 As there is a significant difference in ROS accumulating abilities across the cell lines 
(Fig. 3.4A and 3.4B) and because increased antioxidant expression in the rSUM149 cell 
line has been observed [332], the expression of SOD2 and catalase, two important 
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intracellular antioxidants was examined. Catalase expression did not show any 
significant changes across the cell lines (Fig. 3.5B).  In contrast, SOD2 was significantly 
upregulated in the rSUM149 cells as observed previously, and expression was markedly 
reduced in the rrSUM149 resistance reversal model (Fig. 3.5B).  
Together, these data indicate that rrSUM149 cells are more susceptible to ROS-
mediated cell death than the rSUM149 cells due to reduced expression of anti-apoptotic 
and antioxidant proteins. 
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Figure 3.5: The resistance reversal rrSUM149 cell line model is characterized by 
downregulation of anti-apoptotic proteins and reduced antioxidant capacity 
(A) Western immunoblot analysis of basal anti-apoptotic proteins XIAP, cIAP1, cIAP2, survivin, 
Bcl-2, and Smac expression in untreated SUM149, rSUM149, and rrSUM149 cells. GAPDH was 
used as a loading control. (B) Western immunoblot analysis of basal catalase and SOD2 
expression in untreated SUM149, rSUM149, and rrSUM149 cells. GAPDH and β-actin were used 
as loading controls. 
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3.6 Discussion 
IBC is characterized by rapid progression from onset of disease, therefore early 
and aggressive multimodal therapy is essential to improve patient outcomes. IBC 
tumors are frequently either EGFR/ErbB1- or ErbB2/Her2-positive, and clinical strategies 
using trastuzumab and lapatinib have yielded some success; however, intrinsic and 
acquired resistance to these agents is a significant challenge. Adding to these barriers to 
successful treatment, there is paucity of IBC cellular models in which to study the 
molecular basis for the disease and potential therapeutic regimens. In the present study, 
we have characterized a novel isogenic-derived model of disease progression to drug 
resistance and subsequent resistance reversal. A set of IBC cell lines (SUM149, rSUM149, 
and rrSUM149) representing the basal subtype was profiled in a qHTS format in order to 
identify drugs from the NCI-DTP 89 approved oncology drug library that can potently 
inhibit IBC cell proliferation. 
High throughput profiling and screening have utilized a range of different 
endpoints including cytotoxicity, viability [333], survival [334], growth inhibition [335], 
and proliferation [336]. In this study, the MTT cell proliferation assay was chosen as the 
basis for qHTS screening due to its ease of automation, widespread use, and economical 
cost per well. Using this approach, a subset of drugs exhibiting efficacy in these cell line 
models was rapidly identified and confirmed. 
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As a result of our profiling efforts, we have identified several drug classes 
including anti-metabolites, anti-neoplastic antibiotics, anthracyclines, and a subset of 
tyrosine kinase inhibitors as displaying potency in the SUM149 cell line, a well-
established model of basal type, EGFR-activated IBC [337-341]. In addition, a subset of 
the drugs tested was highly potent even in the acquired lapatinib resistance model 
rSUM149. These agents include dactinomycin, plicamycin, bortezomib, doxorubicin, 
daunorubucin, fludarabine and vorinostat. However, while certain drugs remained 
efficacious in the resistant cell line model, the rSUM149 cells were cross-resistant to a 
number of drugs which were previously found to be efficacious in the parental cells, 
including some tyrosine kinase inhibitors (sorafenib, sunitinib, and gefitinib), 
capecitabine, mitoxantrone, mitomycin, and bleomycin. The results of oncology drug 
profiling in parental and resistant SUM149 cells indicates a mechanism of lapatinib-
induced acquired resistance that promotes cross-resistance to other tyrosine kinase 
inhibitors as well as a subset of drugs that target DNA synthesis and repair.  
The present study shows that removal of lapatinib, the primary drug against 
which resistance was developed in rSUM149 cells, for an extended period led to 
development of a population of cells (rrSUM149) that are resensitized to multiple drugs 
in addition to lapatinib (sorafenib, sunitinib, gefitinib, capecitabine, mitoxantrone, 
mitomycin, and bleomycin; Fig. 3.2 and 3.3, Table 3.2), behaving in a manner similar to 
the parental SUM149 cells. Resensitization was associated with a decrease in expression 
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of anti-apoptotic proteins including XIAP, cIAP1, cIAP2, survivin, and Bcl-2 (Fig. 3.5A) 
as well as the antioxidant SOD2 (Fig. 3.5B) and increased capacity for ROS accumulation 
(Fig. 3.4A and 3.4B).  
In addition, the rrSUM149 cells regained the ability to activate AMPK, a cellular 
metabolic regulator that also acts as a sensor for oxidative stress [342], in response to 
lapatinib exposure (Fig. 3.4C). Thus, the mechanistic phenotype of redox adaptation in 
the rSUM149 cells (Fig. 3.6) supports the observation of cross-resistance to multiple 
drugs, which also occurs commonly in patients; further, decreased expression of 
survival factors and antioxidant mechanisms restored ROS accumulating capabilities in 
the rrSUM149 cell line, leading to resensitization of the cells to a wide variety of 
treatments (Fig. 3.6).  
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Figure 3.6: Schematic representation of drug sensitivity and tolerance in isogenic 
SUM149-derived IBC models 
Cancer cells have inherently high levels of ROS due to oncogenic signals and altered metabolism 
compared to normal cells. Presence of therapeutic insults/cellular stress can cause further 
increase in ROS, which in the absence of adaptive mechanism is associated with drug sensitivity 
and induction of cell death (SUM149). However, chronic stress leads to redox adaptive 
mechanisms such as increases in survival factors and antioxidants/ROS scavenging systems. 
These cells can suppress therapy-mediated ROS induction and/or rapidly clear ROS, which 
selects for a phenotypically distinct drug tolerant subpopulation of cells (rSUM149) that are drug 
tolerant due to their ROS protective mechanisms and contributes to multidrug resistance. Drug 
tolerance in this population of cells can be reversed by removal of the therapeutic stress for an 
extended period; loss of their redox adaptive mechanisms renders the resistant reversal cells 
(rrSUM149) highly therapy-sensitive. 
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From these studies, it appears that mechanisms involving the activation of pro-
survival pathways and redox adaption contribute to the observed therapeutic resistance 
to lapatinib and cross-resistance to other drugs. The reversibility of this resistance to a 
re-sensitized state after removal of drug is intriguing mechanistically. In a recent study, 
the existence of a drug-tolerant sub-population of cells (persisters) termed DTPs has 
been proposed based on observations of acquired drug resistance [343]. The theory 
suggests that within a heterogeneous population of cells, there exists a subpopulation of 
reversibly drug tolerant cells that are dormant until dosed with high concentrations of 
drugs, at which time a subset of DTPs that is able to tolerate growing in the presence of 
drug gives rise to drug-tolerant expanded persisters (DTEPs) [343]. There is some 
evidence that these drug tolerant clones exist de novo and may share some properties 
with cancer stem cells [343]. This DTEP population may be analogous to the rSUM149 
cells in our isogenic model. Indeed, SUM149 cells show significant ALDH positivity 
[344-346], a characteristic that is associated with cancer stem cells, and thus may also 
contain a subpopulation of DTPs. Hence, it may be possible to eliminate the emergence 
of drug tolerant cells from the SUM149 isogenic model by treatment of the parental cells 
with lapatinib in combination with drugs that target the adaptive mechanisms described 
here. These results emphasize the central roles that apoptotic dysregulation and redox 
adaptation play in therapeutic resistance not only to lapatinib, but to a wide range of 
anti-tumoral agents. Thus, the potential therapeutic targets identified in previous studies 
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[78, 114] are confirmed by their loss in the resistance reversal model, strengthening the 
need for novel strategies to relieve apoptotic dysregulation and modulate cellular redox 
to prevent and overcome drug resistance in IBC.   
In conclusion, we report the first description of drug efficacy profiles in isogenic-
derived IBC cells with differential sensitivity phenotypes by screening approved drugs 
that can act as potent inhibitors of IBC cell proliferation. These experiments have the 
potential to identify potent anti-tumoral combinations and facilitate their inclusion in 
clinical trials immediately. Our findings in combination with the currently available 
database of IBC gene signatures facilitate a significant step toward improved treatment 
protocols for patients with IBC and support the idea that anti-apoptotic mechanisms and 
redox adaptation are potential targets for therapeutic intervention that merit further 
investigation as a means of enhancing therapeutic apoptosis and overcoming resistance 
in IBC. 
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4 Targeting IAPs with Smac mimetics with differential 
IAP specificity 
4.1 Introduction 
Acquired therapeutic resistance due to tumor cell adaptation to persistent stress is an 
unmet challenge in IBC [3].  We have identified XIAP overexpression via post-
transcriptional mechanisms as a dominant feature of apoptotic dysregulation involved 
in acquired resistance to the ErbB1/2 tyroskine kinase inhibitor lapatinib, which is 
associated with cross-resistance to other anti-cancer drugs [114, 320]. The importance of 
this resistance mechanism is supported by other studies that have shown consistent 
differences in phenotype at the molecular level between IBC and locally advanced non-
IBC tumors, where IBC is characterized by a hyperproliferative state and apoptotic 
dysregulation [46, 78, 81, 103, 114, 222-224, 347-349]. Further studies revealed 
upregulation of many anti-apoptotic factors in addition to XIAP in the rSUM149 model 
of therapeutic resistance, including cIAP1, cIAP2, survivin, and Bcl-2. Expression of 
these factors was also reduced in a model of resistance reversal (rrSUM149), indicating 
their importance in maintaining the drug resistant phenotype [320]. Thus, the 
development of novel therapeutic strategies targeting the anti-apoptotic axis is highly 
relevant in IBC. 
The IAPs are a highly conserved family of endogenous apoptosis inhibitors that have 
been shown to inhibit apoptosis induced by both extrinsic and intrinsic stimuli; their BIR 
domains are important for anti-apoptotic function and mediate interactions with other 
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proteins.  cIAP1 and cIAP2, which were originally identified as components of the TNF-
α receptor (TNFR) complex, are increasingly recognized as modulators of diverse 
extrinsic signals.  By regulating the ubiquitination states of key substrates via their C-
terminal RING E3 ligae domains, they promote survival signaling.  XIAP, in addition to 
having a C-terminal RING domain, is a direct caspase inhibitor which can bind to 
activated caspases-3, -7, and -9, inhibiting their proteolytic activity [350]. 
While XIAP is not a classical oncogene, it has been detected at elevated levels in 
tumors resistant to chemotherapy and is associated with poor outcome in many cancers 
[215, 319, 351, 352]. Currently, two approaches have been taken in the development of 
clinical XIAP inhibitors: anti-sense oligonucleotides that reduce XIAP expression, and 
small molecule inhibitors that antagonize XIAP’s caspase inhibitory function. These 
molecules are currently being evaluated in preclinical and clinical Phase 1/2 studies [353, 
354]. One class of XIAP inhibitors under development is the Smac mimetics, which are 
modeled after the AVPI tetrapeptide IAP binding motif (IBM) of the endogenous IAP 
inhibitor Smac/DIABLO [355]. Smac/DIABLO is one of the main antagonists of IAPs 
through its ability to bind the BIR3 region of IAP proteins via its N-terminal AVPI 
tetrapeptide. XIAP overexpression can inhibit the release of endogenous Smac from the 
mitochondria, highlighting its importance in the apoptotic process [356]. Recently, 
Smac/DIABLO expression was assessed in 62 breast cancer patient specimens by flow 
cytometry and found to correlate inversely with tumor stage [357]. 
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Smac mimetics are potent pro-apoptotic agents, with mechanisms that include: 1. 
steric hindrance and/or competitive occlusion of the XIAP caspase binding sites; 2. 
degradation of XIAP; 3. induction of TNF-α-mediated cell death (the predominant 
mechanism of many of the Smac mimetics is recognized as being TNF-α dependent [358, 
359]); and 4. inhibition and degradation of other IAP family members. Multiple IAP 
targeting is important due to the fact that in many cases when XIAP is inhibited, other 
IAPs suppress apoptosis by compensatory mechanisms [358, 360-363]. Because Smac is 
known to act as a dimer, bivalent Smac mimetics were introduced with the idea that 
they would be more efficacious than their monovalent counterparts; this has since been 
demonstrated to be true. Currently, Smac mimetics including bivalent Birinapant 
(formerly TL32711) are in clinical trials [364]. While only a subset of tumor cell lines is 
sensitive to single agent Smac mimetic treatment, their combination with different 
therapeutic agents has been shown to increase the potency of those agents [137, 365-369].  
In this study, the effects of Smac mimetics as single agents and in combination 
with TRAIL were examined. TRAIL is classical apoptosis-inducing ligand whose 
binding to DR4 and DR5 on the cell surface results in receptor aggregation, recruitment 
of FADD, DISC formation, and activation of caspase-8, leading to apoptosis [370]. Since 
TRAIL induces tumor cell death via the extrinsic pathway, the status of intracellular 
sensors such as p53 is less relevant, making it attractive as an anti-cancer agent [371].  
While TRAIL is a promising therapeutic due to its cancer cell specificity and low toxicity 
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to normal tissue [372], there is a considerable amount of intrinsic resistance to TRAIL, 
and acquired resistance is common after repeated exposure [373]. Mechanisms of 
resistance include: downregulation of death receptors; constitutive activation of Akt 
and/or NF-κB; overexpression of cFLIP; mutations in the Bax and Bak genes; 
overexpression of anti-apoptotic proteins including the Bcl-2 family and IAPs; and 
defects in the release of mitochondrial proteins [373-377]. Agents that sensitize cells to 
TRAIL-induced apoptosis are attractive candidates for combination cancer therapy; 
thus, IAP-targeting with Smac mimetics is a promising strategy to sensitize resistant 
cells to TRAIL.  
4.2 IAP binding affinity of novel bivalent Smac mimetics 
A fluorescence polarization assay was used to determine the dissociation 
constants (Kd) of Smac mimetics Birinapant and GT13402 for XIAP and cIAP1 by 
monitoring the decrease in fluorescence polarization signal due to competitive 
displacement of an FP peptide from the BIR3/FP peptide binary complex.  Both Smac 
mimetic compounds induced a dose-dependent decrease in the fluorescence signal; the 
Kd of Birinapant for XIAP and cIAP1 were determined to be 45 nM and <1nM 
respectively (Table 4.1). In contrast, GT13402 has lower affinity for XIAP, with a Kd close 
to 1 µM, but similar affinity for cIAP1 (Kd <1 nM).  
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Table 4.1: Binding constants (Kd) of Smac mimetics for IAPs as determined by 
fluorescence polarization assay 




Birinapant 45 <1 
GT13402 997 <1 
 
4.3 Smac mimetics enhance TRAIL potency in TRAIL-sensitive 
SUM149 IBC cells 
The basal-type IBC cell line SUM149 has been observed to be TRAIL-sensitive 
[378, 379], which was supported by data in Figure 4.1A displaying a dose-dependent 
decrease in viability following TRAIL treatment (0-100 ng/mL).  Characterization of the 
Smac mimetic compounds as single agents in SUM149 cells revealed that neither 
Birinapant nor GT13402 induced cell death as measured by trypan blue exclusion assay, 
even at the highest concentrations tested (1000 nM Birinapant, 10,000 nM GT13402- Fig. 
4.1A). However, combinations of TRAIL (10-50 ng/mL) and Birinapant (0-1000 nM) 
enhanced TRAIL potency in SUM149 cells, with a statistically significant ~25% reduction 
in viability achieved with as low as 25 ng/mL TRAIL + 30 nM Birinapant (Fig. 4.1B). 
GT13402, which has low affinity for XIAP compared to Birinapant, did not significantly 
enhance TRAIL potency, even at the highest concentration tested (10,000 nM, Fig. 4.1B).  
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Figure 4.1: Smac mimetics enhance TRAIL-induced cell death in SUM149 cells 
A, Viability as determined by trypan blue exclusion assay of SUM149 cells treated with 
Birinapant (0-1000 nM), GT13402 (0-10,000 nM), and TRAIL (0-100 ng mL-1) alone. Bars represent 
mean±SEM viable cells taken as a percentage of total cells (n=2-3; *P<0.05, #P<0.005, all 
comparisons made to untreated). B, Viability as determined by trypan blue exclusion assay of 
SUM149 cells treated with TRAIL (10-50 ng mL-1) alone or in combination with Birinapant (0-1000 
nM) or GT13402 (0-10,000 nM). Bars represent mean±SEM viable cells taken as a percentage of 
total cells (n=3-5; *P<0.05, #P<0.005, all comparisons made between TRAIL+Smac mimetic and 
same concentration of TRAIL alone). 
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Birinapant as a single agent caused significant degradation of cIAP1 and 2, which 
was not enhanced by addition of TRAIL (Fig. 4.2A). While a slight decrease in XIAP 
expression can be seen following TRAIL treatment, no significant decrease in XIAP was 
observed following combinatorial treatments (Fig. 4.2A). However, Birinapant+TRAIL-
treated cells showed increased levels of active caspases-8 and -3, as well as poly-ADP 
ribose polymerase (PARP) cleavage, over single agents within 4 h of treatment, 
indicative of apoptosis-mediated cell death (Fig. 4.2A). Annexin-V/7-AAD flow 
cytometric staining further confirmed the mechanism of death to be apoptosis, with a 
dose-dependent increase in cells staining positive for Annexin-V (white+gray bar) from 
approximately 30% with TRAIL alone to 50-55% following treatment with TRAIL+ 
Birinapant after 12 h (Fig. 4.2B). 
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Figure 4.2: Birinapant reduces cIAP1/2 expression and induces caspase cleavage to 
enhance TRAIL-mediated apoptosis in SUM149 cells 
A, Western immunoblot analysis of cIAP1, cIAP2, XIAP, caspase-3, caspase-8 and PARP 
expression in SUM149 cells treated with Birinapant (0-1000 nM) ± TRAIL (50 ng/mL). GAPDH 
was used as a loading control. B, Annexin-V/7-AAD flow cytometric staining of SUM149 cells 
treated with Birinapant (0-1000 nM) ± TRAIL (50 ng/mL) (n=2). 
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Because XIAP overexpression has been identified as a critical factor in TRAIL 
resistance [319, 376, 380], we wanted to delineate the role of XIAP expression in 
sensitivity to Smac mimetics. To do this, we characterized both Birinapant and GT13402, 
which have differential affinity for XIAP, in SUM149 wtXIAP, a SUM149-derived 
isogenic cell line with stable exogenous XIAP overexpression [114]. Data in Figure 4.3 
show that Birinapant was more effective in increasing TRAIL potency than GT13402 in 
SUM149 wtXIAP. This reveals the IAP specificity of the Smac mimetics and the 
importance of targeting XIAP along with cIAP1 and 2 in this model. Neither Birinapant 




Figure 4.3: Birinapant is more effective than GT13402 at sensitizing SUM149 wtXIAP 
cells to TRAIL-mediated cell death 
Viability as determined by trypan blue exclusion assay of SUM149 wtXIAP cells treated with 
TRAIL (50 ng/mL) and Birinapant or GT13402 (0-1000 nM). Bars represent mean±SEM viable cells 
taken as a percentage of total cells (n=2-3; *P<0.05, #P<0.005, all comparisons made to untreated). 
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4.4 Smac mimetics induce apoptosis as single agents in TRAIL-
resistant SUM190 cells 
In order to evaluate the efficacy of the Smac mimetics in a TRAIL-resistant cell 
line, we characterized Birinapant and GT13402 in SUM190, a cell line isolated from a 
patient IBC tumor with ErbB2-overexpression and insignificant DR4 expression (a factor 
that can contribute to TRAIL resistance) as shown in Figure 4.4A. SUM190 cells were 
only moderately sensitized to TRAIL (Fig. 4.4C) when XIAP was stably downregulated 




Figure 4.4: TRAIL resistance in SUM190 is mediated in part by XIAP 
A, Western immunoblot analysis showing TRAIL receptor DR4 expression in SUM190 and 
SUM149 cells. GAPDH was used as a loading control. B, XIAP expression in SUM190 FG12 
vector control and SUM190 shXIAP cells. Actin was used as a loading control. C, Viability as 
determined by trypan blue exclusion assay of SUM149, SUM190 and SUM190 shXIAP after 
treatment with TRAIL (0-100 ng/mL) at 24 h. Data represent mean±SEM viable cells taken as a 
percentage of total cells (n=3-5; #P<0.005, all comparisons made between SUM190 and SUM190 
shXIAP at the same concentration of TRAIL).  
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In contrast, Birinapant, which targets cIAP1, cIAP2, and XIAP with high affinity, 
significantly decreased the viability of SUM190 cells in a dose-dependent manner.  Data 
in Figure 4.5A show approximately 50% cell death at 300 nM as measured by trypan 
blue exclusion assay. The requirement of pan-IAP antagonism is supported by the 
observations: 1. Treatment with GT13402 (lower affinity for XIAP) also reduces SUM190 
cell viability as a single agent (Fig. 4.5A); 2. Birinapant (high affinity for cIAP1/2 and 
XIAP) is more potent (20% viability at 1000 nM) than GT13402 (60% viability at 1000 nM) 
in this assay (Fig. 4.5A); 3. Birinapant treatment in the XIAP knockdown cell line 
(SUM190 shXIAP, Fig. 4.5B) caused an overall reduction in viability at lower doses (30-
300 nM) compared to the parental SUM190 cells at the corresponding doses; 4. The 
difference in potency between the two compounds with differential affinity for XIAP 
was attenuated in the XIAP-knock down cell line (Fig. 4.5B). 
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Figure 4.5: Smac mimetics induce death as single agents in SUM190 cells, and 
Birinapant is more efficacious than GT13402 due to its high affinity for XIAP 
A, SUM190 cell viability as determined by trypan blue exclusion assay when treated with 
Birinapant or GT13402 (0-10,000 nM). B, Viability of SUM190 shXIAP cells as determined by 
trypan blue exclusion assay treated with Birinapant or GT13402 (0-10,000 nM). Data represent 
mean±SEM viable cells taken as a percentage of total cells (n=3-5; *P<0.05, all comparisons made 
between Birinapant and GT13402 at the same concentration).  
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To confirm apoptotic cell death with Birinapant treatment, immunoblot analysis 
was conducted, and data in Figure 4.6A show a significant decrease in cIAP1 levels and 
enhanced PARP cleavage. However, no decrease in XIAP expression or change in JNK 
phosphorylation levels was observed (Fig. 4.6A). In addition, Annexin-V/7-AAD 
staining by flow cytometric analysis was carried out at 12 h. Data in Figure 4.6B show an 
increase in Annexin-V positive cells (white+gray bar) with no change in 7-AAD single 
positive cells (black bar), further supporting an apoptotic mechanism of cell death. 
 110 
 
Figure 4.6: Birinapant induces apoptosis as a single agent in SUM190 cells 
A, Western immunoblot analysis of cIAP1, XIAP, and PARP expression, and JNK 
phosphorylation status in SUM190 cells treated with Birinapant (0-1000 nM) for 4 h. GAPDH and 
total JNK were used as loading controls. B, Annexin-V/7-AAD flow cytometric staining of 
SUM190 cells treated with Birinapant (B; 0-1000 nM) or TRAIL (100 ng/mL) (n=2; #P<0.005; all 
comparisons made to the untreated sample based on total Annexin-V staining). 
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Because pro-survival NF-κB signaling can interfere with cell death, we 
conducted a time course study to evaluate its activation post-Birinapant treatment. Data 
in Figure 4.7 show that there is an initial increase in p-NF-κB at 4 h with no change in 
total protein levels. However, at 8-12 h time points, a time-dependent decrease in both 
total and phosphorylated NF-κB is observed. By 24 h, expression of both total and 
phosphorylated protein returns to untreated levels. Thus, NF-κB-mediated protection 
from cell death is unlikely, and Smac mimetics are effective as single agents in the 
SUM190 IBC cellular model. 
 112 
 
Figure 4.7: Birinapant does not activate NF-κB signaling 
Western immunoblot analysis of total NF-κB and phosphorylation status in SUM190 cells treated 




4.5 Smac mimetics inhibit clonogenic growth capacity in 
combination with TRAIL and as single agents 
To determine the effect of Smac mimetics on the growth characteristics of IBC 
cells, clonogenic growth potential was assessed. Data in Figure 4.8A show that in 
TRAIL-sensitive SUM149 cells, Birinapant+TRAIL significantly reduces clonogenic 
potential even at lower doses (40% decrease in colony formation at 30 nM Birinapant + 
10 ng/mL TRAIL compared to 10 ng/mL TRAIL). Representative images show the 
decrease in colonies formed with Birinapant+TRAIL vs. TRAIL alone.  Further, 
Birinapant was more potent than GT13402 in increasing TRAIL efficacy, with only 8% 
colony formation efficiency at 100 nM Birinapant + 50 ng/mL TRAIL, compared to 32% 
with 100 nM GT13402 + 50 ng/mL TRAIL (Fig. 4.8B). Similar to our results from the 
trypan blue exclusion assay in Figure 4.1A, neither Birinapant nor GT13402 caused any 
change in SUM149 colony formation as single agents (data not shown). 
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Figure 4.8: Smac mimetics inhibit clonogenic growth potential in combination with 
TRAIL in SUM149 cells 
A, Clonogenic growth assay in SUM149 cells treated with TRAIL (10 ng/mL) alone or in 
combination with Birinapant (0-1000 nM). Bars represent mean±SEM colonies formed/cells plated 
as a percentage of the untreated sample.  Representative images are shown on the right. B, 
Clonogenic growth assay in SUM149 cells treated with TRAIL (50 ng/mL) alone or in 
combination with Birinapant or GT13402 (0-1000 nM). Bars represent mean±SEM colonies 
formed/cells plated as a percentage of the untreated sample.  Representative images are shown 
on the right. 
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Unlike in SUM149 cells, both Smac mimetics were similarly effective at inhibiting 
the clonogenic growth potential of TRAIL-resistant SUM190 as single agents (Fig. 4.9). 
Representative images show a decrease in SUM190 colony formation following 
treatment with Birinapant and GT13402. 
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Figure 4.9: Smac mimetics inhibit clonogenic growth potential as single agents in 
SUM190 cells 
Clonogenic growth assay in SUM190 cells treated with Birinapant, GT13402 (0-10,000 nM) or 
TRAIL (0-100 ng/mL). Bars represent mean±SEM colonies formed/cells plated as a percentage of 
the untreated sample (*P<0.05, #P<0.005; all comparisons made to the untreated sample). 
Representative images are shown below. 
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4.6 Smac mimetics inhibit anchorage-independent growth 
potential in combination with TRAIL and as a single agent 
Anchorage-independent colony formation in soft agar has been widely used as 
an in vitro model to assess cancer cell tumorigenic potential and is considered to be a 
reasonably good predictor of in vivo activity [381, 382]. Data in Figure 4.10A reveal that 
Birinapant+TRAIL (black bar) causes a 55% reduction in the number of colonies formed 
while TRAIL alone (white bar) causes a 20% decrease relative to untreated. 
Representative images of colonies formed in soft agar show similar sized colonies in all 
treatment groups but a significant reduction in colony number of the Birinapant+TRAIL 
combination. Analysis of AIG in SUM190 cells revealed a dose-dependent decrease in 
AIG following treatment with Birinapant (100-10,000 nM, Fig. 4.10B). Data show a 
significant ~50% decrease in the number of colonies formed with 100 nM Birinapant 
treatment relative to untreated (Fig. 4.10B). Representative images of colonies formed in 
soft agar show a reduction in colony number with increasing dose of Birinapant. 
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Figure 4.10: Birinapant inhibits anchorage-independent growth in combination with 
TRAIL and as a single agent in SUM149 and SUM190 cells respectively 
A, Anchorage-independent growth assay in SUM149 cells treated with TRAIL (50 ng/mL), 
Birinapant (1000 nM), or the combination. Bars represent mean±SEM colonies formed in soft agar 
as a percentage of the untreated sample (#P<0.005; comparisons made to TRAIL alone). 
Representative images are shown on the right. B, Anchorage-independent growth assay of 
SUM190 cells treated with Birinapant (0-10,000 nM). Bars represent mean±SEM colonies formed 
in soft agar as a percentage of the untreated sample (#P<0.005; all comparisons made to the 
untreated sample). Representative images are shown on the right. 
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4.7 Smac mimetic efficacy in SUM149 and SUM190 cells is TNF-
α-independent and caspase-dependent 
Studies were then conducted to evaluate whether TNF-α influences Smac 
mimetic efficacy in IBC cellular models. Since Smac mimetics, in addition to binding 
IAPs, have been shown to induce TNF-α production in sensitive cells, we measured 
TNF-α levels in the conditioned media of Birinapant-treated SUM149 and SUM190 cells 
by ELISA. Data in Figure 4.11A reveal insignificant TNF-α secretion in SUM149; 
SUM190 cells, which are sensitive to Smac mimetics as single agents, produce autocrine 
TNF-α in a dose-dependent fashion in response to Birinapant treatment, although it 
should be noted that the levels were in the low picogram/mL range. Addition of 
exogenous TNF-α (50 ng/mL) in combination with Birinapant in SUM190 cells had no 
additive effect on cell death compared to Birinapant alone as measured by trypan blue 
exclusion (Fig. 4.11B) and assessment of clonogenic growth capacity (Fig. 4.11C).  
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Figure 4.11: SUM190 cells produce low levels of autocrine TNF-α after treatment with 
Birinapant, but exogenous TNF-α does not sensitize SUM190 cells to Birinapant 
A, TNF-α production as determined by ELISA in conditioned media from SUM149 and SUM190 
cells treated with Birinapant (0-1000 nM). Bars represent mean±SEM (n=3). B, Viability as 
determined by trypan blue exclusion assay of SUM190 cells treated with Birinapant (0-1000 nM) 
alone or in combination with TNF-α (50 ng/mL). Data represent mean±SEM viable cells taken as a 
percentage of total cells (n=2-4). C, Clonogenic growth assay of SUM190 cells treated with 
Birinapant (B; 0-1000 nM) alone or in combination with TNF-α (50 ng/mL). Bars represent 
mean±SEM colonies formed/cells plated as a percentage of the untreated sample. 
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Next, the effect of TNF-α receptor (TNFR1) knockdown was evaluated in 
SUM190 cells using TNFR1-targeting siRNA and control scrambled siRNA at 24 h. 
Birinapant-induced cell death was not reversed (Fig. 4.12A) by specific TNFR1 
downregulation (Fig. 4.12B). 
 122 
 
Figure 4.12: Inhibition of TNF-α signaling through knockdown of TNFR1 does not 
inhibit Birinapant-induced cell death in SUM190 cells 
A, Viability as measured by trypan blue exclusion assay of SUM190 cells with TNFR1 
knockdown via siRNA or control siRNA treated with Birinapant (0-1000 nM). Data represent 
mean±SEM viable cells taken as a percentage of total cells (n=1-4). B, Western immunoblot 
analysis of TNFR1 in control SUM190 cells (C) and those transfected with TNFR1-targeting 
siRNA or scrambled siRNA (scr). GAPDH was used as a loading control. 
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Further, addition of a TNF-α neutralizing antibody (10 μg/mL) as in a method 
described previously [383] to SUM149 (Fig. 4.13A and 4.13B) or SUM190 (Fig. 4.13C and 
4.13D) cells did not reverse the decrease in viability or colony formation caused by 
Birinapant in combination or as a single agent. 
In contrast to the TNF-α studies, the apoptosis-inducing effect of 
Birinapant+TRAIL in SUM149 is potently reversed in the presence of pan-caspase 
inhibitor Q-VD-OPh, as evidenced by trypan blue exclusion assay and clonogenic 
growth assay (Fig. 4.13A and 4.13B). Similar reversal using Q-VD-OPh is observed in 
Birinapant-treated SUM190 cells (Fig. 4.13C and 4.13D). Together, these results reveal a 
TNF-α-independent but IAP- and caspase-dependent mechanism of action of Birinapant 
+TRAIL in SUM149 cells and Birinapant as a single agent in SUM190 cells. 
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Figure 4.13: Birinapant acts in a TNF-α-independent, caspase-dependent manner to 
kill SUM190 cells as a single agent and sensitize SUM149 cells to TRAIL 
A, Viability of SUM149 cells treated with TRAIL (50 ng/mL) + Birinapant (0-1000 nM) ± a TNF-α 
neutralizing antibody (10 µg/mL) or pan-caspase inhibitor Q-VD-OPh (20 µM). Data represent 
mean±SEM viable cells as a percentage of total cells (n=2-4, **P<0.01; comparisons made between 
Birinapant+TRAIL and Birinapant+TRAIL+TNF-α Ab or Q-VD-OPh). B, Clonogenic growth assay 
of SUM149 cells treated with TRAIL (50 ng/mL) + Birinapant (1000 nM) ± TNF-α Ab (10 μg/mL) 
or Q-VD-OPh (20 µM). Bars represent mean±SEM colonies formed/cells plated as a percentage of 
untreated. (#P<0.005; comparisons made between Birinapant+TRAIL and 
Birinapant+TRAIL+TNF-α Ab or Q-VD-OPh). C, Viability of SUM190 cells treated with 
Birinapant (0-1000 nM) ± TNF-α Ab (10 μg/mL) or Q-VD-OPh (20 µM). Data represent 
mean±SEM viable cells as a percentage of total cells (n=2-4, *P<0.05, **P<0.01; comparisons made 
between Birinapant and Birinapant+Q-VD-OPh). D, Clonogenic growth assay of SUM190 cells 
treated with Birinapant (1000 nM) ± TNF-α Ab (10 μg/mL) or Q-VD-OPh (20 µM). Bars represent 
mean±SEM colonies formed/cells plated as a percentage of untreated.  (*P<0.05; comparisons 
made between TNF- α Ab or Q-VD-OPh-treated). 
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4.8 Discussion 
We report herein IAP binding affinities of Birinapant and GT13042, two bivalent 
Smac mimetics, and their efficacy in IBC cellular models with differential TRAIL 
sensitivity and XIAP expression. IBC is a particularly aggressive subset of breast cancer 
that is characterized by apoptotic dysregulation, which has been observed in IBC cells 
and patient tumors [46, 78, 81, 103, 114, 224, 349]. Generation of isogenic IBC cell models 
with therapeutic resistance to lapatinib revealed upregulation of several anti-apoptotic 
proteins, and overexpression of XIAP correlated directly with therapeutic resistance [78, 
114, 320]. Thus, it is of particular interest to identify inhibitors of XIAP, as well as other 
members of the IAP family, in order to prevent or reverse acquired therapeutic 
resistance in IBC. It may be possible to treat IBC with an IAP inhibitor alone, or to 
sensitize these tumors to other drugs as part of a combination regimen. One way to 
inhibit the IAP family of proteins is through the use of Smac mimetics, which act 
similarly to Smac/DIABLO, a known endogenous mediator of IAP degradation that 
promotes initiation of apoptosis. 
In the present study, parental SUM149 and SUM190 IBC cell lines and their isogenic 
derivatives with differential XIAP expression (SUM149 wtXIAP and SUM190 shXIAP) 
were characterized for Smac mimetic sensitivity. These multiple lines were treated with 
Birinapant (pan-IAP antagonist with high affinity for cIAP1/2 and XIAP) and GT13402, 
which has lower affinity for XIAP. The differential binding of these two Smac mimetics 
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provides a molecular approach by which to investigate which IAPs are important for 
efficacy of Smac mimetics in IBC. Both Birinapant and GT13402 caused degradation of 
cIAP1 and cIAP2 but did not affect XIAP levels. Birinapant was more efficacious than 
GT13402 in both cell lines, emphasizing the importance of targeting XIAP in these 
models. It has been recently reported that bivalent Smac mimetic BV6 degrades both 
cIAP1 and XIAP but not cIAP2 in glioblastoma cells, revealing mechanistic differences 
associated with different cell models [369]. In general, Smac mimetic compounds are 
more efficacious in increasing potency of other drugs than as single agents [355]; a 
similar phenomenon was observed in the SUM149 cells, which were insensitive to 
Birinapant and GT13402 alone. However, the addition of Birinapant significantly 
enhanced TRAIL efficacy.  
The single agent efficacy of Birinapant in the SUM190 cell line was a significant 
finding. SUM190 does not express the DR4 death receptor and is insensitive to TRAIL 
treatment, which was found to be due at least in part to high XIAP expression. Previous 
studies have shown that Smac mimetics can cause paradoxical activation of pro-survival 
NF-κB signaling by autocrine TNF-α production, which can blunt the efficacy of Smac 
mimetics [358, 359, 363, 384-386], particularly in an in vivo setting. However, Birinapant 
efficacy may not be affected by NF-κB activation in SUM190 cells since only transient 
changes were observed, with slight activation and downregulation at earlier time points, 
while activated and total NF-κB returned to basal levels by 24 h. This is further 
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supported by the observation that Birinapant efficacy is not dependent on TNF-α 
production. The SUM190 cells showed only a modest increase in TNF-α levels in the 
picogram/mL range in culture supernatants from Birinapant-treated cells. This is unique 
in that pro-apoptotic activity of other Smac mimetics is usually associated with 
significant autocrine production of TNF-α and subsequent interaction with death 
receptors [358, 359, 385]. While a recent study in pancreatic cells with another Smac 
mimetic reported that inhibition of TNF-α by a neutralizing antibody reduced activation 
of caspases [386], addition of a neutralizing TNF-α antibody or silencing of TNFR1 using 
siRNA failed to prevent Birinapant-induced cell death in SUM190 cells. A similar result 
was observed in Birinapant+TRAIL-treated SUM149 cells, where addition of a 
neutralizing TNF-α antibody failed to inhibit cell death. Furthermore, addition of 
exogenous TNF-α did not enhance Smac mimetic-mediated cell death in the SUM190 
model, supporting a TNF-α-independent mechanism for Birinapant in the IBC cells.  
Additionally, the effect of Birinapant was further characterized using anchorage-
independent growth as a predictor of in vivo behavior. The ability of cells in vitro to grow 
in the absence of anchorage has been shown to correlate directly with cancer cell 
tumorigenicity in multiple mouse models [381, 387]. Thus, the reduction in anchorage-
independent growth observed in Birinapant+TRAIL-treated SUM149 cells and 
Birinapant-treated SUM190 cells highlights Birinapant’s ability to target tumorigenic 
cells and indicates the potential for in vivo efficacy. 
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The present study shows that Birinapant efficacy corresponded with cIAP1/2 
degradation, apoptotic parameters, and was reversed by addition of a caspase inhibitor. 
In a recent study, a monovalent Smac mimetic (LBW242) similarly induced cell death in 
a TNF-α-independent, caspase-dependent manner in neuroblastoma cell lines without 
degradation of cIAP1/2 [388]. However, IC50 values for LBW242 as a single agent in 
neuroblastoma cells were in the 50 µM concentration range, which caused significant 
toxicity in matched normal cells. Birinapant, however is efficacious at lower nanomolar 
concentrations in the cells tested here and is well tolerated at up to the highest dose 
tested in animals (60 mg/kg)  [364].  
At the present, there is no standard IBC-specific treatment plan for patients with 
advanced disease [3]. A Phase 1a dose escalation study of Birinapant was recently 
completed in patients with refractory solid tumors and lymphoma, and a Phase1b/2a 
trial is ongoing in which Birinapant will be combined with standard of care 
chemotherapies [364]. Through the use of IBC cell lines with differential XIAP 
expression and Smac mimetics with different affinities for XIAP, this study substantiates 
findings from previous work identifying XIAP is an important resistance factor and 
therapeutic target in IBC. By demonstrating that inhibition of XIAP in combination with 
cIAP1/2 using the Smac mimetic Birinapant effectively induces death in a panel of IBC 
cell lines, this study strengthens the feasibility of developing clinical trials for Birinapant 
in IBC. 
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5 Targeting XIAP with the small molecular functional 
inhibitor embelin 
5.1 Introduction 
IBC is often characterized by the acquisition of resistance to chemo-, targeted- 
and radiotherapies, resulting in poor prognosis compared to LABC [3, 12]. Many 
therapeutic agents induce therapeutic apoptosis through increases in ROS [389, 390]; 
however, continuous treatment promotes selection for cells that develop mechanisms to 
cope with increased ROS, resulting in drug resistance [253]. We previously reported that 
overexpression of XIAP is a key feature in acquired resistance to ErbB1/EGFR- and 
ErbB2/Her2-targeting agents in SUM149- and SUM190-derived IBC cell models [103, 
114]. The clonal population of IBC cell lines with acquired therapeutic resistance is also 
characterized by redox adaptation via upregulation of antoxidants SOD1/2 and GSH 
[78]. Together, these characteristics were associated with cross-resistance to oxidative 
stressors such as H2O2 and paraquat [78] as well as a number of targeted and 
chemotherapeutics [320]. Therefore, it is clear that XIAP overexpression and enhanced 
ability to detoxify ROS can contribute to the development of resistance in IBC therapy. 
While it has been found that XIAP expression is key determinant of TRAIL sensitivity in 
the parental SUM149 and SUM190 cells as well as in other cell line models [316, 319, 352, 
353], it is unknown how the altered profile of anti-apoptotic and antioxidant proteins in 
the acquired resistant IBC cell line models will affect the response to TRAIL and whether 
this can be modulated by ROS accumulation.  
 130 
Embelin, a natural plant-derived agent, is a cell permeable, small molecule 
inhibitor of XIAP specifically that was identified through structure-based computational 
screening of a database of traditional herbal medicines [321]. It binds to the BIR3 domain 
of XIAP with affinity similar to natural Smac/DIABLO, blocking XIAP’s interaction with 
caspases and promoting apoptosis. In addition to targeting XIAP, embelin has been 
reported to inhibit NF-κB signaling and to have anti-tumor, anti-inflammatory, and 
analgesic properties [391, 392].  In the present study, we observed that in addition to 
blocking XIAP’s caspase-inhibitory function, embelin suppressed key antioxidants and 
promoted the accumulation of ROS to potentiate TRAIL efficacy, revealing a new 
mechanism of embelin action.  
5.2 XIAP overexpression inversely correlates with TRAIL 
sensitivity in IBC cells 
In this study, the role of XIAP in TRAIL sensitivity was evaluated in SUM149 
cells (TN, EGFR-activated cell line [312]. Isogenic cells with differential XIAP expression 
derived from SUM149 were characterized for TRAIL sensitivity (10-1000 ng/mL) at a 24 
h time period. These include parental SUM149, SUM149 wtXIAP (stable XIAP 
overexpression via a lentiviral construct) and its vector-control counterpart SUM149 FG9 
[114], rSUM149 [114], a model of acquired resistance to an ErbB1/2 targeting agent with 
endogenous high XIAP expression, and rSUM149 with XIAP knockdown (rSUM149 
shXIAP). Cell viability determined by trypan blue exclusion assay shows that parental 
SUM149 cells are significantly more sensitive to TRAIL than rSUM149 (Fig. 5.1A) and 
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SUM149 wtXIAP cells (Fig. 5.1B). Calculated IC50 for cell viability in the presence of 
TRAIL was approximately 770 ng/mL in SUM149wtXIAP cells, 530 ng/mL in 
endogenously XIAP overexpressing rSUM149 cells, and 45 ng/mL (p<0.005) in vector 
control SUM149 cells. To further investigate the role of XIAP in sensitivity to TRAIL, we 
characterized TRAIL efficacy in rSUM149 cells with XIAP knockdown through 
transfection of a plasmid expressing shRNA directed against XIAP (rSUM149 shXIAP). 
Immunoblot analysis is shown in the inset of Figure 5.1C. Data in Figure 5.1C show that 
XIAP knockdown in the rSUM149 cells results in higher sensitivity to TRAIL-induced 
cell death.  Knockdown of XIAP in the rSUM149 cells caused a pronounced decrease in 
IC50 from 530 ng/mL in rSUM149 cells to approximately 30 ng/mL in the rSUM149 
shXIAP cells. XIAP knockdown caused the rSUM149 shXIAP cells to become even more 
sensitive to TRAIL than the parental SUM149 cells, which have some basal level of XIAP 
expression; rSUM149 shXIAP cell viability drops to ~60% upon treatment with 10 ng/mL 
TRAIL, while SUM149 cell viability is about 80% with the same treatment.  
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Figure 5.1: Effect of TRAIL expression on viability of isogenic-derived SUM149 cell 
line models 
A, SUM149 and rSUM149 cells were treated with TRAIL for 24 h, and viability was assessed.  B, 
SUM149 wtXIAP and vector control SUM149 FG9 cells were treated with TRAIL for 24 h, and 
viability was assessed. C, rSUM149 and rSUM149 cells with knockdown of XIAP expression 
(rSUM149 shXIAP) were treated with TRAIL for 24 h, and viability was assessed. Bars represent 
mean±SEM viable cells taken as a percentage of the untreated control (n=2-4). Inset: XIAP 
expression in rSUM149 cells and rSUM149 shXIAP cells. GAPDH was used as a loading control.   
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Cell viability differences were consistent with XIAP downregulation post TRAIL 
treatment in the SUM149 cells compared to the rSUM149 and SUM149wtXIAP cells 
(Figure 5.2A). In addition, a functional assay was used to measure the activity of 
caspases during the apoptotic process; this assay was performed after 4 h of TRAIL 
treatment to ensure that cells were dying but not yet dead, at which point caspase 
activity would be unreadable. XIAP decrease following treatment in the TRAIL-sensitive 
SUM149 cells corresponded with increased caspase-3/7 activity (Figure 5.2B, p<0.005) 
compared to limited caspase activity post-TRAIL treatment in the rSUM149 and 
SUM149wtXIAP cells. These results demonstrate that SUM149 wtXIAP and rSUM149 
cells with XIAP overexpression compared to SUM149 show significantly reduced 
sensitivity to TRAIL-mediated apoptosis.  
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Figure 5.2: TRAIL sensitivity in SUM149 is associated with downregulation of XIAP 
and caspase activation 
A, XIAP immunoblot analysis of rSUM149, SUM149 wtXIAP, and SUM149 FG9 vector control 
cells treated with TRAIL for 24 h.  Treatments are compared to untreated cells. Actin was used as 
a loading control. B, Caspase-3/7 activity in rSUM149, SUM149 wtXIAP, and SUM149 FG9 vector 
control cells after treatment with TRAIL for 3 h. Bars represent mean±SEM RLU (n=3).  **p<0.005.   
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5.3 The XIAP inhibitor embelin enhances TRAIL sensitivity 
Since XIAP overexpression and activity corresponds with decreased TRAIL 
sensitivity in the SUM149 model, we evaluated the effects of embelin, a small molecular 
inhibitor of XIAP, in combination with TRAIL. Combination studies with TRAIL and 
embelin were conducted at 24 h, and viability was assessed by trypan blue exclusion 
assay. Data in Figure 5.3A-C show that embelin at 24 h alone at three concentrations 
(12.5, 25, 50 M) induced a modest decrease (10-25%) in viability in the three cell lines. 
TRAIL (50 ng/mL) alone at 24 h as described in Figure 5.1, shows higher sensitivity in 
the parental SUM149 cells (Fig. 5.3A) compared to the XIAP overexpressing 
SUM149wtXIAP (Fig. 5.3B) and rSUM149 (Fig. 5.3C) isogenic lines. Combining 
increasing concentrations of embelin with TRAIL (50 ng/mL) at 24 h caused a significant 
decrease in cell viability in all three cell lines. Increasing concentrations of TRAIL up to 
100 ng/mL in combination with 25 M or 50 M embelin did not have any significantly 
enhanced response over that seen in Figure 5.3 (data not shown).  
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Figure 5.3: Embelin enhances the pro-apoptotic effects of TRAIL in SUM149, SUM149 
wtXIAP, and rSUM149 
A, SUM149 FG9 vector control, B, SUM149 wtXIAP, and C, rSUM149 cells were treated with 
embelin (12.5-50 µM) and TRAIL (50 ng/mL) alone or in combination for 24 h, and viability was 
assessed by trypan blue exclusion. Bars represent mean±SEM of viable cells (n=2-8).  *p<0.05, 
**p<0.005. 
 137 
In order to characterize the interaction of these two agents, we analyzed the 
results in Figure 5.3 with Calcusyn (Biosoft, Cambridge, UK), a program that employs 
the Chou-Talalay Method, a derivation of the mass-action law principle [326]. When 
experimental data is entered into the program, it produces graphs in which the X axis 
represents the dose of each drug alone or in combination, and the Y axis represents 
treatment efficacy, with an effect of 1.0 meaning 100% cell death, while 0.5 is equal to 
50% cell death. From these graphs (Figure 5.4A-C), the program calculates a 
combination index (CI) that is a quantitative measurement of the relationship between 
two agents; a CI greater than 1 indicates antagonism, while a CI of one indicates an 
additive interaction and a CI less than one indicates synergism. The CI values for the 
interaction between embelin and TRAIL in SUM149, SUM149 wtXIAP and rSUM149 
cells were all calculated to be well below one (Table 5.1, Fig. 5.4), which is indicative of 
strong synergism in all three cell lines.  
Table 5.1: Combination indices (CI) for the interactions between embelin and TRAIL 
in SUM149-derived isogenic cell lines 
Cell Line Combination 
Index (CI) 
SUM149 0.077 




Figure 5.4: Combinatorial analysis reveals synergy between embelin and TRAIL  
Dose effect curves for A, SUM149, B, SUM149 wtXIAP, and C, rSUM149 treated with embelin 
and TRAIL alone as well as the combination created using Calcusyn software. 
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The effects of embelin, TRAIL, or embelin+TRAIL on downstream TRAIL 
signaling pathway proteins in treated lysates were analyzed by western immunoblot. 
Immunoblot analysis of death receptors DR4 and DR5 (Figure 5.5A,B) in SUM149 cells 
revealed no significant upregulation of death receptor expression in response to 
treatment.  The same results were seen in the SUM149 wtXIAP cells upon treatment with 
embelin and/or TRAIL (data not shown).  
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Figure 5.5: Embelin does not effect death receptor expression in SUM149 cells 
Western immunoblot analysis of A, DR4 and B, DR5 expression in SUM149 cells treated with 
embelin, TRAIL, or embelin+TRAIL for 24 h. Treatments were compared to untreated cells (U) or 
DMSO vector control (C). Numbers represent densitometric analysis of protein normalized to 
GAPDH. 
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A decrease in cFLIP, a caspase-8 homolog that binds to the DISC to block caspase 
activation, was observed following treatment with embelin and TRAIL alone as well as 
in combination in the parental SUM149 cells (Figure 5.6A). However, cFLIP levels 
remain unchanged in the XIAP overexpressing cells (Figure 5.6B) treated with embelin, 
TRAIL or embelin+TRAIL, although cell death was significantly increased (Figure 5.3).  
Examination of lysates from SUM149 wtXIAP cells treated with embelin or 
embelin+TRAIL reveal XIAP downregulation upon treatment with embelin compared to 
control. In addition, an XIAP cleavage product (30 kDa) and potent inhibition of full 
length XIAP levels are detected in cells treated with embelin+TRAIL (Figure 5.6C). In 
summary, embelin and TRAIL synergize to increase cell death in the TN IBC cell model. 
 142 
 
Figure 5.6: Sensitization to TRAIL by embelin is associated with reduced XIAP 
expression 
cFLIP western immunoblot analysis of A, SUM149 and B, SUM149 wtXIAP cells treated with 
embelin, TRAIL, or embelin+TRAIL for 24 h. C, XIAP immunoblot analysis of SUM149 wtXIAP 
cells treated with embelin, TRAIL, or embelin+TRAIL for 24 h; full length XIAP and its cleavage 
product are shown. Treatments were compared to untreated cells (U) or DMSO vector control 
(C). Numbers represent densitometric analysis of protein normalized to β-actin or GAPDH. 
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5.4 Embelin modulates the ERK signaling pathway 
To further study the mechanisms behind the combinatorial synergism, signaling 
pathways that are linked to apoptosis were examined in response to treatment. For this 
purpose, SUM149 and SUM149 wtXIAP cells were treated with embelin, TRAIL, or 
embelin+TRAIL at the indicated concentrations for 24 h and then examined for the 
phosphorylation status of extracellular signaling regulated kinase (ERK1/2) and the 
stress-activated protein kinase (SAPK) JNK (Figure 5.7). In SUM149 cells, cell death 
associated with embelin or embelin+TRAIL correlated with a decrease in p-ERK1/2 
(Figure 5.7A). Interestingly, in the SUM149 wtXIAP cells with exogenous XIAP 
overexpression, the basal levels of ERK1/2 phosphorylation were lower than the parental 
SUM149 cells. Further, an increase in p-ERK1/2 was observed in embelin- and 
embelin+TRAIL-treated SUM149 wtXIAP cells compared to vehicle- or TRAIL-treated 
cells (Figure 5.7B). To interrogate the nature of ERK1/2 signaling in this system, we 
added the MEK1/2 inhibitor U0126 to the embelin+TRAIL combination in SUM149 
wtXIAP cells to block ERK1/2 phosphorylation. This resulted in further reduction of cell 
viability from approximately 25% with embelin+TRAIL treatment to less than 1% viable 
cells in the presence of embelin+TRAIL+U0126 (Figure 5.7C). No specific change in p-
JNK levels was observed in the various treatments as compared to vehicle control in the 
SUM149 or SUM149 wtXIAP cells (data not shown). 
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Figure 5.7: Embelin+TRAIL has differential effects on ERK signaling in SUM149 and 
SUM149 wtXIAP cells 
A, Phospho-ERK1/2 (MAPK p44/42) western immunoblot analysis of SUM149 cells treated with 
embelin or embelin+TRAIL for 24 h. B, Phospho-ERK1/2 western immunoblot analysis of 
SUM149 wtXIAP cells treated with embelin, TRAIL, or embelin+TRAIL. Treatments were 
compared to untreated cells (U) or DMSO vector control (C). Numbers represent densitometric 
analysis of p-ERK1/2 normalized to total ERK1/2 protein.  C, Cellular viability as determined by 
trypan blue viability assay for SUM149 wtXIAP cells treated with 50 µM embelin, 50ng/ mL 
TRAIL, or combination, and the combination with the addition of 10 µM U0126 MEK1/2 
inhibitor. 
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5.5 Embelin induces generation of intracellular ROS by 
downregulation of SOD1 and oxidation of glutathione 
Recently we reported [78] that the XIAP overexpressing rSUM149 cells which 
have acquired resistance to therapeutic apoptosis mediated by lapatinib have lost the 
ability to accumulate ROS in the presence of oxidizing agents like paraquat and 
hydrogen peroxide; they also have high expression of key antioxidants SOD1/2 and 
GSH. Interestingly, embelin treatment downregulates SOD1 (Figure 5.8A) and consumes 
GSH (Figure 5.8B, p<0.05) in the rSUM149 cells, inhibiting the detoxification of 
damaging oxidative species. Decrease in antioxidant expression corresponds with an 
increase in mitochondrial superoxides as measured by flow cytometry compared to 
paraquat, a classical ROS generating agent which we have previously reported [78] to 
have insignificant effects on ROS generation in the rSUM149 cells (Figure 5.8C). Embelin 
also decreases mitochondrial membrane potential as measured by TMRE staining, which 
the classical ROS-inducer paraquat fails to do in the rSUM149 cells (Fig. 5.8C). 
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Figure 5.8: Embelin reduces cellular antioxidant capacity and generates ROS in 
rSUM149 cells to induce cell death 
A, Western immunoblot analysis of SOD1 in rSUM149 cells treated with 50 µM embelin or vector 
control (C). Numbers represent densitometric analysis of protein normalized to β-actin. B, 
Glutathione content of cells treated with 50 µM embelin or a vector control. * p< 0.05.   C, Left 
axis displays accumulation of mitochondrial superoxide in cells treated with 50 µM embelin for 1 
h or 5 mM paraquat for 24 h as measured by fold increase in MitoSOX Red staining via flow 
cytometry. Right axis displays decrease in mitochondrial membrane integrity, measured by 
percent of cells with high TMRE staining via flow cytometry.  
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5.6 SOD mimetic/antioxidant reverses efficacy of the 
Embelin+TRAIL combination 
To determine whether the generation of ROS by embelin is specifically 
contributing to enhanced cell death observed with embelin+TRAIL treatment, we tested 
the effect of an SOD mimic (MnTnHex-2-PyP5+) [78, 317], which acts as a potent 
antioxidant  both in vitro and in vivo and was simultaneously added to the combination 
at increasing concentrations. Addition of the SOD mimic to embelin+TRAIL provided 
protection against ROS and resulted in a dose-dependent increase in cellular viability 
(Figure 5.9). Together, these results indicate that the concurrent inhibition of XIAP along 
with modulation of antioxidant molecules and ROS generation by embelin sensitizes 
resistant cells to TRAIL-induced apoptosis. 
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Figure 5.9: Addition of an exogenous antioxidant (SOD mimetic) partially rescues 
embelin+TRAIL-induced cell death in SUM149 wtXIAP cells 
Cellular viability as determined by trypan blue exclusion assay for SUM149 wtXIAP cells treated 
with 50 µM embelin, 50ng /mL TRAIL, or combination (gray bars) and the combination with the 
addition of an SOD mimic (MnTnHex-2-PyP5+) at 10-200 µM (black bars). *p<0.05, **p<0.005. 
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5.7 Discussion 
We report herein an inverse correlation between XIAP expression and TRAIL 
sensitivity in isogenic cell lines developed from the primary patient tumor-derived 
SUM149 cell line [312]. Endogenous and exogenous overexpression of XIAP in SUM149 
cells (rSUM149 and SUM149 wtXIAP) resulted in increased resistance to TRAIL-induced 
apoptosis and reduced caspase activation relative to the parental TRAIL-sensitive 
SUM149 cells. Conversely, knockdown of XIAP in the rSUM149 cells enhanced TRAIL 
efficacy; the knockdown rendered the rSUM149 shXIAP cells even more sensitive to 
TRAIL-induced apoptosis than the parental SUM149 cells, which express basal levels of 
XIAP. In addition, the XIAP inhibitor embelin synergizes with TRAIL to induce 
apoptosis in XIAP-overexpressing IBC cell lines (SUM149 wtXIAP and rSUM149) and 
enhances the potency of TRAIL in the isogenic TRAIL-sensitive counterpart (SUM149), 
the first report of this phenomenon in IBC. Embelin also activated ERK1/2 in SUM149 
wtXIAP cells, and this effect was amplified and accompanied by increased cell death 
when combined with TRAIL. Embelin treatment reversed high SOD1 expression and 
inhibited the increased GSH detoxification capacity in the redox adapted IBC resistance 
model; this led to the accumulation of ROS, identifying a potential new mechanism of 
action for embelin.  
Previous studies evaluating therapeutic agents (such as gossypol, perifosine, and 
zerumbone) and chemotherapies that can potentiate TRAIL efficacy have reported 
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upregulation of TRAIL-specific death receptors as an important mechanism of TRAIL 
sensitization [393-395].  However, no increase in DR expression was observed in the 
embelin-treated cells, indicating that this mechanism was not responsible for 
sensitization of the IBC lines. The caspase-8 homolog cFLIP has previously been 
reported to block apoptosis induced by ligand binding to Fas/CD95, TRAIL, and TNF 
receptors [373, 396, 397]. In certain contexts, inhibiton or downregulation of cFLIP 
sensitizes resistant cells to TRAIL-induced apoptosis [398-403]. In the current study, 
cFLIP protein levels decreased significantly in TRAIL- or embelin+TRAIL-treated 
parental SUM149 cells; however, cFLIP levels were unchanged in embelin+TRAIL-
treated XIAP overexpressing cells even though they underwent apoptosis in response to 
the combination. These observations indicate that cFLIP expression is not sufficient to 
determine TRAIL sensitivity in this model.   
In the present study, single agent embelin treatment caused an increase in 
ERK1/2 phosphorylation in the XIAP overexpressing cell line (SUM149 wtXIAP), and 
this effect was amplified by combination with TRAIL, which corresponded with 
significant cell death. In contrast, treatment with embelin or embelin+TRAIL decreased 
ERK1/2 phosphorylation in SUM149 cells. Interestingly, SUM149 wtXIAP cells have very 
low basal levels of ERK1/2 phosphorylation compared to the parental SUM149 cells. This 
observation is consistent with a previous study in which knockdown of XIAP in a mouse 
model resulted in an increase in ERK1/2 phosphorylation [404]. ERK signaling is largely 
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proliferative [258] and promotes survival [405]; in some cases, downregulation or 
inhibition of ERK1/2 is necessary for apoptosis to occur in normal and cancerous cells. 
Studies in neuronal [406] and leukemia models [407, 408] have reported that concurrent 
activation of p38 MAPK and JNK in conjunction with inhibition of ERK is critical for the 
induction of apoptosis. However, there is also convincing evidence implicating the 
Ras/Raf/ERK pathway in pro-apoptotic signaling events such as the expression of death 
ligands and/or receptors [393], modulation of Bcl-2 family members resulting in 
disruption of the mitochondrial membrane, and suppression of anti-apoptotic signaling 
molecules [409].  In fact, the action of many apoptosis-inducing drugs  including 
estradiol, tamoxifen, and cephalosporin is abrogated by Ras/Raf/ERK pathway 
inhibition [410]. In the parental SUM149 cells, which have basal levels of XIAP 
expression, treatment with embelin correlated with reduced ERK1/2 phosphorylation, 
indicating a pro-survival role of ERK signaling. In the SUM149 wtXIAP cells, which 
overexpress XIAP and have low basal ERK1/2 phosphorylation, treatment with 
apoptosis-inducing agents correlated with increased ERK1/2 phosphorylation, 
suggesting that ERK1/2 signaling may be a compensatory mechanism to oppose 
apoptosis. This is further supported by the observation that addition of U1026, a 
MEK1/2 inhibitor that blocks ERK phosphorylation, to embelin+TRAIL-treated SUM149 
wtXIAP cells resulted in significant cell death beyond the embelin+TRAIL combination.  
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rSUM149 cells overexpress SOD1/2 and possess increased GSH levels, qualities 
which enhance their ability to detoxify ROS in the presence of oxidative agents [78]. 
Embelin caused a significant downregulation of SOD1 and GSH, increased superoxide 
levels, and sensitized rSUM149 cells to apoptosis, revealing an ROS-modulatory 
mechanism of embelin in IBC cells. Furthermore, addition of an SOD mimic (MnTnHex-
2-PyP5+) provided protection against ROS and reduced embelin+TRAIL-associated cell 
death in a dose-dependent manner. This is consistent with previous results in which 
treatment of parental SUM149 cells with an SOD mimic reversed the ability of these cells 
to accumulate ROS in the presence of oxidizing agents [78]. Together, these results 
indicate that embelin sensitizes IBC cells to TRAIL-mediated apoptosis through direct 
inhibition of XIAP’s anti-caspase activity and by shifting the cellular redox balance 
toward oxidative stress-mediated apoptosis. Thus, the targeting of cellular redox 
adaptation through the use of ROS modulators may represent a promising new 
approach for enhancing therapeutic efficacy in IBC. 
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6 Targeting redox adaptation in IBC using the redox 
modulator disulfiram 
6.1 Introduction 
The altered redox status in cancer cells is a biochemical feature that is attractive 
for the development of selective therapeutic strategies [235, 411-413]. However, redox 
adaptive mechanisms including upregulation of ROS scavenging systems and 
antioxidant activity can confer drug resistance [264, 390]. The development of resistance 
to classic anti-tumoral therapies is a common occurrence and significant barrier to the 
successful treatment of IBC [3, 12]. Gene expression analyses indicate that IBC has 
higher expression of genes associated with NF-κB and related survival signaling 
pathways relative to non-IBC tumors [18, 32-34, 224, 414]. Additionally, redox 
adaptation through increased SOD1/2 expression and high levels of GSH was detected 
in acquired therapy-resistant IBC cell lines compared to therapy-sensitive parental cells. 
The increase in antioxidant defense mechanisms prevented the accumulation of ROS, 
significantly suppressed oxidative stress-associated cell death [78], and conferred drug 
resistance to various chemotherapeutics and targeted agents [320].  Reduction of 
antioxidant mechanisms by the XIAP inhibitor embelin was associated with ROS 
accumulation and sensitization of rSUM149 cells to therapeutic apoptosis [415]. These 
data indicate that redox modulators with pro-oxidant properties have the potential to 




One such pharmacological agent is Disulfiram (DSF), a clinically utilized anti-
alcoholism drug that can bind copper to form a complex (DSF-Cu). DSF is FDA-
approved for the treatment of alcoholism and is safe even at high doses; the 
recommended dosage for alcoholic patients is currently 250-500 mg/day [416, 417]. DSF 
has been shown to be cytotoxic in cell line models of melanoma, colorectal, 
hematological, prostate, and breast cancer and is currently in Phase 1/2 clinical trials for 
the treatment of metastatic melanoma and refractory solid tumors of the liver [418]. 
Disulfiram’s reported mechanisms of action include generation of ROS [419-421], 
proteasomal inhibition [422-424], DNA demethylation [425], and modulation of cell 
survival and death signaling pathways [419-422, 426]. 
In this study, DSF was assessed as a single agent and in combination with copper 
(DSF-Cu) in established patient tumor-derived models of IBC, isotype matched drug-
resistant IBC cell lines, and an exogenous model of XIAP overexpression. DSF-Cu led to 
increased ROS accumulation accompanied by decreases in SOD1 expression and GSH 
levels, and addition of an SOD mimetic reversed cell death. Additionally, DSF-Cu 
blocked NF-κB activation, inhibited cancer stem cell-associated ALDH1 activity, 
prevented anchorage-independent cell growth, and induced apoptosis. Taken together, 
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this study provides a rationale for the repurposing of an old and safe drug for targeting 
IBC.   
6.2 DSF induces death in IBC cells, and potency is enhanced by 
the addition of copper 
In an effort to investigate the effects of DSF on IBC cell lines with different subtype 
and redox response status, we treated established patient-derived IBC tumor cell lines, 
isotype-matched cells selected for drug resistance, and a model of exogenous XIAP 
overexpression. The data in Figure 6.1 show treatment with a dose range of DSF alone or 
in the presence of 10 µM copper (DSF-Cu) in three established IBC cell lines: SUM149 
(basal type, ROS sensitive), MDA-IBC-3 (Her2-overexpressing, ROS responsiveness 
unknown), and SUM190 (Her2-overexpressing, ROS sensitive) [312, 314]. DSF induces 
cell death at micromolar concentrations in all three cell lines, although SUM190 cells are 
much more sensitive than SUM149, and MDA-IBC-3 cells are relatively less sensitive 
(Fig 6.1A: SUM149-squares, IC50 of ~17 µM; Fig 6.1B: MDA-IBC-3- squares, IC50 >50 µM; 
Fig 6.1C: SUM190- IC50 of ~2.7 µM). DSF’s potency was significantly enhanced by the 
addition of copper (DSF-Cu) in all three cell lines, with approximately a 100 fold or more 
decrease in IC50 values of SUM149 and MDA-IBC-3 (Fig 6.1A: SUM149- circles, IC50 of 
~200 nM; Fig 6.1B: MDA-IBC-3- circles, IC50 of ~300 nM); SUM190 cells were so sensitive 
to the combination that 100% cell death was observed at the lowest concentration tested 




Figure 6.1: DSF induces cell death in patient-derived IBC cell lines, and potency is 
significantly enhanced by the addition of copper 
Viability of A, SUM149, B, MDA-IBC-3, and C, SUM190 cells treated with DSF (0-50 µM, 
squares), copper (10 µM) or DSF-Cu (100-500 nM + 10 µM Cu, circles) as measured by trypan 
blue exclusion assay. 
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DSF and DSF-Cu were also tested in rSUM149 and rSUM190 (isogenic-
derivatives of SUM149 and SUM190 selected for lapatinib resistance with increased 
SOD1/2 and GSH and reduced ROS-generating capability) and SUM149 wtXIAP cells 
with exogenous XIAP overexpression [78, 114]. The SUM149-derived models rSUM149 
(Fig. 6.2A: squares) and SUM149 wtXIAP (Fig. 6.2B: squares) were somewhat less 
sensitive to disulfiram than the parental line, with IC50s of ~25-30 µM compared to ~17 
µM in SUM149 (Table 6.1). rSUM190 cells (Fig. 6.2A) also showed a slight decrease in 
sensitivity compared to the parental SUM190 model, with an IC50 of ~3.9 µM compared 
to ~2.7 µM in SUM190, and DSF-induced cell death was also enhanced by the addition of 
copper in the resistant rSUM149 (Fig. 6.2A: circles), SUM149 wtXIAP (Fig. 6.2B: circles), 
and resistant rSUM190 models, with IC50s of ~230, and ~125 nM in rSUM149 and 
SUM149 wtXIAP (Table 6.1). Similar to their parental counterparts, rSUM190 cells were 




Figure 6.2: DSF induces cell death in isogenic-derived IBC models of therapeutic 
resistance, and potency is significantly enhanced by the addition of copper 
Viability of A, rSUM149, B, SUM149 wtXIAP, and C, rSUM190 cells treated with DSF (0-70 µM, 




Compared to previous reports of single agent efficacy in a panel of cancer cell 
lines, the IBC cell lines tested here, including SUM190 and rSUM190, are relatively 
insensitive to single agent DSF. The IC50 values for DSF alone and the combination of 
DSF-Cu in each IBC cell line is listed in Table 6.1, along with three non-IBC breast 
cancer, several prostate cancer, and three glioblastoma cell lines previously reported 
[420, 421, 427]. Interestingly, the addition of copper sensitizes the IBC cell lines to DSF-
Cu at concentrations similar to or even lower than the other cancer cell lines (Table 6.1). 
Neither copper at the tested concentration nor DSF in the nanomolar range had an effect 
on cellular viability in any of the cell lines tested. As all cell lines were sensitive to DSF 
and DSF-Cu to some degree and the SUM190 models were too sensitive for any 
mechanistic studies with DSF-Cu, the remainder of the studies was performed in 
SUM149 and rSUM149 cells. 
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Table 6.1: IC50s for DSF and DSF-Cu in cellular models of cancer 







SUM149 17,620 1060 200.4 36.9 IBC  
SUM190 2,969 2,172 <50 NA IBC  
MDA-IBC-3 >50,000 NA 300 100 IBC  
rSUM149 26,520 13,420 234.9 127.2 IBC  
rSUM190 3951 355 <50 NA IBC  
SUM149 wtXIAP 29,710 5,670 126.7 7.3 IBC  
MCF7 456 62 211 23 BC [421] 
MDA-MB-231 495 49 476 48 BC [421] 
T47D 1100 87 443 62 BC [421] 
VCaP 94 19   PC [427] 
DuCaP 60 18   PC [427] 
LNCaP 170 36   PC [427] 
LNCaP C4- 2 97 22   PC [427] 
PC-3 >1000 NA   PC [427] 
CU-145 >10,000 NA   PC [427] 
RWPE-1 >10,000 NA   PC [427] 
EP156T >10,000 NA   PC [427] 
PrEC >10,000 NA   PC [427] 
U251MG >10,000 NA 464.9 236.4 GBM [420] 
U87MG >10,000 NA 242.8 39.4 GBM [420] 




To further investigate the necessity of copper in DSF’s mechanism of action, we 
blocked DSF-Cu binding through the addition of potent copper chelators in molar 
excess. Addition of BCS (white bars), an extracellular copper chelator which cannot cross 
the cell membrane [428], or TM (gray bars), a cell permeable chelator [429], completely 
blocked DSF-Cu-induced cell death (black bars) in SUM149 (Fig. 6.3A) and rSUM149 
(Fig. 6.3B) cells, highlighting the role of copper in enhancing the cytotoxic action of DSF. 
Neither the TM-Cu nor the BCS-Cu combinations caused any cytotoxicity in these 




Figure 6.3: DSF-Cu-mediated cell death is potently reversed by the addition of copper 
chelators 
Viability of A, SUM149 and B, rSUM149 cells treated with DSF-Cu (100-500 nM and 10 µM 
respectively), and the copper chelators bathocuproine disulphonate (BCS, 100 µM) or 
tetrathiomolybdate (TM, 10 µM) as measured by trypan blue exclusion assay. 
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6.3 DSF is a copper ionophore that induces Ctr1-independent 
copper uptake 
DSF has been implicated as a copper ionophore with the ability to bring copper 
into cells independently of copper transporters due to its copper-binding ability and 
high lipophilicity; this would allow it to bypass the tightly regulated mechanisms that 
control intracellular copper levels [428, 430, 431]. However, it has not been explicitly 
proven that DSF can induce Ctr1-independent copper uptake. To test whether DSF can 
induce Ctr1-independent uptake of copper into cells, growth of Ctr1/3 wildtype SEY6210 
Saccharomyces cerevisiae was compared to Ctr1/Ctr3 deletion mutant MPY17 cells [323, 
324] in YPEG media; growth was measured by reading absorbance at 600 nm. Data in 
Figure 6.4 show that while SEY6210 cells (white bars) grow well in unsupplemented 
media, MPY17 cells (black bars) cannot grow in normal YPEG media. However, in the 
presence of low levels of the known copper ionophore ZPT [325], which brings enough 
copper into the cell for normal biological function, MPY17 cells grow similarly to the 
SEY6210 cells. At higher concentrations, ZPT increases cellular copper levels past those 
that support growth, indicated by the reduction in absorbance; SEY6210 cells, which 
take up normal levels of copper on their own, are more sensitive to ZPT-induced growth 
inhibition than MPY17 cells, showing a reduction in growth at 0.39 µM ZPT compared 
to 1.56 µM ZPT respectively (Fig. 6.4A). In this assay format, the addition of low 
concentrations of DSF to MPY17 cells enhanced their growth similar to ZPT treatment. 
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DSF also induced growth inhibition in both SEY6210 and MPY17 cells at concentrations 
of 6.25 µM and greater (Fig. 6.4B). These data indicate that DSF is able to act as an 




Figure 6.4: DSF acts as an ionophore to facilitate the uptake of copper into Ctr1/Ctr3 
mutant yeast  
Growth of Ctr1/Ctr3 wildtype SEY6210 or MPY17 Ctr1/Ctr3 deletion mutant yeast as measured 
by absorbance at 600 nm with the addition of a dose curve of A, known copper ionophore ZPT or 
B, DSF.  
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6.4 DSF strongly induces copper accumulation in IBC cells 
DSF has been implicated as a copper ionophore with the ability to bring copper 
into cells independently of copper transporters due to its Cu-binding ability and high 
lipophilicity, thus bypassing the tightly regulated mechanisms in place to control 
intracellular copper levels [428, 430, 431]. Our results in Figure 6.4B support that claim. 
To determine whether DSF promotes the accumulation of copper in IBC cells, SUM149 
and rSUM149 cells were treated with DSF, copper, or DSF-Cu for 24 h, and then copper 
content of cell lysates was determined by ICP-HRMS. A slight increase in intracellular 
copper concentration was observed upon treatment with 10 µM copper as a single agent, 
but there was a dramatic dose-dependent increase in intracellular copper upon 





Figure 6.5: DSF strongly induces copper uptake in IBC cells, which is associated with 
significant accumulation of ROS 
A, Copper content of SUM149 and rSUM149 cell lysates following 24 h treatment with DSF (300 
nM), copper (10 µM), or DSF-Cu (100-300 nM, 10 µM) as measured by ICP-HRMS. Copper was 
normalized to protein content for each sample. B, Left axis shows fold induction of mitochondrial 
superoxides (lwhite bars), and right axis shows percentage of cells with high cytoplasmic 
superoxides (black bars) as measured by flow cytometric staining with MitoSOX Red or DHE 
respectively in rSUM149 cells treated with DSF (300 nM), copper (10 µM), or DSF-Cu (100-300 
nM, 10 µM). **p<0.005. 
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6.5 DSF-Cu induces ROS accumulation and redox signaling in 
therapy-resistant rSUM149 cells 
Since we observed that DSF-Cu induced cell death in the redox adapted 
rSUM149 cell line, we characterized the effects of DSF alone and DSF-Cu on ROS 
generation and downstream signaling.  Flow cytometric dyes were utilized to measure 
relative levels of various ROS in rSUM149 cells. Data in Figure 6.5B show that while DSF 
and copper did not cause appreciable ROS accumulation as single agents at the 
concentrations tested, the DSF-Cu complex significantly induced the accumulation of 
mitochondrial (Mitosox Red, white bars) and cytoplasmic (DHE, black bars) superoxide 
radicals in rSUM149 cells, which are resistant to classical ROS generating agents such as 
paraquat and hydrogen peroxide, as well as multiple targeted and chemotherapeutics 
[78, 320, 415]. The increase in ROS corresponded with increased phosphorylation of the 
pro-apoptotic stress-related p38 MAPK as early as 4 h post treatment, with sustained 
activation 24 h post-treatment, as well as activation of redox-sensitive ERK1/2 (p44/42 




Figure 6.6: DSF-Cu activates redox-sensitive signaling and inhibits the pro-survival 
NF-κB pathway 
Western immunoblot analysis of p38, ERK1/2, and NF-κB phosphorylation status in SUM149 and 
rSUM149 cells treated with DSF (300 nM), copper (10 µM), or DSF-Cu (100-300 nM, 10 µM) for 4 
(above) or 24 (below) h. Total p38, ERK1/2, NF-κB, and GAPDH were used as loading controls. 
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NF-κB and Nrf2 are two important redox-responsive TFs that are activated by 
oxidative stress and promote the transcription of antioxidant genes and pro-survival 
molecules [36, 285]. DSF-Cu treatment resulted in downregulation of NF-κB 
phosphorylation as early as 4 h following treatment (Fig. 6.6), and this reduction was 
sustained 24 h post-treatment; total NF-κB expression was also reduced in SUM149 cells 
at 24 h (Fig. 6.6). Interrogation of Nrf2 transcriptional activity via an ARE luminescent 
reporter assay revealed that copper (10 µM) and high dose DSF (10-20 µM) induced Nrf2 
transcriptional activity as single agents; however, the strongest Nrf2 induction was 
observed with low dose DSF-Cu treatment (150 nM, Fig. 6.7A). Interestingly, Nrf2 
activation relative to untreated cells was higher in rSUM149 cells in response to reach 
treatment. In summary, DSF-Cu induces a strong oxidative stress response in the redox-




Figure 6.7: DSF-Cu activates the Nrf2 transcription factor but decreases cellular 
antioxidant capacity 
A, Fold induction of Nrf2 activity as measured by ARE-responsive luciferase activity in SUM149 
and rSUM149 cells treated with DSF (10-20 µM), copper (10 µM), or DSF-Cu (150 nM and 10 µM). 
B, Reduced glutathione content of rSUM149 cells treated with DSF (300 nM), copper (10 µM), or 
DSF-Cu (100-300 nM and 10 µM) relative to untreated cells as measured by Promega’s GSH-Glo 
kit. C, Western immunoblot analysis of SOD1/2 expression in rSUM149 cells treated with DSF 




6.6 DSF-Cu inhibits intracellular antioxidants SOD1 and GSH 
Since DSF-Cu increased ROS and redox signaling in the rSUM149 cells, which 
have high basal levels of antioxidants [78], we measured the expression of SOD1/2 and 
GSH in cells treated with DSF or DSF-Cu. The cellular pool of GSH was significantly 
reduced in rSUM149 cells following DSF-Cu treatment (Fig. 6.7B). Additionally, while 
SOD2 levels as measured by western immunoblot remained unchanged, SOD1 
expression was strongly downregulated (Fig. 6.7C) following treatment with doses of 
DSF-Cu which are associated with cell death (Fig. 6.2B). Reduction of the cell’s 
antioxidant defenses allows for the accumulation of ROS, which ultimately triggers 
oxidative stress-induced death as discussed in Section 1.3.2. Incubation of the cells with 
an exogenous SOD mimetic (MnTnHex-2-PyP5+) with potent antioxidant activity 
effectively blocked cell death caused by DSF-Cu treatment (Fig. 6.8), confirming the pro-




Figure 6.8: Addition of an SOD mimetic potently reverses DSF-Cu-mediated cell 
death in rSUM149 cells 
Viability of rSUM149 cells treated with DSF-Cu (200-300 nM and 10 µM) ± an SOD mimetic 
(MnTnHexyl-2-Pyp5+, 100-200 µM) as measured by trypan blue exclusion assay. 
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6.7 DSF-Cu downregulates XIAP and induces apoptosis in IBC 
cells 
Following combination treatment with DSF-Cu and in association with cell 
death, there was a significant reduction in expression of XIAP, which is associated with 
therapeutic resistance in cell line models of IBC [78, 114], in both SUM149 and rSUM149 
cells (Fig. 6.9). There was also an observed decrease in expression of the translation 
initiation factor eIF4G1 (Fig. 6.9), which has been reported to disappear during apoptosis 
due to its role as a substrate of activated caspases [432, 433]. Both of these findings 
indicate oxidative stress-induced apoptosis; an apoptotic mechanism of cell death was 
confirmed via western immunoblot analysis of PARP, which was cleaved in both cell 




Figure 6.9: DSF-Cu reduces XIAP and eIF4G1 expression and induces apoptosis in 
SUM149 and rSUM149 cells 
Western immunoblot analysis of XIAP and eIF4G1 expression and PARP cleavage in SUM149 
(left) and rSUM149 (right) cells treated with DSF (300-500 nM), copper (10 µM), or DSF-Cu (100-
500 nM, 10 µM). GAPDH was used as a loading control. 
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6.8 DSF-Cu inhibits ALDH1 activity in SUM149 IBC cells 
Disulfiram is classically known as an inhibitor of aldehyde dehydrogenases; this 
mechanism is responsible for its anti-alcoholism activity, as it results in the build-up of 
toxic aldehydes when the patient consumes alcohol [434]. Since ALDH1 activity has 
been linked to stem cell-like properties [435] and is associated with increased growth 
capacity in 3D culture conditions and enhanced tumorigenic potential in xenograft 
studies [436-439], we characterized the effect of DSF and DSF-Cu on the ALDH+ stem 
cell-like population of SUM149 cells. SUM149 cells were treated for 24 h with a dose of 
DSF (100 nM) ± copper that induces minimal cell death and then analyzed for ALDH1 
activity using the flow cytometric ALDEFLUOR assay; the specific ALDH inhibitor 
DEAB was used as a negative control for each sample. Data in Figure 6.10 show that 
while neither DSF nor copper as a single agent affected the ALDH+ population, the 
combination of DSF-Cu reduced the proportion of ALDH+ cells in the total population 




Figure 6.10: DSF-Cu inhibits ALDH activity in SUM149 cells 
Representative flow cytometric analysis of ALDH activity in SUM149 IBC cells treated DSF (100 
nM), copper (10 µM), or DSF-Cu (100 nM and 10 µM). Cells were incubated with ALDEFLUOR 
substrate (BAAA) and the specific inhibitor of ALDH, DEAB, was used to establish the baseline 
fluorescence of these cells and to define the ALDEFLUOR-positive region (gated population). 
Numbers shown are mean ± SEM of four separate experiments. 
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6.9 DSF-Cu potently inhibits anchorage-independent growth 
potential in SUM149 and rSUM149 cells 
Anchorage-independent colony formation in soft agar is considered to be a 
reasonably good predictor of in vivo activity [381, 382]. Thus, we examined the effects of 
DSF and DSF-Cu on anchorage-independent growth (AIG) in SUM149 and rSUM149 
cells; AIG was potently blocked by the combination of DSF in the nanomolar range (100-
300 nM) in the presence of copper (Fig. 6.11). Additionally, DSF alone inhibited AIG in a 
dose-dependent manner in the 10-20 µM range in SUM149 cells (data not shown), 
similar to results in 2D culture in Figure 6.1A. Neither copper nor nanomolar doses of 
DSF had any measurable effect on the AIG potential of SUM149 or rSUM149 cells (Fig. 
6.11). Representative images in Figure 6.11 show an abundance of large colonies 





Figure 6.11: DSF-Cu potently inhibits anchorage-independent growth of SUM149 and 
rSUM149 cell lines 
Quantification of anchorage-independent growth assay relative to untreated cells in SUM149 and 
rSUM149 cells treated with DSF (300 nM), copper (10 µM), or DSF-Cu (100-300 nM and 10 µM). 




We report herein the ability of a redox modulatory combination, DSF-Cu, to 
induce apoptotic cell death in IBC cells in a copper- and ROS-dependent manner. The 
combination is effective in patient-derived SUM149, MDA-IBC-3, and SUM190 cells, as 
well as SUM149 and SUM190-derived lapatinib-resistant cells (rSUM149, rSUM190) and 
a model of exogenous XIAP overexpression [78]. It is interesting to consider the 
differential sensitivity of the IBC models to DSF as a single agent; further studies to tease 
out the mechanisms behind this may reveal interesting data as to why the MDA-IBC-3 
cell line, which has not been studied on the basis of redox responses, seems to be 
relatively insensitive to DSF alone. DSF potency was significantly enhanced in all lines 
by the addition of exogenous copper, and cell death was associated with intracellular 
copper accumulation and induction of ROS. Redox-sensitive signaling pathways p38, 
ERK1/2 (p44/42 MAPK), and Nrf2 were activated, while phosphorylation of the classical 
pro-survival factor NF-κB p65 was decreased. Examination of cellular antioxidant status 
revealed that a decrease in radical detoxifying capacity resulting from reduced SOD1 
expression and loss of GSH activity caused the increased capacity for ROS accumulation. 
The cell death caused by DSF-Cu treatment was almost completely reversed by addition 
of an exogenous antioxidant (SOD mimetic), confirming the hypothesis that ROS 
induction is the mechanism of action responsible for DSF’s efficacy in IBC cells. Cell 
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death was accompanied by a reduction in XIAP and eIF4G1 expression as well as PARP 
cleavage. Aldehyde dehydrogenase activity was inhibited by DSF-Cu, and anchorage-
independent growth was negatively affected by the combination. The mechanisms by 




Figure 6.12: Mechanisms of DSF-Cu-induced cell death 
DSF acts as an ionophore, bringing copper into cells in a Ctr1-independent manner. DSF-Cu 
generates a significant amount of ROS through influx of reactive copper ions and inhibition of 
cellular antioxidant capacity, possibly through inhibition of NF-κB, which regulates the 
transcription of many antioxidants as well as the anti-apoptotic protein XIAP. Downregulation of 
XIAP and activation of the pro-apoptotic p-38 pathway by ROS promote apoptotic cell death. 
Additionally, DSF-Cu inhibits ALDH activity, reducing the population of stem-like cells. 
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It is widely known that cancer cells often generate increased levels of ROS 
compared to normal cells, and that this increase in ROS can alter cell signaling pathways 
and induce further mutations to promote cell growth [253, 265, 440]. In order to 
compensate for increased oxidative stress, cancer cells activate redox adaptive 
mechanisms which enhance their ability to detoxify ROS; these changes can lead to 
therapeutic resistance [264]. As discussed in Sections 1.3.4 and 1.3.5, constitutive 
activation of the redox-sensitive TF NF-kB is observed in many cancer types [264, 291], 
and upregulation of antioxidant and ROS scavenging mechanisms have been associated 
with therapeutic resistance in cell line models including our own [78, 225, 441, 442]. The 
constitutive increase in ROS in these adapted cells theoretically makes them more 
sensitive toward therapies that inhibit ROS detoxification or further increase ROS above 
the apoptotic threshold [235, 253], supporting redox modulation as a promising strategy 
for therapeutic intervention. 
Disulfiram is an old drug recently repurposed for cancer therapy, which is 
especially attractive due to the fact that extensive pharmacokinetics, clinical data, and 
FDA approval could facilitate its rapid incorporation into Phase 2 clinical trials. Many 
reports have cited an ROS-dependent mechanism of action for DSF [419-421, 443-445], 
making it an attractive agent for targeting redox adapation in IBC. Additionally, tumor 
cell toxicity has been reported to increase when DSF is used in conjunction with heavy 
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metals including copper, cadmium, and zinc [419, 420, 422-424, 426, 428, 446]. As cancer 
cells often accumulate copper at higher levels than normal tissue [447, 448], DSF’s 
copper-mediated mechanism of action presents a potential method by which to target 
tumor cells preferentially, thus decreasing off target effects and increasing the 
therapeutic index. 
As a single agent, DSF induced toxicity in the IBC cell lines only at 
concentrations in the micromolar range at doses that are not readily achievable in 
human plasma, where the accepted daily dosing of 250-500 mg per day yields a 
concentration of < 2 µM [449]. However, DSF’s potency was significantly enhanced by 
the addition of copper, with IC50s of 300 nM and below. So while these cell lines are 
relatively insensitive to DSF as a single agent compared to other breast cancer cell lines 
that have been tested (IC50s of 400-1100 nM in MCF7, MDA-MB-231, and T47D) [421], 
they become equally or more sensitive than those cell lines upon the addition of copper, 
with cell death occurring at DSF concentrations well below those achievable in vivo.  
Inhibition of antioxidant function has the potential to overcome redox adaptive 
therapeutic resistance. Sensitization of resistant pancreatic cancer cells has been 
achieved through knockdown of SOD2 [450], and downregulation of antioxidant 
capacity reversed paclitaxel resistance in models of bladder and breast cancer [225].   
Analysis of DSF’s proposed redox modulatory mechanism revealed that DSF-Cu not 
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only induces ROS, consistent with previous studies [419-421, 451], but also reduces 
SOD1 expression and GSH activity. Our results are consistent with previous reports that 
ROS induction by DSF is accompanied by oxidation of the intracellular pool of GSH 
[419, 451]; in contrast, Brar et al., who reported a different mechanism of action for DSF, 
did not detect ROS induction or GSH oxidation following treatment [452].  
Whether these effects are mediated by DSF, copper, or the complex remains to be 
determined. It is possible that DSF merely acts as a transporter of copper into cancer 
cells, promoting the accumulation of reactive copper ions above levels that would be 
permitted by the tightly regulated cellular copper transport machinery; indeed, this 
view is supported by several studies including this one that have shown dramatic 
increases in intracellular copper levels following DSF treatment [428, 431]. Interestingly, 
Hothi et al. showed that DSF single agent efficacy was dependent on endogenous 
copper in the media (provided by fetal bovine serum), with the addition of BCS to DSF 
blocking its efficacy [453], while Navratilova et al. determined that insensitivity of 
densely plated cells to DSF compared to sparsely plated cells was due to rapid depletion 
of copper in the media, further supporting the role of copper in DSF ‘single agent 
efficacy’ [454]. Reversal of cell death in SUM149 and rSUM149 cells through copper 
chelation indicates that copper is indeed required for DSF-induced cell death. However, 
none of these results can firmly rule out the possibility that it is the reactive DSF-Cu 
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complex that is responsible for cell death rather than copper alone; determination of this 
requires further study. 
Expression of XIAP, which we and others have previously correlated with 
therapeutic resistance in IBC and other cancer models, was down-regulated by DSF-Cu 
treatment. Reduction in this potent anti-apoptotic protein helps to tip the balance of pro- 
and anti-apoptotic factors in the direction of cell death. This may occur as a result of NF-
κB inhibition or the increased copper levels within the cell; XIAP is regulated by direct 
binding of copper to its cysteine residues, which induces a conformational change that 
decreases XIAP stability and blocks its caspase inhibitory function [455]. Additionally, 
the combination of DSF-Cu reduced expression of the translation initiation factor 
eIF4G1, which is a known caspase substrate whose degradation is indicative of apoptotic 
cell death [432, 433]. As an important mediator of IRES-mediated cap-independent 
translation during times of cellular stress, eIF4G1 is essential to the pathogenesis of IBC 
tumors, promoting the formation of tumor emboli and passive metastasis through 
upregulation of p120 catenin, which anchors E-cadherin at tumor cell-cell adherens 
junctions [46]. The hypoxia/oxidative stress resistance factor VEGF is also under the 
translational control of eIF4G1, and XIAP, which is known to contain an IRES element, 
may also be regulated at least in part by eIF4G1 [50, 114]. Through its effects on these 
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proteins, DSF-Cu has the potential to reduce IBC pathogenicity and sensitize cells 
toward therapeutic apoptosis. 
DSF-Cu potently activates the SAPK p38 MAPK, which is known to mediate 
apoptosis induced by external stimuli including oxidative stress [456].  Activation of p38 
has been observed in response to many pro-oxidant agents [408, 457-461] as well as DSF 
or DSF-Cu [419-421]. Interestingly, the redox-sensitive ERK1/2 pathway is also activated 
in IBC cells exposed to DSF-Cu, while DSF-Cu has previously been reported to inhibit 
ERK1/2 signaling in AML cells [419]. While ERK1/2 generally promotes cell survival, the 
downstream effects of ERK1/2 signaling are known to be cell type- and stimuli-specific, 
and ERK1/2 phosphorylation can also promote apoptosis under certain circumstances 
[405, 410]. In a previous study, we observed ERK1/2 activation as a compensatory 
response to apoptotic stimuli in rSUM149 cells [415]; however, further investigation is 
required to determine the effects of ERK1/2 signaling in IBC cells in response to DSF-Cu.  
NF-κB is a potent pro-survival TF that is activated by oxidative stress [36, 285]. 
NF-κB can protect cells from apoptosis induced by cytokines and chemotherapeutic 
agents through modulation of downstream genes including anti-apoptotic proteins such 
as Bcl-2, Bcl-xL, cIAP1/2, XIAP, and antioxidants including SOD and Trx2 [462]. NF-κB 
serves as a significant barrier to effective cancer treatment, and a number of tumor cell 
types have been reported to express high levels of constitutively active forms of NF-κB 
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[35, 426]. Interestingly, the anti-apoptotic protein XIAP can activate NF-κB signaling 
[197, 463], so targeting either of these molecules may negatively affect the other as well, 
amplifying the pro-apoptotic effects. The ability of DSF-Cu to inhibit NF-κB signaling 
while simultaneously inducing ROS and activating pro-apoptotic p38 signaling indicates 
the potential for strong anti-tumoral efficacy. 
The Nrf2 TF is activated by alteration of cellular redox status due to elevated 
levels of ROS or reduction of antioxidant capacity.  In times of oxidative stress, Nrf2 is 
released from its repressor Keap1, which undergoes oxidative modification, and 
activates genes with an ARE sequence [414]; in this way, Nrf2 serves as a sensor of 
oxidative stress, and its activation in SUM149 and rSUM149 cells (Fig. 3B) following 
DSF-Cu treatment indicates an oxidative intracellular environment. While downstream 
targets of Nrf2 include antioxidant enzymes such as SOD, NQO1, and GST [282, 308, 
414], DSF-Cu treatment induced cell death (Fig. 6.1, 6.2) and decreased SOD and GSH 
(Fig. 6.7B, 6.7C), indicating that Nrf2 activation was not sufficient to overcome the 
massive amounts of ROS induced by DSF-Cu. 
ALDH activity has been linked to cancer stem cells (CSCs) [464-466] and is 
associated with enhanced tumorigenic and metastatic potential [437, 439, 467] as well as 
resistance to chemo- and targeted therapies [468, 469]. Additionally, CSCs exhibit low 
basal levels of ROS [440, 470, 471], and some studies have shown that ALDH1A1 plays 
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an important role in protection again oxidative stress in multiple types of stem cells 
[472-474]. ALDH may be in part responsible for maintenance of low intracellular ROS in 
CSCs, and thus represents an important potential target for anti-tumoral therapy, 
particularly in redox adapted cells. Although DSF is known to be an ALDH inhibitor 
[475, 476], DSF alone did not show any effect on ALDH positivity at the concentrations 
tested, which are far below the IC50 for DSF in this model. However, the combination of 
DSF-Cu at a concentration associated with minimal cell death did inhibit ALDH activity 
in the IBC cells, which is consistent with previous results in glioblastoma [420] and 
breast cancer [421] cell lines where efficacy was observed only when DSF and Cu were 
used in combination. Further, the decrease in ALDH activity correlated with decreased 
tumorigenic properties. Because certain drugs can have differential effects in 2D and 3D 
cell culture models [382]and AIG is predictive of in vivo tumorigenicity [381], consistent 
induction of cell death in both model types provides strong evidence that the DSF-Cu 
combination may be efficacious in vivo. Ongoing studies in our laboratory to investigate 
the efficacy of DSF and DSF-Cu in murine xenograft models of IBC indicate that the 
combination is a potent inhibitor of tumor growth in vivo; completion of these studies 
will help to bolster the translational value of our work. 
Together, these data demonstrate the efficacy of the DSF-Cu combination as an 
inducer of apoptosis in IBC models. DSF-Cu enhances ROS accumulation and apoptotic 
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signaling while inhibiting pro-survival pathways and antioxidant activity. This study 
indicates that DSF-Cu may be a successful therapeutic for IBC patients, including those 
with acquired therapeutic resistance due to redox adaptive mechanisms, and supports 
the translation of this FDA-approved drug into clinical trials for IBC.  
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7 Conclusions and Implications 
In conclusion, the data presented in this dissertation demonstrate the 
reversibility of acquired therapeutic resistance in IBC and enhance the current 
understanding of the mechanisms behind therapeutic resistance and resistance reversal. 
While previous studies had identified potential therapeutic targets associated with 
resistance to the ErbB1/2 inhibitor lapatinib, the extent to which these mechanisms 
contributed to resistance, whether or not that resistance was specific to lapatinib or 
could mediate cross-resistance to other anti-cancer drugs, and the feasibility of targeting 
those resistance mechanisms had yet to be investigated. We determined that rSUM149 
cells were cross-resistant to a multitude of targeted and chemo-therapeutic agents, and 
that resistance reversal was associated with a renewed ability to accumulate ROS and 
activate an oxidative stress response through AMPK, likely due to downregulation of 
protective antioxidants and anti-apoptotic proteins. Targeting of XIAP or redox 
adaptation in the IBC cells was able to overcome therapeutic resistance to apoptosis 
through both the extrinsic and the intrinsic pathways. Interestingly, several of the agents 
used modulated both apoptotic dysregulation and redox adaptive mechanisms to 
induce apoptosis; a schematic of their effects can be found in Figure 7.1. In this chapter, 
the implications of our work will be discussed, as well as new questions that have arisen 




Figure 7.1: Schematic of IBC therapeutic resistance mechanisms and targeting of those 
mechanisms 
Therapeutic resistance to activators of the intrinsic and extrinsic apoptotis pathways in cellular 
models of IBC is mediated through apoptotic dysregulation and redox adaptation. Enhanced 
expression of anti-apoptotic factors, especially the potent caspase inhibitor XIAP, as well as 
activation of pro-survival signaling such as NF-κB, which modulates transcription of the 
apoptotic program, contributes to apoptotic dysregulation. Redox adaptation is achieved through 
activation of redox-sensitive transcription factors and upregulation of the cell’s antioxidant 
capacity. Targeting of apoptotic dysregulation using small molecule inhibitors of the IAPs 
including the Smac mimetic Birinapant and embelin overcomes therapeutic resistance to induce 
apoptosis; targeting of redox adaptation using the redox modulatory combination DSF-Cu also 
overcomes therapeutic resistance to induce apoptosis. Interestingly, the XIAP inhibitor embelin 
also reduces cellular antioxidant capacity, negatively affecting the redox adaptive mechanism; 
further, the redox modulatory combination DSF-Cu also negatively affects expression of XIAP, 
inhibiting the resistance mechanism of apoptotis dysregulation, indicating a potential link 
between the two.  
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The high throughput study investigating sensitivity of three progressive, 
isogenic-derived models of IBC was motivated by the observations that acquired 
therapeutic resistance in the rSUM149 and rSUM190 models was associated with distinct 
changes which reduced sensitivity toward classical ROS-inducing agents in addition to 
lapatinib. We questioned the reversibility of this resistance; were the changes involved 
the result of random mutations that were propagated due to a selective growth 
advantage, or were these features the result of some sort of stress response? In the event 
that the resistant cells were employing a stress responsive mechanism, it would be likely 
that resistance could be reversed by removal of the selective pressure, i.e. the stressor. 
The previous finding that XIAP overexpression in the resistant lines was the result of 
post-translational upregulation via an IRES element suggests the involvement of an 
inducible stress response, and the discovery that acquired resistance was reversible 
through lapatinib removal indicates a non-mutational mechanism, supporting this 
theory. Further interrogation of signaling including pro-survival NF-κB and the SAPKs 
JNK and p38 in the isogenic cell line models may help to determine the pathways that 
drive this response. Additionally, it is interesting to contemplate whether or not the IBC 
pathogenesis factor eIF4G1 might be involved in IRES-mediated upregulation of XIAP. 
eIF4G1 mediates cap-independent translation in times of cell stress and has been found 
to drive the translation of other IRES-containing mRNAs including p120 catenin and 
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VEGF in IBC [46, 50]; therefore, the upregulation of another IRES-containing protein in 
IBC cells in response to cellular stress raises the question of eIF4G1’s potential 
involvement.  
According to the DTP/DTEP concept, drug resistant cells may exist de novo in a 
heterogeneous population, but are selected for and allowed to grow out when sensitive 
cells are killed by treatment [477]. Indeed, these drug resistant cells may represent a 
subpopulation of cancer stem cells, which are known to exhibit reduced drug sensitivity 
[468, 469]. Measurement and comparison of stem cell markers including ALDH, CD24, 
and CD44 [478] in the parental cells and their resistant counterparts may help to 
determine whether this is the case. Interestingly, these two theories are not mutually 
exclusive; it may be that only cancer stem cells have the capability to combat cellular 
stress with an adaptive response, so that the resistant populations are the result of the 
expansion of a stem cell-like population when the drug resistant cells were killed off as a 
result of their inability to mount a protective response.  
In addition to determining the reversibility of resistance in the rSUM149 cell line, 
the qHTS study confirmed a state of cross-resistance in those cells which was protective 
against the tyrosine kinase inhibitors sorafenib, sunitinib, and gefitinib as well as several 
chemotherapeutics that target DNA synthesis and repair (capecitabine, mitoxantrone, 
bleomycin, and mitomycin), all of which are known to induce oxidative stress [479-488]. 
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These results make a very strong case for causal involvement of redox adaptation in 
therapeutic resistance in the rSUM149 cells. Further, reversal of resistance to lapatinib, 
associated with increased ROS-generating capabilities and reduced antioxidant and anti-
apoptotic protein expression, was associated with resensitization to the same drugs. 
These results reiterate the importance of targeting the IAPs and/or the redox adaptive 
phenotype as a means of preventing or overcoming therapeutic resistance to a variety of 
anti-cancer agents and served as a rationale for the studies in Chapters 4, 5, and 6. An 
important future direction from this and previous studies is the validation of the 
resistance mechanisms observed in our cell line models in IBC patient tissue. Analysis of 
anti-apoptotic molecules and antioxidants at the protein level (because post-
transcriptional modulation has been identied in these models) in matched pre- and post-
treatment patient biopsies would enable us to evaluate the proposed resistance 
mechanisms in vivo; correlation of our in vitro findings with clinical data is an important 
step to substantiate the relevance of our work and determine whether our studies could 
translate to improved patient care. 
 Studies utilizing the Smac mimetics stemmed from the observed inverse 
correlation between IAP expression and drug sensitivity in rSUM190, rSUM149, and 
rrSUM149 cells. The use of two Smac mimetics with differential affinities for XIAP 
allowed us to tease out the involvement of XIAP specifically in resistance to TRAIL, a 
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highly clinically relevant agent. While the rSUM149 cells show increased expression of 
many anti-apoptotic factors, inhibition of cIAP1/2 alone by GT13042 was much less 
effective than inhibition of XIAP and cIAP1/2 by Birinapant in both SUM190 and 
SUM149. Interestingly, the SUM190 cells, which express high levels of XIAP mRNA and 
protein relative to SUM149 [103, 114] and are inherently resistant to TRAIL, were 
sensitive to the Smac mimetics as single agents, which is rather uncommon [365, 367-
369]. These observations suggest a sort of ‘IAP addiction’ in the Her2-overexpressing 
SUM190 model, where the cells are highly dependent on IAP expression for survival. 
This phenomenon requires futher investigation, but determination of factors associated 
with increased reliance on the IAPs could be useful in predicting patient responses and 
choosing therapies. Studies in this chapter confirmed the utility of targeting the IAPs, 
XIAP in particular, and indicate that the Smac mimetics merit further study in animal 
models of IBC, which could pave the way for clinical trials.  
While studies in Chapter 4 highlighted the importance of the IAPs in mediating 
drug resistance, the experiments in Chapter 5 confirmed the importance of redox 
modulation as a mechanism of therapeutic sensitization. While embelin effectively 
reduced the expression of XIAP, embelin+TRAIL-induced cell death was partially 
reversible through the addition of an exogenous antioxidant, indicating that ROS 
generation was a significant contributor to the combination’s cytotoxicity. It is 
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interesting to contemplate whether embelin is an XIAP inhibitor and an ROS-inducing 
agent, or whether embelin induces ROS through its XIAP inhibitory function. XIAP 
expression and the levels of cellular antioxidants have correlated directly in all of the 
studies undertaken in this dissertation; XIAP, SOD1/2, and GSH are all overexpressed in 
the resistant cell lines, and XIAP and SOD1 were decreased in the resistance reversal 
cells (GSH levels were not tested, and SOD2 was not reduced in the rrSUM149 cells, data 
not shown). Treatment of rSUM149 cells with the XIAP inhibitor embelin 
downregulated SOD1 expression and decreased cellular GSH content, and targeting of 
the redox adapted state in rSUM149 with DSF resulted in decreases in both antioxidants 
SOD1 and GSH as well as XIAP. All of these data indicate that XIAP may modulate 
antioxidant capacity, and perhaps vice versa. There is evidence that XIAP can regulate 
the expression of certain antioxidants in a number of normal cell types [462, 489, 490]; 
one group tracked this function to modulation of NF-κB signaling [462]. Additionally, 
XIAP is known to promote SOD1 activity through activating ubiquitination of the 
copper chaperone CCS [455]. Conversely, studies in an animal model of transient focal 
cerebral ischemia determined that residues in XIAP undergo oxidation by ROS, which 
appears to negatively affect its anti-apoptotic functions; oxidation of XIAP was 
prevented by overexpression of SOD1 [491]. This study provides evidence that cellular 
redox status and antioxidant expression can also affect XIAP. Ongoing studies in our lab 
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utilizing the ectopic XIAP overexpression model SUM149 wtXIAP are aimed at 
determining whether XIAP does indeed play a role in regulating the redox capacity of 
IBC cells. We also plan to investigate whether these cells exhibit cross-resistance to other 
therapeutics as the rSUM149 cells do, and whether the same alterations in cellular redox 
capacity are involved.  
The studies in Chapter 6, which were based on our understanding of the 
resistance and resistance reversal models of IBC, were focused on determining the 
feasibility of targeting the redox adaptive phenotype observed in rSUM149 and 
rSUM190 cells. Because therapeutic resistance is so common in IBC and this mechanism 
is associated with such a broad spectrum of resistance, strategies to overcome redox 
adaptation may be highly relevant to the IBC population. Although modulation of this 
axis using embelin was effective in rSUM149, embelin’s reported effects on 
inflammation [392], hormone regulation [492], and antioxidant pathways [493] may 
blunt its efficacy or cause off target effects in vivo; thus, the development of other, more 
clinically relevant drugs is needed. DSF is an especially attractive redox modulator due 
to its multiple levels for cancer cell specificity; because its mechanism of action is 
copper-dependent, it is likely to preferentially target cells with high levels of copper. In 
fact, copper levels are elevated in a number of cancers, although copper measurement 
has never been performed on IBC patient tissue [447]; thus, analysis of copper levels in 
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IBC tissue merits future study. Further, the suggested ‘threshold model’ of ROS-induced 
apoptosis indicates that cancer cells, which often contain higher levels of ROS than 
normal cells, should be more vulnerable to additional oxidative insults because they are 
already near the threshold for apoptosis; it is suggested that their antioxidant defenses 
are already operating at maximum capacity to maintain homeostasis in the presence of 
high ROS, whereas normal cells with low ROS levels have a ‘reserve’ of antioxidants 
with which to combat exogenous oxidative stress [253].  
Interestingly, DSF not only targeted the redox adaptive mechanism in IBC cells, 
inducing copper-dependent ROS accumulation in order to promote apoptotic cell death, 
but also reduced expression of XIAP, which we have now shown to be a potent mediator 
of therapeutic resistance through apoptotic dysregulation. This may occur through DSF-
Cu-mediated inhibition of pro-survival NF-κB signaling, or perhaps the massive influx 
of copper into the cell caused by DSF facilitates copper binding to XIAP, promoting its 
destabilization and reduction in steady state levels [494]; additionally, XIAP may 
undergo oxidation by ROS [491]. Regardless of how the reduction in XIAP expression 
occurs, the effect is sensitization toward apoptotic cell death; it is interesting that the 
drug which was chosen for its redox modulatory abilities also negatively affects the 
other mechanism of therapeutic resistance identified by our studies. The fact that DSF-
Cu inhibits both apoptotic dysregulation through downregulation of XIAP and redox 
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adaptation through reduction of the cell’s antioxidant capacity may explain its very 
strong potency in the IBC cell lines, which is very promising from a therapeutic 
standpoint. The crosstalk between these two mechanisms and potential for modulation 
of antioxidant capacity by XIAP and vice versa merits further study. 
In addition to downregulating XIAP and activating oxidative stress-induced 
apoptosis, DSF-Cu also inhibited the CSC-associated marker ALDH. This is intriguing in 
that if the original development of resistance in the rSUM149 and rSUM190 cell lines is 
due to the outgrowth of highly therapy-resistant stem cell-like cells, co-treatment with 
DSF-Cu could potentially prevent the development of resistance in the first place. 
Additionally, inhibition of NF-κB activity by DSF-Cu blocks the development of 
resistance through enhanced survival signaling, which is a common mechanism in many 
cancer types including IBC [35, 36]. DSF’s efficacy in combination with copper at low 
concentrations that are readily achievable in humans suggests a promising future for 
this strategy; the incorporation of DSF or DSF-Cu into clinical trials for IBC in 
combination with standard therapeutics may prove to be beneficial for patients. 
The development of biomarkers both for the rational selection of treatment 
regimens and as a measurement of therapeutic efficacy is important for improving CR 
rates. Due to the copper-dependent nature of DSF, intratumoral copper levels represent 
a potential biomarker for patients that might respond well to this sort of therapy, with 
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higher copper levels predicting a higher therapeutic index and increased tumor cell 
sensitivity. Since sensitivity to DSF-Cu-mediated cell death was associated with an 
increase in intracellular copper following treatment, copper levels could also potentially 
serve as a biomarker for treatment efficacy. The measurement of oxidative stress by non-
invasive methods such as quantification of allantoins, F2-isoprostanes, and 8-OHdG in 
the urine has recently come to light as a quick and easy way to monitor patient 
responses to ROS generating therapies [495, 496]. This technique represents a way to 
easily monitor oxidative stress and tumor response over time in order to determine 
whether DSF is effective in patients. The inclusion of biomarkers like these represents a 
step towards personalized medicine that could enhance our understanding of oxidative 
stress responses in patients; thus, these applications require further investigation. 
The studies described here detail the first model of drug resistance reversal in 
IBC and provide mechanistic proof that XIAP and antioxidant overexpression are key 
mediators of therapeutic resistance in IBC cell line models. Further, these results provide 
evidence that XIAP may mediate cancer cell adaptation to oxidative stress through 
modulation of cellular antioxidant status, indicating yet another mechanism by which 
this potent IAP counteracts apoptosis. The utilization of clinical inhibitors of these 
resistance factors- Birinapant, which is in Phase 2 clinical trials for cancer, and DSF, 
which is FDA-approved for an alternate indication and currently in Phase 1, 2, and 3 
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clinical trials for the treatment of cancer- with promising results will hopefully facilitate 
the introduction of these agents into clinical trials targeting IBC and help to improve 
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